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More than 40% of the world's population still live under the threat of 
malaria. Present drug and vaccine strategies are failing to eradicate or even 
control the disease. A greater ,understanding of the molecular biology of the 
intracellular parasite is necessary in order to develop better chemotherapy and 
vaccine strategies. One aspect of the parasite's biology which may yield new drug 
targets, are novel trafficking pathways which are established when it invades a red 
blood cell. 
In order to study the mechanisms involved in such pathways, specific 
proteins found in defined locations in the host cell must be studied. One group 
of proteins that may prove useful in such studies are exported integral membrane 
proteins because they may act as markers for the polarity of certain membranes. 
Previous work in our laboratory has focused on the integral membrane protein 
exp-1. In order to test the validity of a model proposed for its transport to the 
cytoplasm other exported, parasite encoded, integral membrane proteins need to 
be identified. 
This thesis has focused on other parasite encoded proteins which appear 
to be exported by the parasite to the parasitophorous vacuole membrane (PVM) 
The initial approach adopted was to study a protein recognised by a specific 
monoclonal antibody, 7.7. Using a double labelling indirect immunofluorescence 
technique this antigen, termed exp-2, was shown to be co-localised with exp-1 in 
the PVM and in vesicle-like structures in the erythrocyte cytoplasm. 
In the course of attempting to isolate the exp-2 gene another antigen, exp-
3, was isolated. Further characterization of exp-3 indicated that it was a member 
of a two gene family. Both genes were isolated and found to be located on 
chromosome 13. Sequence analysis of the two genes showed that the genes 
appear to be highly conserved at the amino terminus and diverge in a repeat 
region towards their C-terminus. They also both contain potential transmembrane 
domains. Antisera to both antigens were raised and used to perform localization 
studies which suggested that the exp-3 antigens are also localised to the PVM. 
iv 







CHAPTER 1: INTRODUCTION 	 1 	 1 
1.1 The Life Cycle of Malarial Parasite in Man 	 3 
1.1.1 Invasion and formation of the parasitophorous vacuole 	 5 
1.2 The Parasite Genome 	 7 
1.3 Malarial Vaccines 	 9 
1.3.1 Current malaria vaccine development 	 9 
1.3.2 Evasive responses of the parasite to the host immune response 
1.4 Chemotherapy 	 14 
1.4.1 Anti-malarial drugs 	 14 
1.4.2 Spread of drug resistance 	 16 
1.4.3 Chloroquine resistance 16 
1.4.4 Pyrimethamine and cycloguanil resistance 	 17 
1.5 Intracellular Trafficking in the P.falciparum infected RBC 	 18 
1.5.1 Alterations in the red blood cell membrane 	 19 
1.5.2 Endocytosis and exocytosis in higher eukaryotes 	 20 
1.5.3 Synthesis and secretion of parasite proteins 	 24 
1.5.3.1 Immunolocalization studies 	 24 
1.5.3.2 Effects of Brefeldin A on parasite protein release 	 27 
v 
1.5.3.3 Investigations into malarial protein secretion 
using cell-free systems 	 28 
1.5.4 Import of proteins and nutrients into the intracellular parasite 	31 
1.5.4.1 Endocytosis 	 31 
1.5.4.2 The 'parasitophorous duct' 	 31 
1.5.5 Intracellular trafficking in the P.falciparum infected RBC: Conclusions 33 
1.6 Summary and Scope of this Thesis 	 33 
CHAPTER 2: MATERIALS AND METHODS 	 35 
PART I: MATERIALS 
2.1 Chemicals and Equipment 	 36 
2.1.1 Chemicals 	 36 
2.1.2 Centrifugation 	 36 
2.2 Microbiology 	 36 
2.2.1 Parasites 	 36 
2.2.2 Genomic Libraries 	 36 
2.2.3 Bacterial Strains, Bacteriophage and Plasmid Vectors 	 37 
2.3 General Stock Solutions and Media 	 38 
PART II: METHODS 
2.4 DNA METHODS 	 41 
2.4.1 Phenol/Chloroform Extraction and Ethanol Precipitation of DNA 	41 
2.4.2 Preparation of DNA 	 41 
2.4.2.1 Preparation of P.falczpamm DNA 	 41 
2.4.2.2 Mini-Prep of Plasmid DNA 	 42 
2.4.2.3 Maxi-Prep of Plasmid DNA 	 43 
2.4.2.4 Preparation of DNA from Phage Lambda 	 43 
vi 
2.4.3 Estimation of DNA Concentration 44 
2.4.4 Agarose Gel Electrophoresis 44 
2.4.4.1 Mini- and midi-gels 44 
2.4.4.2 Horizontal maxi-gels 44 
2.4.4.3 Pulsed field gel electrophoresis 45 
2.4.5 DNA Molecular Weight Markers 45 
2.4.6 Photography 45 
2.4.7 Southern Transfer 45 
2.4.7.1 Dry Blot 45 
2.4.7.2 Wet Blot 46 
2.4.7.3 Dot Blotting 46 
2.4.8 Radioactive Labelling of DNA 46 
2.4.8.1 Random Priming 46 
2.4.8.2 Purification of labelled double-stranded DNA 47 
2.4.8.3 Labelling of oligonucleotides 47 
2.4.9 Hybridisation 48 
2.4.9.1 Hybridisation with random labelled DNA probes 48 
2.4.9.2 Hybridisation with oligonucleotides 48 
2.4.10 Removal of Probes from DNA Blots 49 
2.4.11 Autoradiography 49 
2.4.12 Densitometry 49 
2.4.13 Scintillation 49 
2.4.14 DNA Restriction 49 
2.4.15 Purification of DNA Fragments from Agarose 51 
2.4.15.1 Phenol extraction 5 1 
2.4.15.2 Geneclean II Kit (BlO 101 Inc.) 51 
2.4.16 Phosphatase Treatment of Cut DNA 51 
2.4.17 Filling-in of Cut DNA 3' Recessed Ends 52 
2.4.18 Ligation of DNA 52 
2.4.19 Preparation of Competent Cells 52 
2.4.20 Transformation of E.Coli 53 
vii 
2.4.21 Colony Screening 53 
2.4.22 Preparation of Plating Cells 53 
2.4.23 Plating of Phage Lambda 54 
2.4.24 Preparation of Lysogens 54 
2.4.25 Plaque Screening 54 
2.4.26 DNA Sequence Determination 55 
2.4.27 Sequencing Gel Electrophoresis 56 
2.4.28 DNA Sequence Data Analysis 56 
2.4.29 Polymerase Chain Reaction (PCR) 56 
2.5 RNA METHODS 57 
2.5.1 Preparation of mRNA 57 
2.5.2 Gel Electrophoresis 58 
2.5.3 RNA Molecular Weight Markers 59 
2.5.4 Northern Blotting 59 
2.5.6 Removal of Probes from Northern Blots 59 
2.6 PROTEIN METHODS 59 
2.6.1 Indirect Immunofluorescence Assay (IFA) 59 
2.6.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 60 
2.6.3 Protein Molecular Weight Markers 61 
2.6.4 Protein Gel Staining 62 
2.6.4.1 Coomassie Brilliant Blue (Fixing) 62 
2.6.4.2 Coomassie Brilliant Blue (Non-Fixing) 62 
2.6.4.3 Silver staining 62 
2.6.5 Western Transfer 63 
2.6.6 Dot Blotting 63 
2.6.7 Detection of Protein Bound to Nitrocellulose 63 
2.6.7.1 Ponceau S 63 
2.6.7.2 Immunological detection of bound antigens 64 
2.6.8 Expression Library Screening 64 
viii 
2.6.9 Purification of Monoclonal Antibody 7.7 65 
2.6.9.1 Ammonium Sulphate Precipitation 65 
2.6.9.2 DEAE-Cellulose column preparation and use 65 
2.6.10 Monoclonal Antibody 7.7 Affinity Column Preparation 66 
2.6.11 Preparation of Total Proteins from P.falciparwn 67 
2.6.12 Affinity Purification of Exp-2 67 
2.6.13 Crude Protein Preparations from AGT11 Lysogens 68 
2.6.14 Raising Antisera to a P.falciparum Encoded Polypeptide 
Expressed in pMS 68 
2.6.14.1 Expression of 3-galactosidase fusion proteins 68 
2.6.14.2 Affinity purification of a 	-galactosidase fusion protein 69 
2.6.14.3 Immunization of mice with the purified polypeptide 69 
2.6. 14.4 Preparation, purification and analysis of mouse sera 70 
2.6.15 Raising Antisera to Recombinant Glutathione S-transferase (GST) 
Fusion Proteins 70 
2.6.15.1 Expression of GST fusion proteins 70 
2.6.15.2 Purification of GST fusion proteins 71 
2.6.15.3 Removal of the GST carrier by protease cleavage 72 
2.6.15.4 Immunization of animals with protein from pGEX 
constructs 73 
2.6.15.5 Preparation, purification and analysis of rabbit sera 74 
CHAPTER 3: CHARACTERIZATION OF THE PARASITE ENCODED 
PROTEIN EXP-2 	 75 
3.1 Introduètion 	 76 
3.1.1 Previous characterization of the 7.7 monoclonal antibody antigen 	77 
3.1.2 Exp-2 is an integral membrane protein 	 78 
3.2 Exp-1 and Exp-2 co-localise to the same compartment in the 
infected RBC 	 78 
x 
3.3 Affinity purification of exp-2 	 84 
3.4 Does Band III co-purify with exp-2? 	 87 
3.5 Location of the erythrocyte anion transporter Band III in the 
ihfected RBC 	 90 
3.6 Discussion 	 93 
CHAPTER 4: ATTEMPTS TO CLONE EXP-2 AND THE IDENTIFICATION 
OF ANOTHER ANTIGEN LOCALISED TO THE PVM 	96 
4.1 Introduction 	 97 
4.2 Isolation and identification of a clone 	 99 
43 Analysis of crude lysates prepared from Agtll lysogens 	 102 
4.4 Analysis of proteins expressed by pMS SL13 constructs 	 103 
4.4.1 Subcloning strategy 	 104 
4.4.2 Sequence analysis of the three pMS 5L13 constructs 	 104 
4.4.3 Expression analysis 	 109 
4.5 Sequence analysis of the 1.8kb insert 	 109 
4.6 Characterization and subcellular localization of the antigen 
encoded by clone 5L13 	 112 
4.7 Discussion 	 120 
x 
CHAPTER 5: IDENTIFICATION OF TWO MEMBERS OF A 
GENE FAMILY 	 121 
5.1 Introduction 	 122 
5.2 Identification of two genomic EcoRI fragments related to the 
clone SL13 	 122 
5.3 PCR analysis 	 122 
5.4 Isolation and analysis of a 4.3kb EcoRI fragment 	 125 
5.4.1 Preliminary sequence analysis of the 2.2kb EcoRI/HindIII fragment 	126 
5.5 Confirmation that there are two related sequences 	 127 
5.6 Identifying further genomic clones from a sheared library 	 131 
5.7 Identifying a 5' HindIll overlapping clone 	 133 
5.8 Identifying a 5' EcoPJ overlapping clone 	 135 
5.9 Copy number analysis of the 3.8kb EcoRl fragment 	 140 
5.10 Sequence analysis of the exp-3a and exp-3b genes 	 145 
5.10.1 Sequence comparison 	 164 
5.11 Protein secondary structure prediction 	 166 
5.12 Data base searches 	 169 
5.13 Chromosome mapping 	 174 
x 
5.14 Northern blotting analysis 	 177 
5.15 Discussion 177 
CHAPTER 6: FURTHER CHARACTERIZATION OF 
EXP-3A AND EXP-3R 182 
6.1 Introduction 183 
6.1.1 The pGEX vector expression system 184 
6.2 Strategies used for subcloning fragments of exp-3a and 
exp-3b into pGEX 184 
6.3 Expression, purification and raising antisera to GST fusion proteins 188 
6.4 Initial characterization of the antisera 191 
6.5 Western blotting analysis 195 
6.6 Immunolocalization of exp-3a and exp-3b 199 
6.7 Discussion 208 
CHAPTER 7: DISCUSSION 209 
7.1 Characterization of exp-1 and exp-2 210 
7.2 Identification and characterization of the exp-3 gene family 211 










I am indebted to the late John Scaife for introducing me to this subject and 
for his enthusiasm. I am alsoextremely grateful to Robert Ridley without whose 
supervision and help this thesis would not have taken this final form. 
I wish to thank members of the group past and present for providing an 
instructive, stimulating and friendly working environment; Robert Ridley, Brian 
Kilbey, Michael Goman, Sybil McAleese, Richard Moon, John White, Pongchai 
Harnyuttanakorn, Shiu-wan Chan, Sandy Edgar, Mohammed Shahabuddin and 
Sandie Cheeseman. I would also like to thank, Klaus Lingelbach for his advice 
and guidance, along with Kathrin Gunther, Iris Ansorge and other members of the 
Bernhard-Nocht Institute, Hamburg, for their friendship and support. 
Thanks to David Walliker and Renee McKenzie who performed the 
immunization procedures, Graham Brown and Frank Johnstone for the 
photographic work and Jean Ramsey for glassware. Also, John Collins for his 
assistance with data base searches. 
I also wish to thank Mary Plumpton, Tom Smith, Sarah McQuay, Sharon 
Dickson, Roger Sayle, Linda Hirons, Fiona Parry, Michelle Gardner and Mike 
Rossner whose friendship, encouragement and understanding made my life, while 
in Edinburgh, fun!. 
Finally,, this research was financially supported by the Medical Research 




ATP adenosine 5'-triphosphate 
his, bisacrylamide NN'-methylene-bisacrylamide 
BCIP 5-bromo-4-chloro-3-indolyl phosphate 
bp base pair(s) 
USA bovine serum albumin 
CIP calf intestine phosphatase 
DAPI 4,6-diamidino-2-phenylindole 
dATP deoxyadenosine triphosphate 
dCTP deoxycytidine triphosphate 
ddATP dideoxyadenosine triphosphate 
ddCTP dideoxycytidine triphosphate 
ddH20 double distilled water 
ddGTP dideoxyguanosine triphosphate 
ddNTP dideoxynucleoside triphosphate 
ddTIlP dideoxythymidine triphosphate 
DEPC diethylaminopyrocarbonate 
DEAE diethyl amino ethyl 
dGTP deoxyguanosine triphosphate 
DNA deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
DOC deoxycholic acid (sodium salt) 
Dfl dithiothreitol 
dflP deoxythymidine triphosphate 
EDTA diaminothanetetra-acetic acid (sodium salt) 
EGTA ethylene glycol-bis( -aminoethyl ether)-N,N,N',N'-tetra-acetic acid 
EtBr ethidium bromide 
Fig. Figure 
GST Glutathione S transferase 
IFA indirect immunofluorescence assay 
Kul 
IgG immunoglobulin G 
IPTG isopropyl-1-thio- -D-galactoside 
kb 	double stranded DNA = kilobase pairs 
single stranded DNA and RNA = kilobase 
kDa kilodalton(s) 
LB Luria-Bertani medium 
LB-amp LB supplemented with ampicillin to 50sg-100pgIml 
McAb monoclonal antibody 
MOPS morpholinepropanesulfonic acid 
mRNA messenger ribonucleic acid 
NBT nitro blue tetrazolium 
NP40 nonidet P40 
01ff open reading frame 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PeAb polyclonal antibody 
PEG polyethylene glycol 
pfu plaque forming units 
PMSF phenylmethylsulfonyl fluoride 
PV Parasitophorous Vacuole 
PYM Parasitophorous Vacuole Membrane 
RBC Red Blood Cell 
RNA ribonucleic acid 
RNase ribonuclease 
rRNA ribosomal ribonucleic acid 
SDS sodium dodecyl sulfate 
TCA trichioroacetic acid 
TEMED N,N,N',N'-tetraethylmethylenediamine 
Tris tris(hydroxymethyl)aminomethane 
Tris.C1 Tris hydrochloride 
XgaI 5-Bromo-4-chloro-3-indolyl- 3-D-galactoside 
L.a-I 
Abbreviations for amino acids 
Amino Acid 	 Three-letter 	One-letter 
abbreviation 	symbol 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamine Gin Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine lie I 
Leucine Len L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Vaiine Val V 
xvii 
Abbreviations for Plasmodium antigens 
Antigen 	 Abbreviation Alternative name 
exported protein-i exp-i 
exported protein-2 exp-2 
exported protein-3 exp-3 
histidine rich protein-i HRP-i 
knob associated histidine-rich protein KAHRP 
histidine rich protein-2 HRP-2 
glycophorin binding protein GBP130 
serine repeat protein or antigen SERP or SERA 
rhoptry associated protein-i RAP-1 
merozoite surface protein-1 or antigen-1 MSP-i or MSA-i 
merozoite surface protein-2 or antigen-2 MSP-2 or MSA-2 
thrombospondin related anonymous TRAP 
protein 
P.falciparum sporozoite surface P[SSP2 
protein 2 
circumsporozoite protein CS protein 









Malaria is a mosquito-borne infection caused by protozoa of the genus 
Plasmodium. Earliest medical writers in China, Assyria and India described 
malaria-like intermittent fever which they attributed to evil spirits. Later it was 
associated with the air above areas of swamp hence giving rise to its name 
Malaria, mal:bad and aria:air. Malaria's ancient origins are reflected in the fact 
that to date nearly one hundred and twenty species of Plasmodia have been 
identified as infecting vertebrate hosts. These hosts include birds, rodents, 
primates, reptiles and man (Bruce-Chwatt, 1985). Four of these one hundred plus 
Plasmodia species infect man. They are P.falciparum, P.malariae, P.vivax and 
P.ovale of which P.falciparum causes the most severe form of malaria. 
More than 40% of the total world population live in malarious areas. 
Areas which include Central Africa, South America, India and Malaysia. There 
has been a dramatic increase in the number of cases in the last two years which 
is thought due to many reasons including poverty, population movement and the 
spread of drug-resistant parasites. It is estimated that 280 million people are 
infected with malarial parasites, at least 110 million develop the disease and up 
to 2 million people die from the disease every year (Brown, 1992). World Health 
Organization programmes which had, by 1970, been successful in non-endemic 
malarious areas accounting for 53% of the people originally at risk, have failed 
in the endemic areas (Bruce-Chwatt, 1985). This has been partly due to control 
programmes based on the extensive use of insecticides and chemoprophylactics 
and has resulted in the emergence of insecticide and larvicide-resistant mosquitoes 
and drug-resistant strains of the asexual parasite. Drug-resistant parasites now 
affect almost every country where the disease is endemic. For example in parts 
of Thailand half the cases of malaria are resistant to treatment with mefloquine, 
a drug that was licensed in 1985 (Nosten et al., 1991). As a consequence, 
strategies of malaria control have been directed to the development of new 
antimalarial drugs and vaccines. These strategies require a greater understanding 
of the molecular biology of the intracellular parasite. One aspect of this is the 
mechanism of import and export of molecules into and from the erythrocytic stage 
of the parasite. 
2 
This chapter will review some present vaccine and drug strategies and 
intracellular trafficking in malaria, but first some general aspects of the life cycle 
and biology of Plasmodia spp. will be described. 
1.1 The Life Cycle of the Malarial Parasite in Man 
The life cycle comprises of two phases (Fig.1.1), an endogenous asexual 
phase (schizogony) with multiplication in the vertebrate host and an exogenous 
sexual phase (sporogony) with multiplication in certain Anopheles mosquitoes 
(Bruce-Chwatt, 1985, Phillips, 1983). 
Infection begins when the vertebrate host is bitten by an infected female 
mosquito. While taking the blood meal the mosquito injects saliva containing 
sporozoites into the host skin capillary bed. Once in the capillaries, the motile 
sporozoites enter the main blood-stream where they can only be found for about 
half an hour following inoculation. Many are destroyed by phagocytes but some 
enter parenchymal cells of the liver (hepatocytes). Within the hepatocyte the 
parasite undergoes a process of development and multiplication known as pre-
erythrocytic schizogony i.e. the parasite divides into thousands of merozoites. 
These develop, the schizonts burst and mature merozoites are released into the 
host's blood-stream. Within twenty seconds the merozoites recognise, attach to 
and invade host red blood cells. Once in the erythrocyte the parasite undergoes 
further stages of development. 
The youngest of these stages is the ring form, a small circular form some 
of which contain a vacuole. These grow in size and become irregular in shape 
and are termed trophozoites. After a period of growth the trophozoite undergoes 
an asexual dividing process of erythrocytic schizogony and the nucleus of the 
parasite divides three to five times. This is followed by the division of cytoplasm 
forming a schizont. These forms now contained in the schizont are called 
merozoites. Once schizogony is completed the red blood cell bursts and the 
merozoites are released into the blood-stream. The merozoites then invade new 
erythrocytes in which another generation of parasites is produced by the same 
process. This cycle is repeated over and over again and this results in all the 
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symptoms of malaria ranging from the fevers that coincide with the release of 
merozoites, to anaemia and blockage of the brain capillaries by infected cells. 
The level of parasitaemia rises, until the process is slowed down by the immune 
response of the host. 
It is essential for completion of the life cycle that sexual stages of the 
parasite develop for fertilization in the mosquito mid-gut. Following erythrocyte 
invasion some merozoites develop into sexually differentiated forms (gametocytes). 
The factors affecting this differentiation are poorly understood but thought to 
involve factors such as body temperature, host immunity and nutrient levels. 
There are two types of gametocytes: female or macrogametocytes and male 
or microgametocytes. When a female Anopheles mosquito ingests the blood of a 
infected human host the parasites are released from erythrocytes in the mosquito 
stomach. Only the mature gametocytes survive digestion and undergo further 
development (gametogenesis). The microgametocyte divides mitotically three 
times to give 8 nuclei which combine with cytoplasm to form microgametes. The 
macrogametocyte on shedding the red blood cell membrane becomes the 
macrogamete and is fertilized by a microgamete. In the zygote soon after 
fertilization meiosis is thought probably to occur. Over the next 12-18 hours the 
zygote develops into an ookinete. The mature ookinete passes through the mid-
gut epithelium to rest between the basement cell membrane and the basal lamina 
of the mid-gut wall. There it differentiates into an oocyst which enlarges and 
matures over the next 10-12 days. During this development the nuclei undergo 
mitotic divisions and several thousand sporozoites are formed each containing a 
single nucleus. Finally the elongated motile sporozoites are released from the 
oocyst. Via the haemocoel the sporozoites reach and penetrate the salivary glands 
where they are ready to be injected into the host when the next blood meal is 
taken. 
1.1.1 Invasion and formation of the parasitophorous vacuole 
There is a sequence of five events involved in the invasion of the red blood 
cell by the merozoite (Aikawa, et al., 1983) (see Fig.1.2). 
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1.2: Diagrammatic representation the invasion of a RBC by a 
rel 
These are: 
Initial recognition of, and attachment of the merozoite to the erythrocyte 
membrane. 
Formation of a junction between the apical end of the merozoite and the 
erythrocyte. 
Creation of a vacuole membrane. 
Entry of the parasite into the vacuole by a moving junction around the 
merozoite. 
Sealing off the erythrocyte and vacuole membranes after completion of 
Itii'a}.lo)iu 
As invasion progresses, the depression of the erythrocyte membrane 
conforms to the shape of the merozoite (Aikawa et al., 1978, Bannister et cii., 
1975). The movement of the junction during invasion is an important component 
by which the merozoite enters the erythrocyte. When invasion is complete the 
merozoite is surrounded by a membrane termed the parasitophorous vacuole 
membrane (PVM). Recently it has been demonstrated that the lipid found in the 
newly formed PVM is wholly or partly derived from the lipid pre-existing in the 
rhoptries and micronemes of the parasite (Dluzewski et aL, 1992). Dluzewski and 
colleagues suggest that the lipid forms a pool at the point of attachment which 
normally expands inwards to form the vacuole into which the parasite passes. 
Consistent with the theory that the PVM is at least partly derived from parasite 
material are the observations that the newly formed vacuole membrane of 
P.knowlesi is almost entirely devoid of intramembranous particles (McLaren et aL, 
1979) and furthermore the mature PVM is devoid of major red cell membrane 
proteins (Atkinson et aL, 1987). 
1.2 The Parasite Genome 
The P.falciparum genome is haploid throughout most of the life cycle, with 
zygote formation and meiosis only occurring during the mosquito phase of 
development (Walliker et cii., 1987). The number of chromosomes in the haploid 
genome is fourteen and this has been determined both by resolving the number 
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of bands by pulsed field gel electrophoresis (PFGE) (Kemp et al., 1987, Wellems 
et al., 1987) and by counting the number of centromeres in the mitotic spindle of 
young schizont nuclei (Prensier and Slomianny, 1986). The chromosomes range 
in size from approximately 650kb (chromosome 1) to over 3Mb (chromosome 14). 
To date low-resolution full-length restrithion maps of 9 of the 14 chromosomes 
have been constructed (see review of Triglia et aL, 1992). 
The haploid genome size is in the range of 2 to 4xlO 7bp (Goman et aL, 
1982, Wellems et aL, 1987). A remarkable feature of the genome is the bias in 
base composition. The DNA has a Tm value of 62.50C. P.falciparum has an 
A+T content averaging 69% in coding regions and as high as 90-95% in non-
coding regions (Pollack et aL, 1982, Weber, 1987). Codons with T or especially 
A in the third position are preferred and the C residue is under represented. In 
the genes sequenced to date TAA is the most common stop codon (Weber, 1987). 
Extensive chromosomal polymorphisms have been observed in different 
geographical isolates of Rfalczparum which vary in size by up to 20% between 
different isolates (Kemp et aL, 1985, Van der Ploeg et al., 1985, Sinnis and 
Wellems, 1988). Chromosome size polymorphisms have also been observed for 
isolates maintained over a long period of time (Corcoran et aL, 1986, Biggs et aL, 
1991). Characterization of these polymorphic chromosomes has revealed the 
presence of large deletions that arise mitotically during the asexual life cycle of the 
parasite both in vivo and in vitro (Van der Ploeg et aL, 1985, Pologe and Ravetch, 
1986). Also, non-parental karyotypes have been identified after genome cross of 
two cloned isolates indicating the chromosome polymorphisms also arise 
meiotically (Walliker a aL, 1987, Sinnis and Wellems, 1988). These 
polymorphisms may reflect the mechanism by which some antigenic diversity arises 
(Pologe and Ravetch, 1986, Wellems et aL, 1987). The molecular basis for this 
chromosomal variation is thought to involve chromosome breakage and healing 
of subtelomeric regions, frequent crossover events during meiosis and 
amplifications and deamplifications of the genome (see review of Foote and 
Kemp, 1989). 
Many P.falciparum antigens contain repetitive polypeptides which often 
vary from isolate to isolate for example; circumsporozoite (CS) protein (Dame et 
aL, 1984, Enea a aL, 1984), Knob associated histidine-rich protein (KAHRP, 
HRP-i) (Triglia a aL, 1987), major surface antigens (MSA-1 and MSA-2) Mackay 
et aL, 1985, Tanabe et aL, 1987) and S-antigens (Cowman a aL, 1985, Coppel a 
aL, 1983). These repeats may have evolved to serve a number of purposes. Due 
to the fact they are often the immunodominant region of the protein it has been 
suggested that they play a role in immune invasion i.e. they hyperstimulate an 
ineffectual irrelevant B-cell response which leads to a less effective response 
against critical 'protective epitopes' (Kemp et aL, 1987). They also may function 
in the generation of antigenic variation. While in other proteins they may retain 
critical functions. 
1.3 Malarial Vaccines 
1.3.1 Current malaria vaccine development 
P.falciparum causes the most severe form of malaria and therefore the 
majority of vaccine development is directed towards this particular species. It has 
been widely observed that people continually exposed to the disease in endemic 
areas eventually become clinically immune (Kwiatkowski, 1992). This observation 
has led to optimism that a vaccine could be developed against P.falczpamm. In 
theory a malaria vaccine could be directed against any stage(s) of the 
development of P.falciparum in its life cycle e.g sporozoites, merozoites, intra-
erythrocytic or even against zygote/ookinete stage parasites. However, each stage 
of the malaria life cycle expresses quite distinct and unique antigens which implies 
that a vaccine directed against any stage would not be effective against another. 
Perhaps, therefore the best hope of a vaccine is the development of a 
multicomponent vaccine which could include both antitoxic and antiparasitic 
elements which would contain epitopes from all stages of the malarial parasite 
found in man. There are many potential vaccine candidates for inclusion into 
such a multicomponent vaccine. 
Anti sporozoite vaccine strategies are targeted towards blocking the initial 
infection of the liver. The sporozoite vaccine candidates include CS protein 
(Ballou et al., 1987) and thrombospondin related anonymous protein (TRAP) 
(Robson et at, 1988) also known as P.falciparum sporozoite surface protein 2 
(PfSSP2) (Rogers et al.,1992). In P.yoelii infection of mice by vaccination with 
PySSP2 and CS protein protects against malaria (Khusmith et at, 1991). Trials 
on volunteers vaccinated with irradiated sporozoites proved successful; however, 
in field trials with the recombinant vaccine based on CS protein the protective 
efficacy was negligible (Ballou et at, 1987). This and other trials have indicated 
the poor correlation between antibodies to the repeat region of CS protein and 
protection against malaria in endemic areas (Hoffman et at, 1987). Recently the 
region of CS protein which acts as a ligand that binds the receptor on the host 
hepatocyte has been identified and this could be a better vaccine target since 
hopefully it is conserved from isolate to isolate (Cerami ci at, 1992). This region, 
region II, bears a striking homology to a cell adhesion domain of thrombospondin 
(Prater et at, 1991) and regions of several other proteins (Clarke et at, 1990) 
including TRAP the other potential sporozoite vaccine target (Robson et aL, 
1988). Human volunteers immunized with irradiated sporozoites and protected 
against malaria, develop an antibody response against PfSSP2 (Rogers ci at ,1992). 
This - suggests that TRAPIP[SSP2 is a target of protective immunity and would also 
be a suitable component of a multicomponent vaccine. 
There are several candidates for an asexual blood-stage vaccine. The most 
obvious vaccine candidates are antigens which are found on the surface of 
merozoites since they are directly accessible to immune attack. Two merozoite 
surface antigens MSA-1 and MSA-2, also known as merozoite surface proteins 
MSP-1 and MSP-2, also have been extensively studied (Holder and Freeman, 
1982, Symthe et at, 1988). Naturally acquired immune responses to the C-
terminus of MSP-1 are associated with reduced malaria morbidity (Riley ci at, 
1992). Monkeys immunized with synthetic recombinant proteins derived from 
PfMSP1 are partially or completely protected against challenge (Patarroyo, et at, 
1987) and also a human vaccination trial which included a peptide from PfMSP1 
into the immunizing mixture reported success (Patarroyo et at, 1988). Antibodies 
against MSP-2 have been shown to inhibit invasion of erythrocytes by merozoites 
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in vitro (Miettinen-Baumann et aL, 1988). However unlike MSP-1, MSP-2 
contains repeat regions which vary considerably from isolate to isolate (Symthe et 
aL, 1991, Marshall et aL, 1991). This suggests that this molecule may not be 
conserved enough to be a suitable vaccine component but this requires further 
assessment. 
Mother group of blood stage antigens, which are vaccine candidates, are 
those secreted by the merozoite as it invades the red blood cell. The proteins are 
secreted from organelles called rhoptries and micronemes. They are thought to 
function in facilitating the entry of the parasite into the RBC and presumably a 
vaccine strategy based on this stage in the life cycle would aim to block this 
process. The vaccine candidates of this stage include the rhoptry associated 
protein (RAP) complex. Saimirisciureus monkeys immunized with affinity purified 
RAP complex are protected from a lethal blood-stage infection of malaria (Ridley 
et aL, 1990a). 
The sexual stages of the parasite's life cycle are another vaccine target. It 
is these stages which carry the infection from the human host to the mosquito. 
Antibodies against these stages would not give direct protection to the recipient 
of the vaccine but they would block transmission of the parasite to other 
individuals. In addition because they would act on a stage never inside the human 
host they should not put selection pressure on the parasite to develop resistance. 
Transmission blocking antibodies would work in the following manner; after 
a blood meal on a malaria infected person, antibodies against gamete antigens will 
come into contact with gametes released from the RBCs in the mosquito midgut. 
The antibodies could then interfere with further development of the parasite. 
Three surface antigens of gametes and zygotes of P. falciparum have been 
demonstrated, by the use of monoclonal antibodies, to be targets of transmission 
blocking antibodies, Pfs230, Pfs48145 and Pfs25 (Rener et aL, 1983, Quakyi et aL, 
1987). Pfs230 and Pfs48/45 are found on the surface of male and female gametes 
and antibodies against these antigens disrupt development of the parasite before 
fertilization occurs. However, the antibody response to these two antigens, in sera 
from endemic areas, is highly variable suggesting that these antigens are poor 
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immunogens (Graves a at, 1988, Carter a at, 1989). Pfs25 is found on the 
surface of the zygote/ookinete. Immunizations of humans, mice and monkeys with 
recombinant Pfs25 elicits antibodies which block transmission of the parasite in 
mosquitoes (Barr et at, 1991). Furthermore, anti-Pfs25kDa transmission blocking 
antibody, given to infected mosquitoes in an additional blood meal, 3-6 days after 
being fed gametocyte infected blood, penetrated the oocyst and reacts with the 
25kDa protein within it. This reaction caused a significant reduction in the 
number of developing sporozoites (Lensen et at, 1992). 
All the potential vaccine candidates described so far are aimed at the 
parasite. There is another possible vaccine strategy which is the development of 
an 'anti-disease' vaccine i.e. a vaccine which will prevent the consequences of 
malarial infection which are often non-specific and depend on the release of 
parasite toxins and host cytokines. Only 1% of all infections lead to severe 
falciparum malaria of which the case fatality is about a third. Identification of a 
pathway that leads to the development of the severe disease i.e. cerebral malaria 
and severe anaemia, might allow new targets for vaccines to be developed. 
Interestingly plasma concentrations of tumour necrosis factor (TNF) are a marker 
for cerebral malaria (Grau et at, 1989). Plasma levels of TNF were significantly 
higher in Gambian children with uncomplicated P.falciparum malaria than in 
children with other illnesses. Furthermore, TNF levels were twice as high in 
cerebral malaria survivors compared to levels found in children with 
uncomplicated malaria and were ten times higher in fatal cases (Kwiatkowski et 
A, 1988). Kwiatkowski and colleagues concluded that increased TNF production 
is a normal host response to P.falciparum infection but that excessive levels of 
production may predispose to cerebral malaria and fatal outcome. They 
suggested that it might do so by upregulating cytoadherence. Recently they 
reported the result of anti-TNF therapy in Gambian children with cerebral 
malaria. TNF bioactivity was reduced in antibody-treated patients as shown by 
a dose-dependent fall in fever suggesting that by retaining TNF in the circulation, 
antibody may partly prevent the local and systemic effects of TNF (Kwiatkowski 
et at, 1992). The role of cytokines, including TNF and other nonspecific immune 
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responses, in the pathogenesis of malaria are discussed in more detail in a review 
by Kwiatkowski, (1992). 
1.3.2 Evasive responses of the parasite to the host immune response 
Of course even if the development of a multicomponent vaccine is possible 
there are many potential difficulties which can not be underestimated particularly 
that of the parasite's ability to evade the body's defences by expression of variable 
cell-surface molecules. This is likely to be of considerable relevance to the design 
of vaccines. Even in the absence of immune pressure antigens of the parasitized 
cell surface undergo clonal variation in vitro at the rate of 2% per generation 
(Roberts et gL, 1992). The disappointing results observed with the recombinant 
CS protein vaccine (Ballou et al., 1987) may be due to the genetic restriction in 
host response to certain antigens and it has been reported for CS protein that the 
T helper cell epitopes map to the polymorphic region of the molecule (Good a 
al., 1988). 
Malarial antigens are very diverse. This has arisen in part because in 
natural infections of P.falciparum individual patients are often infected with a 
mixture of genetically distinct parasites (Rosario, 1981, Thaithong et al., 1984) and 
mosquito transmission of such mixtures provides an efficient means for the 
generation of parasites with novel genotypes (Walliker et aL, 1987). For example 
seven allelic forms of MSP-1 have been demonstrated in a study of 37 isolates 
using specific monoclonal antibodies (McBride et aL, 1985). 
The parasite is also able to evade the hosts innate immune system. It is 
thought that some strains of P.falciparum express receptors on the infected RBC 
surface for uninfected RBCs to allow the formation of rosettes which can 
sequester from the peripheral circulation (Udomsangpetch et aL, 1989). Some 
strains of P.falciparuni also express, on the surface of mature-infected RBCs, 
receptors for endothelial cells. It is thought that these receptors are responsible 
for cytoadherence of infected RBCs to microvessels and prevent the parasites 
from passing through the spleen (Macpherson et aL, 1985, Magowan et aL, 1988). 
This cytoadherence, which causes the life-threatening complications in cerebral 
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malaria, is thought to be mediated by erythrocyte membrane protein 1 (PfEMP1) 
(Leech a al., 1984b). Antibodies which block or reverse cytoadherence are strain-
specific indicating that the corresponding antigen on the surface of the infected 
erythrocyte is also strain-specific (Udeinya et at, 1983). Cloned lines of 
P.falciparum can change the antigenic specificity for PfEMP1 in vitro (Biggs a at, 
1991). 
1.4 Chemotherapy 
1.4.1 Anti-malarial drugs 
Even before the identification of malaria-causing agents, herbalists selected 
medicinal plants and exploited their antimalarial potentials (Guerra, 1977, Khalid 
et at, 1986, Xiao a al., 1986, Phillipson et at, 1986). The bark of the cinchona 
tree was introduced to European medicine in the first part of the 17th century 
(Guerra, 1977). The cinchona alkaloids have been used ever since to treat 
malaria except for the period between 1935-1965 when mepacrine and 
chloroquine were widely used. There are four principle alkaloids of cinchona 
bark, quinine, cinchonodine, quinidine and cinchonine which are all effective 
antimalarials. The structure of quinine was used for the basis of synthesis of 
primaquine, mepacrine, chloroquine, mefloquine and other 4-aminoquinolines. 
Chloroquine, quinine and related quinoline-ring antimalarial drugs are 
effective against the intraerythrocytic stages of pigment producing malaria 
parasites (White, 1988). Since the stages in the liver, mosquito and mature 
gametocyte are not killed by these drugs it was thought that the drug action was 
related to pigment production by the parasite. This is indeed the case. The mode 
of action of chloroquine and other related compounds has been recently 
identified. Chloroquine interferes with a haem detoxification enzyme that is 
essential to the survival of the malaria parasites in red blood cells (Slater and 
Cerami, 1992). The digestion of haemoglobin results in the formation of a haem 
moiety, ferriprotoporphyrin IX (FPIX), which is toxic to the parasite. An enzyme 
in P.falczpamm polymerizes the haem and the parasite sequesters FPIX in food 
vacuoles as haemozoin/malaria pigment. Slater and Cerami's (1992) results 
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indicated that quinoline-ring antimalarial drugs inhibited the haem polymerase 
which polymerizes and detoxifies FPIX. In addition they demonstrated that 
quinoline-ring antimalarial drugs inhibited the haem polymerization according to 
the extent of their antimalarial activity which is consistent with the hypothesis that 
haem polymerase is the physiological target for these drugs. 
A chinese herbal medicine Qinghaosu (Artemisinin), a natural extract of 
Artemisia annua, has been used in traditional medicine to treat malaria and fevers 
for almost 2000 years and is unrelated to other malaria compounds (Klayman, 
1985). It has been used successfully to treat chioroquine resistant malaria (Li et 
al., 1984). The ester and ether derivatives (artesunate and artemether) have been 
shown to have greater antimalarial activity than the parent compound. They 
rapidly kill the asexual stages of the parasite and also have been successfully used 
in clinical trials for treating even severe types of falceparum malaria in China 
(Rosenblatt, 1992). These drugs are generally not available outside China and 
Burma but companies in Europe are investigating these compounds. 
Another group of antimalarials are the antifolates cycloguanil and 
pyrimethamine which inhibit parasite dihydrofolate reductase (DHFR) a key 
enzyme in the pathway of deoxythymidine synthesis (Ferone et aL, 1969). 
Cycloguanil acts on both hepatic and erythrocytic stages as well as in the phase 
of development of the parasite in the mosquito and is used widely for long-term 
prophylaxis (White, 1988). Pyrimethamine is used widely in prophylaxis and 
treatment both alone and in combination with sulphamides or sulphones since 
they act sequentially on the metabolic pathway of folic acid synthesis (World 
Health Organization, 1988). 
New fluoroquinolone antimicrobial agents, including ciprofloxacin, have 
been shown to be effective against P.falciparum chloroquine susceptible and 
resistant parasites in vitro. Their antibacterial action appears to be mainly due to 
inhibition of DNA gyrase but whether this contributes to their antimalarial activity 
is unknown (Divo el aL, 1988). 
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1.4.2 Spread of drug resistance 
Drug-resistant parasites first appeared in Latin America and Southeast 
Asia in, the early 1960s. Most strains of P.vivax and P.ovale are chloroquine 
sensitive but only a few strains of P.falciparum are and these are found mainly in 
western Africa, the Middle East, Central America and the Caribbean (Rosenblatt, 
1992). In almost every country where malaria is endemic there is widespread 
resistance of P.falciparutn to chloroquine and other drugs which has complicated 
the treatment and prophylaxis of this type of malaria (Webster et aL, 1985, 
Suebsaeng ci at, 1986, Gilles, 1987, World Health Organization, 1988). This 
problem is even further complicated by the rapid development of resistance to 
relatively new drugs. For example mefloquine trials, which is the only generally 
available alternative for the treatment of multi-drug resistant falciparum malaria, 
were carried out in 1980/81 and the drug introduced for use in Thailand under 
strict control in 1985 (Harinsuta et aL, 1983). In 1985/86 it cured over 98% of 
patients yet only 4 years later the cure rate had reduced to 70.8% (Nosten et aL, 
1991). Halofantrine is also effective in the treatment of chloroquine-resistant 
falciparum (Watkins et al., 1988, Wirima et at, 1988), but it is structurally related 
to the quinoline antimalarials and there is evidence of cross resistance (Webster 
ci at, 1985). Thai strains of P.falciparum are also insensitive to ciprofloxacin a 
fluoroquinolone with the most potent DNA gyrase activity (Watt et at, 1991). In 
many parts of the world P.falczpamm and P.vivax are also insensitive to 
pyrimethamine and/or cycloguanil (Dixon et at, 1982, Watkins, 1984). It is 
obvious that new drugs are needed desperately, but with limited commercial 
incentive for development of antimalarials where will they come from? 
1.43 Chloroquine resistance 
If the mechanisms of drug resistance were understood perhaps more active 
drugs could be developed or the ones in use made more effective. The 
observation that chloroquine resistant P.falczpamm accumulates less chloroquine 
than chloroquine sensitive parasites is thought to be the basis of resistance 
(Krogstad and Schlesinger, 1987, Krogstad et at, 1987). This can be explained in 
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that resistant parasites releases chioroquine 40-50 times more rapidly than the 
sensitive parasites even though the initial rates of chloroquine are the same 
(Krogstad a al., 1987). This chioroquine resistance can be reversed by verapamil 
a calcium channel blocker but has no effect on chloroquine sensitive parasites 
(Martin et al, 1987). Furthermore verapamil reversed resistance in multiple drug 
resistant neoplastic cells suggesting chloroquine resistance in P.falciparum may be 
due to a multiple drug resistant (mdr) phenotype i.e. both involve expulsion of 
drug from the cell and both can be reversed by calcium channel antagonists 
(Martin a al., 1987). Two mdr genes related to the mammalian mdr genes have 
been identified in malaria. Amplification of these genes is linked to resistance 
only in some chloroquine resistant isolates of P.falczpamm (Foote a al., 1989, 
Wilson a al, 1989). To determine if either mdr gene is linked to chioroquine 
resistance a genetic cross was performed between a chloroquine resistant and a 
chloroquine sensitive clone of P.falciparum. Examination of the 16 recombinant 
progeny indicated that the rapid efflux phenotype is controlled by a single gene 
or group of genes but that there was no linkage between the rapid efflux 
phenotype and either of the mdr genes or amplification of those genes (Wellems 
et al., 1990). Inheritance data from the 16 independent progeny showed that the 
rapid efflux phenotype is governed by a single locus within approximately 400kb 
region of chromosome 7 (Wellems et al., 1991) whereas the mdr genes map to 
chromosomes 5 and 14 (Triglia et al., 1992). This strongly suggests that there is 
another genetic locus governing chloroquine resistance independent of the mdr-
like genes. 
1.4.4 Pyrimethamine and cycloguanit resistance 
Resistance to pyrimethamine and cycloguanil in isolates of P.falcipamm is 
thought to be caused by changes in the structure of the dihydrofolate reductase 
(DHFR) molecule. Evidence for this comes from studies of a number of naturally 
pyrimethamine resistant isolates of P.falciparum (Peterson et al., 1988, Cowman 
a al., 1988, ZoIg a al., 1989). Changes in the amino acids .at certain positions 
(especially 108) have been shown to correlate to pyrimethámine resistance in the 
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parasite (Peterson et at, 1988, Cowman et al., 1988, ZoIg et at, 1989, Tanaka ci 
at, 1990). For example analysis of a genetic cross between pyrimethamine 
sensitive and pyrimethamine resistant parasites showed that resistance is linked 
to a single point mutation in the DHFR gene (Thr 108/Ser108 to Asn108) and that 
additional point mutations (Asn51 to Tie51 and Lys59 to Arg59) were associated 
with increased resistance to pyrimethamine (Peterson et at, 1988). Another 
mechanism which has been implicated in resistance to pyrimethamine is a gene 
duplication of DHFR leading to higher DHFR production (Inselburg ci at, 1987). 
Also there is evidence of another mechanism of pyrimethamine resistance, 
perhaps a change effecting gene expression, which can not be explained by either 
a mutation in the DHFR gene or gene amplification that is induced in vitro using 
chemical mutagens (Thaithong ci at, 1992). The amino acid substitutions in 
DHFR involved in P.falciparum resistance to cycioguanil are different than those 
observed for pyrimethamine. One of the mutations involved however, is at the 
same position (Ser108 to Thr108) the other is at position 16 (Ala16 to Val16) 
(Foote ci at, 1990, Peterson et al., 1990). Cross resistance to both drugs is also 
observed which is conferred by two mutations in the DHFR gene (Ser 108 to 
Asn108 and lie164 to LeuTh'l) (Peterson et al., 1990). 
1.5 Intracellular Trafficking in the P.falciparum infected RBC 
The previous sections have highlighted the parasites ability to evade the 
host immune system and develop drug-resistance. There is a need not only to 
understand the mechanisms involved in immune evasion and drug-resistance but 
also to identify new vaccine targets and drug targets. Possible drug targets maybe 
discovered by identification of potentially sensitive points in parasite physiology 
or biochemistry and this may be found in any compartment of the parasitized cell 
(Fairlamb, 1989). A group of potential parasite pathways which could be the 
target of cytotoxic drugs are the trafficking routes set up by the parasite to 
transport material into and from the parasite. These could not only be a drug 
target but may also serve as a route for the delivery of cytotoxic drugs which are 




1.5.1 Alterations in the red blood cell membrane 
The mature red blood cell, since it is a non-nucleated erythrocyte, is devoid 
of machinery for protein synthesis, membrane biogenesis and protein transport. 
Therefore in order to survive and multiply within the host cell the invading 
parasite must alter the composition and properties of the cell cytoplasm and 
membranes to suit its own requirements. Indeed alterations in the RBC 
membrane structure and function are observed following parasitization (Sherman, 
1985, 1988). 
Changes occur in the permeabilization properties of RBC membrane for 
substances including glucose, amino acids, purine nucleosides, sodium, potassium, 
calcium, zinc, iron and several antimalarial drugs such as chloroquine and 
mefloquine (Sherman, 1988). These changes in permeability are not a result of 
invasion but have been shown to be related to parasite growth (Kutner et at, 
1985) i.e. it depends on de novo protein synthesis. No changes in permeation 
occurred when the biosynthetic machinery of the parasitized cell was arrested with 
cycloheximide (Kutner et at, 1985). The nature of the new permeation pathways 
has not been determined but it has been suggested that proteins synthesized by 
the parasite after invasion are inserted into the host cell membrane and serve as 
pores (Ginsburg et at, 1985). 
During intra-erythrocytic growth the phospholipid composition of the 
erythrocyte membrane is considerably altered (Hsiao et al., 1991). Since mature 
erythrocytes have negligible lipid synthesis and metabolism it is reasonable to 
suggest that these alterations are a result of bidirectional lipid trafficking between 
the parasite and erythrocyte membranes. Indeed it has been demonstrated that 
the parasite imports lipid precursors, synthesizes them into lipid which is 
subsequently trafficked to the host cell membrane (Hsiao et aL, 1991, Hunter et 
at, 1991). The most extensive period of lipid content modification in the RBC 
membrane is during the development of the parasite from the ring to trophozoite 
(Hsiao et at, 1991). This is also the time when major changes in the influx of 
amino acid precursors occurs (Elford et at, 1985). Various parasite encoded 
proteins are found inserted into and associated with the RBC membrane for 
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example PfEMP-1 (Leech ci aL, 1984a) and the ring-infected erythrocyte surface 
antigen (RESA) (Foley ci al., 1991). These proteins may be associated with 
changes in antigenicity and ultrastructure of the membrane. 
It is assumed that these changes in the structure and function of the RBC 
membrane are brought about by the interaction of various parasite proteins with 
the host cell membrane. Coincidental with the changes in the RBC membrane 
is the appearance of new vesicular and membrane structures within the host cell 
cytoplasm. Various parasite proteins are associated with these vesicles and they 
are thought to provide a subcellular transport route for proteins in the RBC 
(Howard, 1982, Barnwell, 1990). However, there is very little definitive data 
concerning the mechanisms involved in transport across the various membranes 
and one can only speculate about the signals required. Further studies of 
transported antigens and vesicle-associated proteins are needed. Prior to 
discussing what is presently known about transport in malaria infected erythrocytes 
a brief summary of endocytosis and exocytosis in other eukaryotic cells will be 
given. 
1.5.2 Endocytosis and exocytosis in higher eukaryotes 
In eukaryotic cells the transport of nutrients, secreted proteins and 
membrane proteins occurs by several endocytic and exocytic pathways which 
involve vesicles (Palade, 1975). Endocytosis is the mechanism whereby cells 
internalise their own plasma membrane and macromolecules from their external 
environment. It is a time, temperature and energy dependent process and occurs 
by two distinct mechanisms (Glick and Rothman, 1987). These are nonspecific 
uptake of solutes by fluid-phase endocytosis and receptor-mediated endocytosis. 
In fluid-phase endocytosis, the internalized molecule does not bind to a 
receptor. The cell, therefore, does not concentrate molecules and is not saturable 
with respect to ligand. In receptor mediated endocytosis, cells express surface 
receptors which bind, and thereby concentrate, certain molecules so that they can 
be taken up in sufficient quantities even when extracellular concentrations are low. 
The process can be broken down into several stages. The molecules first bind to 
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receptors localized in clathrin coated pits on the plasma membrane which are 30-
200m in diameter. These coated pits bud into the cyoplasm forming a coated 
vesicle. The vesicle sheds its coat during transit and following fusion with a larger 
vesicular compartment the ligands are uncoupled from the receptors. The 
receptors are further sorted among small vesicles which bud from the large vesicle 
and are returned to the cell surface. The pits act as filters selecting specific 
molecules. The major protein associated with these pits is clathrin which is 
thought to be a structural protein. It is a 180kDa nonglycosylated protein which 
is found on the outer surface of the coated vesicles and its sequence seems to be 
highly conserved between species (Payne and Schekman, 1985). An example of 
a molecule taken up by endocytosis is the low density lipoprotein (LDL) the major 
cholesterol carrying protein in human plasma (Goldstein and Brown, 1977). This 
protein is associated to coated pits on the cell surface and to endocytic vesicles 
which fuse with other vesicles (Anderson et al., 1977). Studies using 
immunofluorescence demonstrated that LDL receptors are associated with pits 
and are internalized bound to LDL until the complex dissociates before fusion 
with lysosomes (Anderson et aL, 1982). 
There are several steps involved in the path followed by secreted proteins 
in the cell. Essentially they are synthesized, translocated across the endoplasmic 
reticulum membrane and then further transported in vesicles though the Golgi 
apparatus to the plasma membrane either directly (constitutive secretion) or via 
secretory granules (regulated secretion) see summary shown in Fig.1.3 (Palade, 
1975). 
Closer analysis of such a pathway shows that secretory proteins are 
synthesized in the cytoplasm, by a single class of ribosomes, with a leader peptide 
sequence which acts as a signal to translocate it across the rough endoplasmic 
reticulum (Milstein et aL, 1972). The signal sequence usually consists of 16-20 
amino acid residues with a polar basic amino terminus and a central, apolar 
domain (von Heijne, 1985). As it emerges from the ribosome the signal sequence 
is bound by a signal recognition particle (SRP). The ribosome-SRP complex is 
then targeted to the rough endoplasmic reticulum due to the presence of the 
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docking protein. The signal sequence then interacts with a rough endoplasmic 
reticulum associated transmembrane glycoprotein, the signal sequence receptor 
(Wiedman a aL, 1987). The growing polypeptide chain is then transferred across 
rough endoplasmic reticulum membrane by an unknown mechanism either directly 
or via a protein pore. Transmembrane proteins in addition to the hydrophobic 
cleavable signal sequence contain one or more stretches of 15-25 mostly 
hydrophobic residues which anchors the growing polypeptide in the phospholipid 
bilayer of the endoplasmic reticulum and prevents it from passing completely into 
the endoplasmic reticulum lumen (Singer and Yaffe 1990). On arrival in the 
lumen of the rough endoplasmic reticulum the majority of signal peptides are 
cleaved by a specific signal peptidase however these signal peptides need not be 
removed in order to for them to function (Evans et al., 1983 Verner and Schatz, 
1988). Within the lumen, proteins may also be proteolytically processed, folded 
and receive oligosaccharide modifications (Glabe et OL, 1990). 
The newly synthesized proteins are then packaged into vesicles and 
transported to the Golgi apparatus where further protein maturation occurs. The 
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process of exocytosis from the rough endoplasmic reticulum to the plasma 
membrane involves at least two types of vesicles different from clathrin coated 
vesicles. It is thought that non-clathrin coated vesicles transport protein from the 
rough endoplasmic reticulum to the Golgi cisternae and between the cis-, medial-
and trans-Golgi compartments (Braell et aL, 1984, Balch et aL, 1984). The 
majority of transport of membrane components from the trans-Golgi network to 
the plasma membrane is by uncoated vesicles that arise form the coated trans 
Golgi pits (Orci et aL, 1986, 1989). Clathrin coated vesicles also form and bud 
from the membranes of the trans-Golgi network (Orci et aL, 1989). 
There are at least twenty limited compartments of a mammalian cell and 
each contain a particular set of proteins that enables it to carry out specific 
functions. Accurate and rapid delivery of proteins to their correct compartment 
is important. Since virtually all proteins destined for different compartments in 
the cell are synthesized in the cytoplasm by a single class of ribosomes there must 
be signals that specify the localization of each nascent protein to a specific 
destination and these must reside in its sequence or structure. As already 
mentioned protein destined for secretion contain a cleavable signal sequence while 
integral membrane proteins also contain a region of hydrophobic residues. In the 
'bulk flow' model of Munro and Pelham (1987) it is proposed that in the absence 
of any additional sorting signal proteins are exported from the Golgi to the cell 
surface and therefore for a protein to take another path it must contain a sorting 
signal. For example proteins destined to remain in the endoplasmic reticulum 
possess a C-terminal tetra peptide sequence Lys-Asp-Glu-Leu for retention 
(Munro and Pelham, 1987). While transport from the Golgi to the lysosomal 
system involves mannose 6-phosphate receptors (von Figura and Hasilik, 1986). 
The transport machinery must recognise these signals and distribute distinct 
sets of proteins to distinct compartments. The transport vesicles contain 
complexes of proteins that are involved in this distribution and function to direct 
and mediate the translocation of membrane and secretory proteins to their 
cellular locations. 
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1.53 Synthesis and Secretion of Parasite Proteins 
As P.falczpamm develops from the ring stage to the trophozoite stage it 
extensively modifies the host cell plasma membrane. It is assumed that these 
changes are brought about by the interaction of various parasite proteins with the 
host cell membrane. The transport of parasite encoded proteins in malaria-
infected cells is complex particularly because there are several membranes to 
cross. Some parasite proteins synthesized by the parasite must cross the parasite 
membrane, the parasitophorous vacuole membrane and the RBC membrane. In 
addition, since various proteins are found in different and specific compartments 
in the infected RBC it implies the existence of targeting signals in the transported 
parasite polypeptide and perhaps transport mediating proteins. 
Very little is known about protein export in malaria but since the malarial 
parasite is a eukaryote it seems reasonable to assume that aspects of its protein 
transport are similar to that of higher eukaryotes. In higher eukaryotic cells 
protein secretion has been defined by transport through the endoplasmic 
reticulum and Golgi to distinct compartments with characteristic processing events 
occurring at different steps of the transport process. In malaria infected RBCs 
there is evidence of the endoplasmic reticulum but well defined Golgi stacks are 
not detected by transmission electron microscopy (Lanners, 1991). Also there is 
an apparent lack of N-linked glycosylation in at least the asexual intraerythrocytic 
stages of P.falciparum (Dieckmann-Schuppert et al., 1992). However, there is 
evidence that parasite proteins are exported via a vesicle mediated secretory 
pathway. The majority of evidence for this comes from immunolocalization 
studies of exported malarial proteins. Other more direct information has come 
from investigations into synthesis and secretion of proteins by released malarial 
parasites and also from synthesis and membrane translocation of malarial proteins 
in a cell-free translation system. 
1.5.3.1 Immunolocalization studies 
As the intracellular parasite matures from the ring-stage to the trophozoite 
unit-membrane-limited-vacuoles, termed clefts/vesicles appear in the cytoplasm of 
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the RBC. Studies have indicated that these originate from the PVM (Kara et aL, 
1988). Three different types of vesicles have been described. These are: 1) 
Maurer's clefts which are long slender vesicles of variable length with a single 
vesicle unit membrane; 2) large circular vesicles with extra layered unit 
membranes that give a whorled appearance and 3) a smaller and round vesicle 
with what may be an enclosing unit membrane and with an electron dense interior 
(Barnwell, 1990). In addition 'clumps' of electron-dense material (EDM) are seen 
in the PV, budding from the PVM and also associated with unit membrane bound 
Maurer's clefts (Aikawa et at, 1986). These clefts, vesicles and secretory granule 
like spheres are thought to be involved in the transport of material from the 
parasite to other locations in the infected RBC. Immunoelectron microscopic 
studies based on visualising antibodies bound to parasite proteins support this 
hypothesis. 
A summary of various P.falcipamm proteins which have been localized to 
vesicular structures or granule like spheres or membranes outside the 
intraerythrocytic parasite are shown in Table 1.1. 
As shown in Table 1.1 a large number of P.falcjparum proteins are found 
outside the intracellular parasite. The location of these proteins to distinct 
structures in the infected RBC suggests that there are distinct paths of protein 
transport in malaria infected erythrocytes. What are the signals required to 
determine the location for a given antigen and how are the different membranes 
traversed? Based on present data the answers to these questions are very limited. 
From the localization of certain antigens and examination of their predicted 
protein sequences one can speculate about the signals required. For instance 
KAHRP (Triglia et at, 1987), HRP-2 (Wellems et at, 1986), glycophorin binding 
protein (GBP130) (Kochan et at, 1986), exported protein-1 (exp-1) (Simmons et 
at, 1987), 41.2 (Knapp a at, 1989a), serine repeat protein (SERP) (Knapp et aL, 
1989b) and S-antigens (Cowman et at, 1985) contain hydrophobic regions 
considered to be part of a signal peptide and are all transported outside the 
parasite. This suggests that they are transported via a classical secretory pathway 
involving the rough endoplasmic reticulum. Also antigens found in the RBC 
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Table 1.1: P.falczpamm proteins localized to vesicular structures or granule-like 
spheres or membranes outside the intraerythrocytic parasite 
Parasite Protein Location(s) in infected Reference(s) 
RBCs 
HRP-2 dense aggregates in RBC Howard a aL, 1986 
cytoplasm, RBCM 
surface, secreted 
FfEMP-1 RBC cytoskeleton, spans Leech a al., 1984b 
RBCM 
MESA/EMP-2 PVM, V, internal face of Howard et al., 1987 
RBC cytoskeleton,  
KAHRP/HRP-1 (PPM), PVM, V, RBC Taylor et aL, 1987 
cytoskeleton under knobs Leech a aL, 1984a 
RESAIPI155 dense granules in RBC Udomsangpetch et aL, 
cytoplasm, interior of 1989, Foley a aL, 1991 
RBC cytoskeleton,  
41.2 internal face of RBC Knapp et aL, 1989a 
cytoskeleton, MC 
Pf332 V Mattei et aL, 1992 
exp-1/CRAIQf 116 PVM, MC Simmons et aL, 1987 
Pf50/43 MC Etzion & Perkins, 1989 
Pf46 MC Hui & Siddiqui, 1988 
GBP130 PV, V, RBC cytoplasm Perkins, 1988 
S-Antigen PV Cowman et aL, 1985 
SERNSERP/p126 PV, MC Knapp cit al., 1989b, 
Delpiace cit al., 1987 
PV, parasitophorous vacuole; PVM, PV membrane; V, vesicle; MC, Maurer's 
clefts; RBC, red blood cell; PPM, parasite plasma membrane 
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cytosol, KAHRP, HRP-2, GBP130, exp-1 and SERP, with the exception of 41.2 
have the leader sequence encoded by an exon separated from the rest of the gene 
by a small intron. Perhaps this is a functional unit which directs the protein to its 
particular cellular location. 
In other eukaryotes protein sorting information can also come from a 
'chaperone' protein. The chaperone associates with the protein to be sorted and 
can prevent or disrupt an inappropriate conformation which would impair its 
correct sorting (Pelham et at, 1989). Genes coding for potential P.falcipamm 
chaperones have been identified by homology to the D.melanogaster chaperone 
heat-shock protein 70 (hsp-70) (Bianco et at, 1986, Mattei et at, 1988, Yang et at, 
1987). These potential chaperones may associate with proteins which may lack 
a sorting signal but once associated with a chaperone protein are correctly sorted. 
Interestingly the predicted amino acid sequences of KAHRP and HRP-2 
do not contain any typical hydrophobic transmembrane domains and these 
proteins are apparently transported via vesicles. This poses the question whether 
or not there are proteins in the vesicles which function as 'carriers' for these 
antigens or do these proteins enter vesicles via a default pathway?. It seems 
unlikely that a default pathway exists since SERP and S-antigens, proteins found 
in the PV contain typical signal sequences yet are not found in the RBC. 
cytoplasm. As yet though no potential 'carrier' proteins have been identified. 
There are several proteins whose final destinations appear not be the RBC 
surface or cytoskeleton but are localized to clefts for example the integral 
membrane protein ëxp-1 (GUnther et at, 1991) and Pf46 (Hui and Siddiqui, 1988). 
The function of these clefts and the proteins localized to them is unclear. It is 
tempting to speculate that they perform a role in shuttling proteins to the 
erythrocyte membrane and perhaps they also perform a role in the import of 
proteins and nutrients. 
1.5.3.2 Effects of Brefeldin A on parasite protein release 
Recent studies of Elmendorf et at, (1992), and Crary and Haldar, (1992) 
have investigated synthesis and secretion of proteins by malarial parasites. Both 
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studies examined the effects of Brefeldin A (BFA) on parasite protein release. 
BFA blocks secretory export to post-Golgi compartments in mammalian cells and 
is thought to be directed at a G protein (Donaldson et at, 1991) associated with 
or close to the Golgi (Ktistakis et at, 1991). It does not however, affect cellular 
ATP levels or rates of protein synthesis. 
Crary and Haldar (1992), selectively permeabilized ring infected 
erythrocytes with saponin and analyzed protein secretion from these cells in the 
absence and presence of BFA. Essentially they found that soluble protein export 
was completely blocked in the presence of BFA suggesting that the dominant 
pathway for transport to the erythrocyte cytosol in rings is through a classic 
eukaryotic secretory pathway. They also found that newly synthesized ring 
proteins traffic through a site which can be reversibly blocked by BFA. They 
concluded that their results also suggest that the early rings can perform all the 
metabolic functions necessary for their immediate survival in the absence of 
secretory export but can not sustain or alter cell functions in a manner necessary 
for maturation. 
The studies of Elmendorf et al., (1992) were very similar to Crary and 
Haldar (1992) except that they examined protein synthesis and secretion of 
released trophozoite stage parasites in the presence and absence of BFA. They 
found that the majority of soluble protein secretion was BFA sensitive suggesting 
the presence of a classical secretory pathway which they showed to be necessary 
for cell viability. Some protein secretion was reproducibly insensitive to BFA 
treatment suggesting that there is also an alternative secretion pathway operating. 
Proteins that are secreted by a novel secretory route not involving a classical 
secretory route have been described in other eukatyotes (Moesch et at, 1990). 
1.53.3 Investigations into malarial protein secretion using cell-free systems 
Using a reconstituted cell-free system to follow the targeting of malarial 
proteins into the secretory pathway other researchers have also concluded that 
malarial proteins are transported by a secretory pathway, similar to the classical 
secretory pathway of higher eukaryotes, and by a non-classical pathway (Ragge et 
at, 1990, Shahabuddin et at, 1991). The cell-free system used involves 
translocation of the nascent polypeptide into the lumen of canine pancreatic 
microsomes where proteolysis of the signal sequence occurs (Blobel and 
Dobberstein, 1975). The translocated polypeptide is then resistant to protease 
digestion. 
Using this system Ragge et at, (1990) investigated the translocation of the 
P.falciparum parasitophorous vacuole localized antigen SERF. The SERP gene 
was transcribed and the RNA product translated in vitro. SERP was found to be 
translocated co-translationally across canine pancreatic microsomes and the 
process required the presence of the SRP. In addition the signal peptide was 
cleaved and the translocated protein was protected from proteinase digestion. 
Their results suggest that SERP is translocated by a pathway similar to the 
classical secretory pathway found in higher eukaryotes i.e. the polypeptide is 
exported via the endoplasmic reticulum, it requires the SRP and the signal peptide 
is cleaved. 
The synthesis and membrane translocation of exp-1, a P.falciparwn protein 
localized to the parasitophorous vacuole membrane and vesicular structures in the 
RBC cytoplasm, has been investigated in a cell-free system (Gunther et al., 1991). 
Like SERF it is translocated into pancreatic microsomes, is SRP dependent and 
is accompanied by signal peptide cleavage. The use of segment specific antibodies 
indicated that only the N-terminal half of the protein was protected from 
proteinase digestion suggesting that exp-1 is an integral membrane protein. These 
results are consistent with its predicted protein sequence which contains a N-
terminal signal sequence and a hydrophobic transmembrane region (Hope et al., 
1985). Gunther et at, (1991) also investigated the topology of exp-1 in vivo. They 
found that exp-1 is membrane associated, resistant to alkali extraction and that N-
terminus of the protein faces the inside of membranous compartments. They 
concluded that since upon insertion integral membrane proteins retain their 
orientation with respect to the polarity of the membrane, transport of the protein 
can only occur via membrane-bound vesicles, in an alternating succession of 
membrane fusion and membrane budding events. As previously discussed such 
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vesicular transport is thought to be a mechanism by which parasite-encoded 
proteins are transported across the PVM to the RBC cytoplasm. Based on the 
deduced topology of exp-1 from the in vitro translocation studies and from the in 
vivo results they proposed a fusion-budding model for the transport of exp-1 
across the PVM (see figure 1.4). 
'di! 
PPM 	PVM 	RBCM • - hydrophobic sequence 
by which exp-1 Is anchored 
in the membrane. 
-. - exp-1 is drawn as a pin, with the 
head representing the N-terminus 
of the protein. 
ure 1.4: Membrane Topology of exp-1. A) Orientation of exp-1 in the 
doplasmic reticulum membrane. B) Fusion-budding model for the transport 
exp-1 across the parasitophorous vacuole membrane (see text for explanation). 
According to the model the N-terminus of exp-1 is located on the luminal 
side of the transport vesicle (1) within the parasite, and subsequently it will be 
exposed on the extracytoplasmic side of the parasite plasma membrane (PPM). 
After budding from the PPM the N-terminus will be located on the outer face of 
the vesicle (2). After fusion with the PVM the protein would assume the opposite 
orientation to its orientation in the PPM. Then in the intraerythrocytic vesicle the 
N-terminus should be located on the luminal side (3). The validity of this model 
remains to be tested and will discussed later. 
Studies of the targeting of P.falciparum hypoxanthine phosphoribosyl 
transferase (HPRT) in a cell-free system suggests that this protein reaches its 
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destination via a different route from the classical secretory pathway (Shahabuddin 
et at, 1992). HPRT unlike exp-1 does not contain a potential signal sequence. 
When translation of HPRT RNA was carried out in the presence of microsomes 
the translation product was unaltered and after proteinase K addition HPRT was 
completely digested. They concluded that HPRT does not enter microsomes and 
that this suggests that in vivo the protein does not enter the classical secretory 
pathway. Interestingly Pf155/RESA like HPRT is localized in dense granules in 
the infected RBC cytoplasm and its N-terminus lacks a signal peptide (Aikawa et 
at, 1990, Favaloro et al., 1986, Aikawa et aL, 1986). It is tempting to speculate 
that Pf155/RESA may also be exported by a non-classical secretory pathway. 
1.5.4 Import of proteins and nutrients into the intracellular parasite 
1.5.4.1 Endocytosis 
In the classic eukaryotic import pathway nutrients and proteins are taken 
up into the cell via fluid-phase and receptor-mediated endocytosis. In 
P.falciparum infected erythrocytes vesicular trafficking of lipids from the outside 
of the cell into the erythrocytic parasite has been observed (Hunter et at, 1991, 
Grellier et aL, 1991). This is thought to represent classic endocytic vesicular 
trafficking however, clathrin coated pits and specific receptors have yet to be 
identified in malaria-infected RBCs. In addition it has not been determined 
whether the same vesicles which appear to be associated with the export of 
parasite encoded antigens are also involved in the shuttling of proteins and 
nutrients into the parasite. 
1.5.4.2. The 'parasitophorous duct' 
Recently Pouvelle a at, (1991), suggested that there is direct access to 
serum molecules by intraerythrocytic malaria parasites via a structure termed the 
'parasitophorous duct'. Evidence for this structure includes 1) surface labelling 
of the parasite with fluorescent markers under conditions that block endocytosis 
(40C, ATP depletion) and 2) visualization of membranes that appear to be 
continuous between the parasitophorous vacuole and erythrocyte membrane. 
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Trophozoite stage P.falciparurn-infected cells were incubated with either 
rhodamine or fluorescein dextrans at 37 0C and 40C. The cells were then 
examined by confocal fluorescence imaging microscopy which indicated that 
parasites were labelled only at 37 0C and not at 40C. However, at 40C the 
external membranes were labelled i.e. the erythrocyte, parasitophorous vacuole 
and parasite membranes. This suggested that the labelled dextrans do not cross 
either the erythrocyte or parasitophorous vacuole membranes by endocytosis but 
gain direct access to the space around the parasite. The molecules are then 
internalized by the parasite by fluid-phase endocytosis. The duct was visualized 
by confocal fluorescence imaging microscopy of living trophozoites incubated with 
N-4-nitrobenzo-2-oxa-1,3-diazole (NBD)-labelled phospholipids. Tubular 
extensions of membrane which appeared to bridge the erythrocyte and 
parasitophorous vacuole membranes were observed which were termed 
'parasitophorous ducts'. Similar structures were also visualized when infected 
eij'throcytes were incubated at either 37 0C or 40C with highly charged fluorescent 
latex beads. On the basis of these observations Pouvelle et al., (1991) postulated 
a model of molecular trafficking in malaria infected RBCs which included the 
following points 1) molecules would enter the infected RBC via the through the 
duct by passive diffusion; 2) molecular uptake by the parasite would be by 
endocytosis and 3) parasite product export would be via exocytosis. 
Further evidence for the presence of a duct comes from investigations into 
lipid trafficking in the infected RBC membrane. Fluorescently labelled lipids 
added to tissue culture medium rapidly cross the erythrocyte membrane and label 
internal parasite membranes under conditions that block endocytosis (Hsiao et aL, 
1991, Hunter et al., 1991). Also, structures suggestive of membrane continuity 
between the parasite and erythrocyte membrane were observed (Hunter et aL, 
1991). Grellier et aL, (1991) using fluorescently labelled lipid and fluorescence 
videomicroscopy investigated high density lipoprotein trafficking in P.falciparum 
infected RBCs. They observed staining of the PVM and/or the parasite 
membrane, vesicle movement between the parasitophorous vacuole and 
erythrocyte membranes and, a flapping movement of tubular structures in the 
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cytoplasm (the parasitophorous duct?). The greatest staining was observed in late 
trophozoite and early-schizont stage parasites. This is when considerable 
morphological changes take place in the infected cell and the parasite increases 
in size. 
Elford et aL, (1985) also postulated direct communication between the 
parasite and the culture medium via a 'window' in young trophozoites. The influx 
of labelled precursor amino acids into infected RBCs was investigated and 
constant rates of protein synthesis were found with [ 3H] glycine and [31­1] 
isoleucine. This suggests that the enzymes utilized for protein synthesis by the 
parasite interact with a pool of amino acids of constant specific activity. 
1.5.5 Intracellular trafficking in the F.falciparum infected RBC: Conclusions 
In conclusion it appears that transport pathways in malaria infected RBCs 
are similar in many respects to that found in other eukaryotes and there is a 
definite involvement of vesicle-mediated transport. This has been demonstrated 
by the localization of parasite encoded proteins, by investigations into synthesis 
and secretion of proteins by malarial parasites and from the translation of malarial 
antigens in cell-free systems. The functions of the various parasite proteins 
localised to vesicles however, is unclear and one can only speculate that they may 
play a role in shuttling other antigens and nutrients to and from the RBC 
membrane. 
1.6 Summary and Scope of this Thesis 
Malaria causes several million deaths every year. Present drug and vaccine 
strategies are failing to eradicate or even control the disease due to factors 
including the parasite's ability to develop drug resistance and evade the host 
immune response. A more thorough understanding of the biochemistry and cell 
biology of this parasite is required in order to develop better chemotherapy and 
vaccination strategies. One aspect of the parasite's biology, which may yield new 
drug targets, are novel trafficking pathways which are established when it invades 
a RBC. 
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In order to study the mechanisms involved in such pathways, specific 
proteins found in defined locations in the host cell must be studied. One group 
of proteins that may prove useful in such studies are exported integral membrane 
proteins because they may act as markers for the polarity of certain membranes. 
Previous work in our laboratory has focused on the integral membrane protein 
exp-1. Based on studies involving the use of segment specific antibodies its 
topology in parasite membranes was deduced and a model for its transport from 
the parasite to the cytoplasm via vesicles was hypothesized (Gunther a al., 1991). 
In order to test the validity of this model other exported, parasite encoded, 
integral membrane proteins need to be identified. 
One of the broad aims of this thesis was to study exported parasite 
encoded proteins. The initial approach adopted was to study a protein recognised 
by a specific monoclonal antibody, 7.7. Like exp-1 this protein is found in the 
PVM and membranous structures in the RBC cytoplasm. In the course of 
characterizing this antigen and attempting to isolate its gene another antigen was 
isolated. This antigen also appeared to be localised in the PVM. Further 




MATERIALS AND METHODS 
PART I MATERIALS 
2.1 Chemicals and Equipment 
2.1.1 Chemicals 
Unless stated otherwise in the text all chemicals were supplied by BDH plc. 
or Sigma Chemical Co. Ltd., UK and were of analytical grade. Solvents were 
supplied by FSA Laboratory supplies and radioactive nucleotides were supplied 
by Amersham International plc. 
2.1.2 Centrifugation 
Centrifugation was routinely performed in a benchtop chill-spin centrifuge 
(WIFUG) with a swing-out rotor. Higher speed spins were performed in either 
a high speed centrifuge (Sorvall) or ultracentrifuge (Sorvall), unless otherwise 




Two strains of P.falciparurn were used in this study. The Ki isolate 
(Thaithong and Beale 1981) and the cloned line 3137 (Walliker et aL, 1987). 
2.2.2 Genomic Libraries 
During the course of this study a range of genomic Plasmodium falciparum 
Thai isolate Ki (Thaithong and Beale 1981) DNA libraries were screened (see 
Table 2.1). 
The ANM1149 (Hohn and Murray, 1977) HindIII genomic library was 
constructed from HindIII digested genomic DNA ligated into the unique HindIII 
cloning site of ANM1149. The ANM1149 EcoRI library was similarly constructed 
using EcoRI digested genomic DNA. The Agtll partial Dral library was made by 
digesting the genomic DNA partially with Dral, ligating it to EcoRI linkers and 
then cloning into the EcoRI site of kgtll. The other Agtll library was constructed 
by shearing genomic DNA, ligating it to EcoRI linkers and cloning into the unique 
EcoRI site within the lacZ gene of the vector. 
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Table 2.1: Genomic libraries used in the course of this study. 
Library Source Reference 
1NM1149, Ki, HindIII M. Goman, University of Goman et aL 1982 
digested, genomic DNA. Edinburgh  
ANM1149, Ki, EcoRT M. Goman, University of Goman et al. 1982 
digested, genomic DNA. Edinburgh  
Agtl 1, Ki, partial DraI U.Certa Hoffmann-La- Certa a al., 1988 
digested genomic DNA, Roche Basel. 
EcoRI linkered. 
Agtll, K1, sheared U.Certa Hoffmann-La- Certa a al., 1988 
genomic DNA, EcoRI Roche Basel. 
linkered expression. 
2.2.3 Bacterial strains, Bacteriophage and Plasmid vectors 
The following bacterial strains, bacteriophages and plasmid vectors were 
used in the course of this study: 
Table 2.2: E.coli strains used in the course of this study.  
E.coli strain Genotype Reference 
DilSu F, 480dlacZAM15, recAl, endAl, Hanahan, 1983 
gyrA96, thi-1, hsdR17, (rK,mK), 
supE44, relAl, deoR, LSQacZYA- 
_________________ argF)U169  
NM522 F, supE, thi, A(lac-proAB), Ahsd5 (r,m), Gough & Murray, 
[F', proAB, 1acIZAM15] 1983 
JM83 F, ara, A(lac-proAB), ipsL, Yanisch-Perron et 
480dlacZAM15 at, 1985 
BL21 F, hsd, Sgal, rBmB Studier & Moffat, 
1986 
Y1089 F, A(lacUl69), proA, A(lon) araD139, Huynb et al., 1985 
strA, hfiA150, [chr:TnlO(te{)], (pMC9)  
Y1090 F, A(1acU169), proA, A(lon), araD139, Huyith et al., 1985 
strA, supF, [tipC22::TnlO(teI)], (pMC9) 
hsdR(rK,mKj I 
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Table 2.3: Bacteriophage used in the course of this study.  
Bacteriophage Genotype Reference 
Agtll A, lacS, nin5, c1857, SamlOO Young & Davis, 
1983(a) 
NM1149 X1mm 434, b(538) Murray, 1983 
Table 2.4: Plasmids used in the course of this study. 
Plasmid Reference 
pUC19 Yanisch-Perron et al., 1985 
pUBS Goman et at, 1991 
pMS1S,2S,3S Shahabuddin et al., 1992 
pGEX-2T,3X Smith & Johnson 1988 
2.3 General Stock Solutions and Media 
TBE 	lOx stock solution 	 lx working solution 
108g Tris base 	 89mM Tris base 
55g boric acid 	 89mM boric acid 
40m1 0.5M EDTA pH 8.0 	2mM EDTA 
H20 to 1 litre 
TAE 	50x stock solution 	 lx working solution 
242g Tris base 	 40mM Tris acetate 
57.1ml glacial acetic acid 	2mM EDTA 
37.2g Na2EDTA.2H20 
H20 to 1 litre 
SSC 	20x stock solution 
175g NaCl 
88g Na3citrate.21420 
adjusted to pH 7.0 
H20 to 1 litre 
Phosphate Buffered Saline (PBS) 
1 tablet (Flow) was 
dissolved in lOOmI 
of ddH2O 
lOx working solution 
1.5M NaCl 
0.15M Na3citrate.2H20 










10mM Tris-HC1 pH 8.0 
1mM EDTA pH 8.0 
Phage Buffer 	 0.3% KH2HPO4 




lml/l 1% gelatin solution 
Spitzizen salts (5x) 0.2% (NH4)2SO4 
0.14% K2HPO4 
0.6% KH2PO4 
0.1% trisodium citrate 
0.2% MgSO4 
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All general solid and liquid media were supplied by the department media service. 
Luria-Bertani 	 1% Bacto-tryptone 
medium (LB) 	 0.5% Bacto-yeast extract 
1% NaCl 
adjusted to pH 7.2 with NaOH 
LB agar 	 LB medium with 1.5% agar 




BBL Top Agar 	As for BBL agar but only 0.65% agar 
Minimal Media Agar 	lOOml/l Spitzizen salts (5x) 
1.5% Agar 
lOml/l Glucose (20% (w/v)) 
50mg/I Vitamin BI 
LB-amp, 	 LB supplemented with 
ampicillin to 50pg-100sgIml. 
Xgal indicator plates 	Fresh dry LB agar plates were spread with 
200i.sl LB containing 30sl of X-Gal 
(20mglml in dimethlformamide) and 
20p0 of 100mM JPTG. 
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METHODS 
2.4 DNA Methods 
Unless otherwise stated in the text the methods used were based on that 
found in Sambrook et aL, 1989. 
2.4.1 Phenol/Chloroform Extraction and Ethanol Precipitation of DNA 
In order to remove contaminating proteins DNA was usually extracted 
twice with a phenol/chloroform solution. The solution was prepared by mixing an 
equal volume of phenol (equilibrated against TE) with an equal volume of 
chloroform. The mixture was stored, wrapped in foil, at 4 0C and was stable for 
several months. 
To the DNA in TE was added an equal volume of the phenol/chloroform 
solution. This was mixed and then microcentrifuged for 5 minutes. Under these 
conditions contaminating proteins precipitate and migrate to the interface. The 
aqueous upper phase was removed, phenol/chloroform extracted a second time 
and any phenol residues removed by extraction with an equal volume of 
chloroform. The aqueous phase was transferred into a fresh Eppendorf tube and 
the DNA precipitated by the addition of 0.1 volumes of 3M NaAc pH 5.2 and 2 
volumes of absolute ethanol. This was either incubated at -70 0C for 10 minutes 
or overnight at -20 0C. The DNA was then collected by microcentrifugation for 
10 minutes, the pellet washed in 70% ethanol, dried under vacuum and 
resuspended in TE buffer. 
2.4.2 Preparation of DNA 
2.4.2.1 Preparation of P.falciparum DNA: P.falcipamm parasites were 
cultured in vitro by a laboratory technician following the method of Trager and 
Jensen, (1976) later modified by ZoIg et aL, (1982). 
Harvested parasitised red blood cells, lOOmI at approximately 10% 
parasitaemia, were washed in incomplete RPMI medium 10.4gIl RPMI 1640 
(GIBCO), 6.870 N-tris [Hydroxymethyl] methyl-2-aminoethanesulfonic acid, 2g/l 
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glucose, 50mg/I gentamicin sulphate, 2.250 NaHC0 31  pH 7.25) and collected by 
centrifugation, using a benchtop centrifuge, at 3,500rpm for 15 minutes at 4 0C. 
This step was repeated twice and the cells resuspended in 1.5 volumes of 
incomplete medium containing 0.14% saponin. This was incubated at room 
temperature for 5 minutes in order to lyse the red blood cells. 
The released parasites were then collected by centrifugation, washed in 
incomplete medium as before, resuspended in 9m1 of lx SSC and lysed by the 
addition of 2ml of 20% sodium lauroyl sarcosine. The preparation was made up 
to 22m] with lx SSC, 20.9g of CsC1 and 0.2m1 of lOmg/ml EtBr, and the 
preparation was dispensed into 2 heat sealed tubes. The parasite DNA was then 
banded by caesium chloride gradient ultraceñtrifugation. Ultracentrifugation was 
performed at 180C for 48 hours at 38,000rpm (Ti 50, Beckman) and the DNA 
band collected. The EtBr was removed by extracting the DNA several times with 
an equal volume of water saturated iso-propanol. The DNA solution was then 
dialysed against TE, ethanol precipitated (see method 2.4.1) and resuspended in 
Intl of TE. 
2.4.2.2 Mini-Prep of plasmid DNA: It was often necessary to prepare small 
amounts of plasmid DNA from several clones. 
Single colonies were picked into 5m1 of LB-amp and grown overnight at 
370C with shaking. The bacteria from 1.5ml of the overnight culture were 
pelleted by microcentrifugation for 5 minutes and resuspended in 100j0 of solution 
1 (50mM glucose, 10mM EDTA, 25mM Tris-CI pH 8.0). The cells were then 
lysed by the addition of 200.d of solution 2 (0.2M NaOH, 1% SDS) and after 
mixing by inversion the mixture was incubated on ice for 5 minutes. This was 
followed by the addition of lSOpl of Solution 3 (3M K SM Ac pH 4.8), mixing and 
incubation on ice for 5 minutes. In order to pellet precipitated bacterial proteins 
and DNA the solution was microcentrifuged for 5 minutes and the supernatant 
transferred to a fresh Eppendorf tube. The solution was then extracted once with 
phenol/chloroform (see method 2.4.1) and the DNA precipitated by addition of 
2 volumes of ethanol. The DNA resuspended in 501.d of TE buffer. 
2.4.2.3 Maxi-Prep of Plasmid DNA: Large scale preparations of plasmid 
DNA were prepared using a commercially available kit, QIAGEN, following the 
manufacturer's recommended protocol. 
A single colony was picked into 50ml of LB-amp and grown overnight at 
370C with shaking. The bacteria were pelleted by centrifugation at 3000rpm for 
10 minutes at 40C and the pellet resuspended in 4m1 of buffer P1 (lOOp.gIml 
RNase A, 50mM Tris-HC1, 10mM EDTA, pH 8.0). The cells were lysed by the 
addition of 4m1 of buffer P2 (200mM NaOH, 1% SDS). The suspension was 
mixed and incubated at room temperature for 5 minutes. After the addition of 
4m1 of Buffer P3 (2.55M KAc pH 4.8) and mixing, the solution was centrifuged 
at 11,500rpm (SS-34 rotor, Sorvall) for 30 minutes at 4 0C to pellet the bacterial 
debris. The supernatant was then centrifuged again for 10 minutes to ensure 
removal of all debris. Meanwhile, a QIAGEN Tip 100 column was equilibrated 
with 3m1 of a low salt buffer QBT (750mM NaCl, 50mM MOPS, 15% ethanol pH 
7.0, 0.15% Triton X-100). The supernatant was applied to the column and 
allowed to enter by gravity flow. The column was washed with lOml of a medium 
salt buffer QC (1.OM NaCl, 50mM MOPS, 1.5% ethanol pH 7.0) and the DNA 
eluted with Sml of a high salt Buffer QF (1.25M NaCl, 50 mM MOPS, 15% 
ethanol pH 8.2). DNA was precipitated at room temperature with 0.7 volumes 
of isopropanol for 10 minutes and pelleted by centrifugation at 12,000rpm (SS-34 
rotor, Sorvall) for 30 minutes at room temperature. The DNA was washed with 
1 ml of 70% ethanol, air dried and dissolved in 20Osl of TE buffer. 
2.4.2.4. Preparation of DNA from Phage Lambda: The method used was 
essentially that described by Grossberger (1987). 
A fresh plaque was picked into 0.3 ml of adsorption buffer (10mM MgCl 2  
and 10mM CaCl2)  and incubated at 370C for 10 minutes with 0.2ml of an 
exponential culture of Y1090, grown in LB supplemented with 0.4% maltose. 
Following addition of LB medium containing 10mM MgCl2 and 0.1% glucose 
(lOml) incubation continued with rotation overnight at 37 0C at a 450 incline. 
Bacteria and bacterial debris were pelleted by centrifugation at 3000rpm for 10 
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minutes at 40C and the supernatant was then spun, at 27,000rpm (AH-627 rotor, 
Sorvall) for 2 hours at 40C, to pellet phage. The phage were resuspended in 
39041 of phage buffer and 10111 of 20mg/mi proteinase K added. This was 
incubated at 370C for 2 hours. The phage suspension was then phenol/chloroform 
extracted, ethanol precipitated (see method 2.4. 1) and the DNA dissolved in 200 41 
of TE buffer. 
2.4.3 Estimation of DNA Concentration 
The concentration of DNA in solution was estimated by measuring its 
absorbence at 260nm in a spectrophotometer. It was assumed that an optical 
density (OD)260 of 1.0 is equivalent to a concentration of 50sg/m1 for double 
stranded DNA and 35pg/ml for oligonucleotides (17mer). 
2.4.4 Agarose Gel Electrophoresis 
2.4.4.1 Mini- and midi-gels: Agarose (1%(w/v)) mini- and midi-gels were 
used to check the integrity of DNA and to analyze restriction enzyme digests. 
They were prepared and run in lx TBE buffer with EtBr included in the gel and 
buffer at a concentration of 0.5 sg/m1. The appropriate amount of DNA was 
mixed with 0.1 volumes of loading buffer (95% formamide, 20mM EDTA pH 8.0, 
0.05% bromophenol blue, 0.05% xylene cyanol) and loaded into the submerged 
gel. Electrophoresis was carried out at 120V and the DNA binding EtBr 
visualised by short wave-length ultra violet (UV) light and photographed. 
2.4.4.2 Horizontal maxi-gels: Maxi-gels were used to fractionate enzyme 
restricted genomic DNA prior to blotting and probing. Agarose (1%(w/v)) gels 
were prepared and run in lx TAB buffer with EtBr included at 0.54g/ml in the 
gel and buffer. Samples were mixed with 0.1 volumes of loading buffer and 
electrophoresis was carried out overnight at 70V. The gel was not submerged in 
buffer but connected to it at either end by cloth wicks and the buffer tanks were 
connected by a salt bridge. DNA was visualised by short wave-length UV light 
and the gel photographed. 
2.4.4.3 Pulsed field gel electrophoresis: Pulsed field gel electrophoresis of 
parasite DNA was performed by Michael Goman as described by Ridley et at 
(1991) and Southern blotted as described by Delves a at (1989). 
2.4.5 DNA Molecular Weight Markers 
In order to estimate the size of DNA fragments 3 V of DNA markers were 
loaded adjacent to the DNA samples on agarose gels. The standards, a Hind III 
digest of AcT857 (Boehringer Mannheim) consisted of the following sized 
fragments (bp): 23,130; 9,416; 6,562; 4,368; 2,322; 2,027; 564 and 125. 
2.4.6 Photography 
Ethidium bromide stained DNA was visualised on a UV transilluminator 
(UVP) using short wave-length UV light. A photograph of the gel was produced 
by exposing it to Polaroid 667 professional film. 
2.4.7 Southern Transfer 
2.4.7.1 Dry Blot: This method was used to transfer DNA from mini- and 
midi-gels onto Hybond-N membrane (Amersham) prior to probing with specific 
DNA sequences (Southern 1975). 
The agarose gel containing the fractionated DNA was soaked in 
denaturation solution (0.5M NaOH, 1.5M NaCI) for 2x 15 minutes and then 
transferred into neutralization solution (1M NH 4Ac, 0.02M NaOH) 2x 20 minutes. 
The gel was then placed onto a clean glass plate and overlaid with a piece of 
Hybpnd-N membrane and 3 sheets of blotting paper all pre-wetted in 
neutralization solution. Onto this was placed 3 sheets of dry blotting paper, a 
stack of paper towels, a glass plate and a weight. After transfer for 4-15 hours, 
the membrane removed, rinsed in 2x SSC and air-dried. The membrane was then 
placed DNA side down on a UV transilluminator and exposed to short wave-
length UV light for 4 minutes to cross link the DNA to the membrane. The 
membrane was then ready for prehybridization and probing (method 2.4.9). 
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2.4.7.2 Wet Blot: This method was used to transfer DNA from maxi-gels 
onto Hybond-N membrane prior to probing. Prior to denaturation and 
neutralization solution treatment, as described for dry blotting, the agarose gel was 
soaked in 0.25M HCl for 10 minutes in order to partially depurinate the DNA. 
The gel was then rinsed in lOx SSC and the blot set up. The gel was placed on 
a paper wick, connected at either end to a reservoir containing lOx SSC, overlaid 
with a Hybond N membrane and 3 pieces of blotting paper all cut to size and 
prewetted in lOx SSC. Onto this was placed 3 sheets of dry blotting paper, a 
stack of paper towels, a glass plate and a weight. Exposed areas of the paper 
wick were covered with cling-film in order to minimize evaporation and to ensure 
the flow of lOx SSC was only through the blot. After overnight transfer the 
membrane was removed and processed as described for the dry blot. 
2.4.73 Dot Blotting: Cut plasmid DNA or P.falcipamm genomic DNA was 
appropriately diluted in TE, denatured by heating to 95 0C for 5 minutes and left 
on ice for at least 2 minutes. lOpl samples were spotted onto Hybond-N in 2 pl 
aliquots and allowed to dry between application of each aliquot. The membrane 
was then placed on filter paper pre-wetted with denaturation solution (1.5M NaCl, 
0.5M NaOH) for 1 minute , and then transferred onto filter paper pre-wetted with 
neutralization solution (1.5M NaCl, 0.5M Tris-HCI pH 7.2) for 3 minutes. The 
filter was then air-dried and UV irradiated for 4 minutes DNA side down. The 
membrane was then incubated in prehybridization buffer and hybridised to the 
appropriate probe as described (2.4.9). 
2.4.8 Radioactive Labelling of DNA 
2.4.8.1 Random Priming: This method was used for labelling, to a high 
specific activity, double stranded DNA fragments (Feinberg and Vogelstein, 1983). 
The method utilizes Klenow, the large fragment of E.coli DNA polymerase I, 
which has 5'-3' polymerase activity. A mixture of random DNA hexanucleotides 
are used to prime the DNA and the complementary strand synthesized from the 
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3'OH termini of the primers with the incorporation of radiolabelled dNTP. 
The method uses oligo labelling buffer (OLB) which contains nucleotides 
and random primers. The buffer is prepared as follows: SOj.sl of solution A 
(1.25M Tris-HC1 pH 8.0, 125mM MgC12, 25mM -mercaptoethanol, 0.5mM of 
each of dGTP, dflP, dCTP/dATP), mixed with 125 VI of solution B (2M HEPES 
buffer pH 6.6) and 75pl of solution C (random hexanucleotides (Pharmacia) 
0D260=90 in TE). This was stored at -200C and thawed as required. 
Approximately lOOng of DNA in TB, made up to a volume of 7.5pJ with 
ddH20, was denatured by boiling for 2 minutes, collected by spinning in a 
microfuge for 5 seconds and incubated on ice for a few minutes. To this was 
added 11.4pd of OLB, 2j11 of 10mg/mI BSA, 30p.Ci of [a-32P] dATP/[a-32P] dCTP 
(Amersham) and 1 unit of Klenow fragment (Pharmacia). This was incubated at 
room temperature, in a lead pot, for 4-15 hours and the unincorporated 
nucleotides separated from the labelled DNA by chromatography as described in 
the next section. 
2.4.8.2 Purification of labelled double-stranded DNA: This was achieved by 
passing the labelling reaction over a sephade* G-50 column. The column was 
made by packing a plugged imi plastic syringe with sephadex G-50 prepared in 
TES buffer (10mM Tris-HCI pH 7.5, 1mM EDTA, 100mM NaC1). The column 
was centrifuged at 1000rpm for 4 minutes, equilibrated with lOOisl of TES and 
centrifuged as before. The total volume of the labelling reaction was made up to 
100 jil with TES buffer, applied to the column, centrifuged as before and the 
labelled DNA collected in an eppendorf. A further lOOp.l of TES buffer was 
applied to the column, centrifuged and the eluted second fraction of labelled 
DNA collected. The 2 fractions of probe were then pooled and boiled for 5 
minutes prior to use. 
2.4.83 Labelling of oligonucleotides: This method was used to label the 5' 
end of oligonucleotides with y-321? dATP in a kinase reaction. T4 polynucleotide 
kinase catalyses the transfer of an ATP y-phosphate to a 5'OH terminus of DNA. 
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The labelling reaction consisted of 2jsl of 20ngIsl oligonucleotide in ddH 20 
(synthesized by OSWEL DNA service, University of Edinburgh), 101.sCi y- 32P 
ATP (Amersham), 2sl of lOx kinase buffer (500mM Tris-HC1 pH 7.6, 100mM 
MgC12, 50mM Dfl, 1mM spermidine, 1mM EDTA) and 2U T4 polynucleotide 
kinase. The total reaction volume was made up to 20pl with ddH 20, incubated 
at 370C for 1 hour. These conditions ensured a molar excess of oligonucleotide 
over ATP and resulted in little, if any, unincorporated nucleotide. The 
reaction mix could therefore be used directly without further purification of the 
labelled oligonucleotide. 
2.4.9 DNA hybridisation conditions 
All hybridisations were performed in a hybridisation oven (HB.1 Techne). 
2.4.9.1 Hybridisation with random labelled DNA probes: All Southern 
blots, northern blots and filters, in the course of this study, were probed for 
homologous DNA sequences, and hybridisation was performed under stringent 
conditions throughout. - 
Prehybridisation was carried out in 10-20m1 of 0.5M sodium phosphate 
(Na2HPO4/NaH2PO4 pH 7.5), 7% SDS at 65 0C for 1 hour. The boiled, 
denatured probe was then added and hybridisation continued overnight. The next 
day non-specific bound DNA was removed by washing the membrane stringently 
in 0.2x SSC, 0.1% SDS at 65 0C (4 x 15 minutes). Filters were then placed in a 
heat-sealed plastic bag ("Seal-a-Meal") and autoradiographed (method 2.4.10). 
2.4.9.2 Hybridisation with oligonucleotides: Hybridisation with 
oligonucleotide probes was performed under less stringent conditions, due to the 
nature of the probes. 
Filters were prehybridised in 10-20 ml of hybridisation solution (6x SSC, 
500.sgIm1 heparin, 0.1% SDS, 0.1% sodium pyrophosphate) for 30 minutes or 
more at 370C. The probe was then added and hybridisation continued for 2-15 
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hours. The filters were washed in 6x SSC, 0.1% SDS, 3 x 10 minutes at 37 0C 
using approximately 50 ml of solution per wash. Filters were then placed in a 
heat-sealed plastic bag ("Seal-a-Meal) and autoradiographed (method 2.4.10). 
2.4.10 Removal of Probes from DNA Blots 
Prior to reprobing, blots were stripped. Filters were incubated at 450C for 
30 minutes in 0.4M NaOH and then in neutralization solution (0.1x SSC, 0.1% 
SDS, 0.2M Tris-CI pH7.5) for 15 minutes. The filter was then autoradiographed 
in order to check complete removal of the probe. 
2.4.11 Autoradiography 
This was performed using CRONEX 4 X-ray film, pre-flashed for 
probed filters, in a cassette containing intensifying screens. The cassettes 
containing 32P probed fiters were stored at -70 0C while those containing 35S 
labelled gels were stored at room temperature. After the appropriate length of 
time the film was developed using a X-O'GRAPH Xl automatic X-ray film 
processor. 
2.4.12 Densitometry 
Densitometiy of autoradiographs was performed at 550nm using a dual 
wavelength scanner CS-930 (Shimadzu) linked to a data recorder (DR-2). 
2.4.13 Scintillation 
Prior to scintillation 3m1 of Ecoscint A (National Diagnostics) was added 
to the sample and mixed. Liquid scintillation was performed in a Beckman LS 
7000 scintillator set to count 32P. 
2.4.14 DNA Restriction 
Restriction endonucleases were supplied by Boehringer Mannheim and 
reactions were performed in the appropriate buffer (Table 2.5) according to the 
manufacturers' recommendations (Table 2.6). In general, 3-10U of restriction 
endonuclease were used per sg of DNA and incubated for 2-15 hours at the 
recommended temperature usually 37 0C. 
Table 2.5: Composition of the Boehringer Mannheim incubation buffers 
Buffer component 
Final concentration in mM (1:10 diluted 
set buffer)  
A B L M H 
Tris acetate 33 - - - - 
Tris-HCI - 10 10 10 50 
Magnesium acetate 10 - - - - 
MgC12 - 5 10 10 10 
Potassium acetate 66 - - - - 
NaCl - 100 - 50 100 
Dithioerythritol - - 1 1 1 
Dithiothreitol 0.5 - - - - 
-mercaptoethano1 - 1 - - - 
pH at 370C 7.9 8.0 7.5 7.5 7.5 
Table 2.6: Percentage activity in the 5-buffer system, optimal buffer shown in bold. 
Enzyme A B L M H 
AccI 100 0-10 10-25 0-10 0-10 
BamHI 100 100 75-100 100 25-50 
BglTI 100 100 25-50 100 100 
Dral 100 75-100 100 100 50-75 
EcoRI 100 100 25-50 50-75 100 
Hindll 100 100 25-50 100 50-75 
HindIII 50-75 100 25-50 100 10-25 
KpnI 75-100 0-25 100 25-50 0-10 
ScaT 0-10 100 10-25 75-100 100 
SmaI 100 0-10 0-10 0-10 0-10 
SspI 75-100 100 10-25 100 100 
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2.4.15 Purification of DNA Fragments from Agarose 
2.4.15.1 Phenol extraction: DNA was routinely purified from agarose by 
phenol extraction. The agarose containing the DNA was excised from the gel, 
placed into an eppendorf tube and the gel slice broken up using a needle. Phenol 
(lOOpl) was added, the mixture vortexed for a few seconds and then frozen at - 
700C. The mixture was microcentrifuged for 10 minutes and the aqueous upper 
phase, containing the DNA, transferred into a clean Eppendorf tube. This 
solution was then phenol/chloroform extracted, the DNA precipitated by the 
addition of sodium acetate and ethanol, (method 2.4.1) and dissolved in lOsl of 
TE buffer. 
2.4.15.2 Geneclean II Kit (BlO 101 Inc.): DNA contained in agarose gel 
slices was also purified using a Geneclean II Kit according to the manufacturers' 
protocol. The gel slice was dissolved at 55 0C in 2.4 volumes of NaT solution and 
1 volume of TBE modifier solution. Glassmilk (a suspension of silica) was then 
added at SpA per 5jsg of DNA plus li.sl for every additional 0.5isg DNA and the 
solution incubated at 40C for 5 minutes. The Glassmilk was pelleted by 
microcentrifugation for 5 seconds, washed 3 times in 0.5m1 of NEW WASH and 
eluted from the glassmilk in a equal volume of TE at 550C for 5 minutes. The 
glassmilk was spun down (microfuge, 30 seconds) and the supernatant containing 
the DNA recovered. 
2.4.16 Phosphatase Treatment of Cut DNA 
In order to prevent the religation of the compatible ends of digested 
plasmid, linearized DNA was treated with CIP which removes the 5'-phosphate 
residues from DNA. 
After digestion of the plasmid with the appropriate restriction 
endonuclease, 1U of CIP (Boehringer Mannheim) was added and incubated at. 
370C for 30 minutes. To this was added 0.1 volumes of 250mM EGTA pH 8.0 
and the solution incubated at 70 0C for 10 minutes. 
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2.4.17 Filling-in of Cut DNA 3' Recessed Ends 
If necessary, 3' recessed ends were end-filled in order to create blunt ends. 
To 2Op.l of cut DNA was added Spl of dNTP solution (0.2mM each of dCTP, 
dATP, dYFP, dGTP, 500mM Tris-HC1 pH 7.8, 50mM MgCl 2, 100mM 13-
mercaptoethanol) and 1U of Klenow fragment (Boehringer Mannheim). This was 
incubated at room temperature for 30 minutes. The solution was then 
phenol/chloroform extracted, ethanol precipitated (method 2.4.1) and resuspended 
in lOpI of YE buffer. 
2.4.18 Ligation of DNA 
Vector DNA (SOng) and insert DNA were cut with suitable restriction 
endonucleases (method 2.4.14), and if necessary treated with phosphatase (method 
2.4.16), end-filled (method 2.4.17) or purified (method 2.4.15). Ligation of insert 
to vector was performed at a ratio of approximately 3 molecules of insert to 1 
molecule of vector. To the mixture of vector and insert DNA, in TE, was added 
lj.sl of lOx ligase buffer (500mM Tris-HC1 pH 7.5; 100mM MgCl 2; 100mM DTI; 
100mM ATP), Hi of T4 DNA ligase (Boehringer Mannheim) and the total 
reaction volume made up to lOpl with ddH 20. The reaction was incubated at 
150C overnight and then diluted 5-fold with ddH20 prior to E.coli transformation 
(2.4.19). 
2.4.19 Preparation of Competent Cells 
A single colony of the appropriate E.coli strain was picked into Sml of LB 
and grown overnight at 370C with shaking. The following day the culture was 
diluted 50-fold in LB and incubation continued until the culture reached mid-
logarithmic growth, (approximately 2 hours). The culture was incubated on ice 
for 15 minutes and then the bacteria were collected by centrifugation, then 
pelleted at 2,500rpm for 15 minutes at 4 0C and resuspended in ice-cold 0.1M 
MgC12 at half the original culture volume. The cells were then collected again 
and resuspended 1/20 in ice-cold 0.1M CaC1 2 at 1/20 original culture volume. The 
cells were incubated on ice for 30 minutes. They could then be stored at -70 0C 
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after the addition of glycerol to 15% v/v or could be used the same day. 
2.4.20 Transformation of E.coli 
Competent cells (lSoisl)  were mixed with either 25jsl of a 5-fold diluted 
ligation reaction or 20ng of uncut plasmid DNA. The cells were then incubated 
on ice for 30 minutes, heat shocked at 42 0C for 3 minutes and incubated on ice 
for a further 30 minutes. To each transformation, imI of LB was then added and 
the cells incubated at 370C for 1 hour. Cells were then plated out on appropriate 
selective LB agarose and incubated overnight at 37 0C. 
2.4.21 Colony Screening 
The procedure used was that described by Buluwela et al. (1989) in which 
colony lysis, DNA denaturation and DNA fixation to the membrane is carried out 
in a single step. 
Bacterial colonies were replica plated onto a master LB-amp and a LB-
amp plate overlaid with Hybond-N (Amersham). The plates were incubated 
overnight at 370C and the following day the filters were removed and placed for 
2 minutes, colony side up, onto filter paper pre-wetted with denaturation solution 
(5% SDS, 2x SSC). The filters were removed, microwaved on a high setting for 
1 minute in order to lyse the cells, denature and fix the DNA to the membrane. 
They were then rinsed in 2x SSC to remove bacterial debris. Filters were then 
ready to be pre-hybridised and probed (method 2.4.9). Positive signals were then 
identified and the appropriate colony on the master plate picked for further 
analysis. 
2.4.22 Preparation of Plating Cells 
A single colony of E.coli strain Y1090 was picked into 5m1 of LB-amp and 
grown overnight at 370C with shaking. The following day the culture was diluted 
25-fold in LB supplemented with 0.2% maltose and 10mM MgSO4. The cells 
were grown at 370C with shaking for 3 1/2 hours and then collected by 
centrifugation at 3,000rpm for 10 minutes. Cells were resuspended in 10mM 
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MgSO4 and stored at 40C for up to 2 weeks. 
2.4.23 Plating of Phage Lambda 
Aliquots (lOOpl) of phage lambda suitably diluted in phage buffer (3,000-
5,000 pfu per plate), were incubated with lOOpi of Y1090 plating cells at 37 0C for 
10 minutes to allow phage attachment, then mixed with 2.5 ml of molten BBL and 
poured onto a dry BBL plate. Plates were then incubated at 37 0C overnight 
prior to screening with DNA probes (method 2.4.25) or at 42 0C for 3 1/2 hours 
prior antibody screening. 
2.4.24 Preparation of Lysogens 
In order to prepare -galactosidase fusion protein encoded by a Agtll 
recombinant, it is necessary to express the Agtll clone as a lysogen in E.coli. The 
method used to prepare lysogens was that described by Huynh et al., 1985. 
A single colony of E.coli strain Y1089 was picked into Sml of LB-amp and 
grown overnight at 370C. The following day 100p1 of this culture was used to 
inoculate a 5m1 culture of LB-atnp supplemented with 0.2% maltose. The cells 
were grown at 37 0C until the culture reached mid-log growth, approximately 
8x107 bacteria/mi. A SOpl aliquot of cells were infected with the Agtll 
recombinant phage at a multiplicity ratio of 1:5 of bacteria to phage and 
incubated at room temperature for 10 minutes then plated out (method 2.4.23). 
Plates were incubated overnight at 30 0C. Single colonies were tested for 
temperature sensitivity by replica streaking onto two LB-amp plates and 
incubating one plate at 30 0C and the other at 420C overnight. Colonies which 
only grew at 300C were assumed to be lysogens. 
2.4.25 Plaque Screening 
The phage library was plated out and incubated overnight at 37 0C. The 
following day the plates were overlaid with a Hybond-N filter for 1 minute and the 
prientation of the filter marked using a needle. The filter was then removed and 
placed, DNA side up, onto filter paper pre-wetted with denaturation solution 
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(1.5M NaCl, 0.5M NaOH) for one minute. The filters were then transferred onto 
filter paper pre-wetted with neutralization solution (1.5M NaCl, 0.5M Tris-HC1 pH 
7.2) for 3 minutes. The neutralization step was repeated and the membrane 
filters rinsed in 2x SSC. The filters were then air dried and exposed DNA side 
down to short-wave UV light for 4 minutes in order to cross-link the DNA to the 
filter. The membranes were then ready for pre-hybridisation and probing. 
Positive clones were identified and the corresponding plaque picked into imI of 
phage buffer or into adsorption buffer. 
2.4.26 DNA Sequence Determination 
DNA sequence determination was performed by the chain termination 
method of Sanger et al. (1977), using a Sequenase version 2.0 kit (USB), based 
on T7 DNA polymerase. The primers used were synthetic 17-mer 
oligonucleotides prepared by the University of Edinburgh OSWEL DNA service. 
Approximately 51ig of double stranded DNA in 201.il TE was incubated 
with 5 V of denaturation solution (1M NaOH, 1mM EDTA) for 5 minutes at room 
temperature and then spun dialysed through a Sepharose-CL613 column at 200xg 
for 4 minutes. The spin column was prepared in a 0.5m1 Eppendorf tube, pierced 
with a 210 syringe needle, containing 20pJ of water-washed 200 micron glass 
beads and 20Osl  of Sepharose-CL613 prepared in T0.1E (0.1mM EDTA, 10mM 
Tris-HCI pH 8.0). Prior to use the column was spun at 1000rpm for 4 minutes in 
a 15m] Corex tube. 
M aliquot (7pJ) of the spun dialysed, denatured template was used for 
subsequent sequencing reactions. It was added to 21il of reaction buffer (200mM 
Tris-HCI pH 7.5, 100mM MgCl2, 250mM MCI), mixed with ipi of primer 
(lOng/pI) and the annealing reaction performed at 37 0C for 15 minutes. To this 
was added 'R1  of 0.1M DTT, 2R1  of labelling mix (0.375 pM each of dGTP, dTTP, 
dCTP), lpl  (lOp.Ci) [u-35S]dATP and 2 units of Sequenase version 2. The 
solution was mixed thoroughly and incubated at room temperature for 5 minutes. 
Then 3.5p.l of the solution was transferred into 4 tubes, pre-warmed to 37 0C, 
containing 2.sl of a specific termination mix G,T,A or C (50mM NaCl, 80pM 
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dGTP, 80pM dflP, 80sM dATP, 801sM dCTP and 81sM of either ddGTP, 
ddflP, ddATP or ddCTP). The termination reaction was performed for 5 
minutes at 370C and then 4pl of stop solution (95% formamide, 20mM EDTA, 
0.05% Bromophenol Blue, 0.05% Xylene Cyanol FF) added. Samples were boiled 
for 3 minutes prior to loading, 2p1 per well, into a 6% polyacrylamide gel. 
2.4.27 Sequencing Gel Electrophoresis 
Sequencing reactions were separated on a 380mm x 170mm x 0.3mm, 6% 
polyacrylamide gel (60ml of: 6M Urea, 5.7% acrylamide, 0.3% bisacrylamide, lx 
TBE polymerized by the addition of 360p.l  of 10% ammonium persulphate and 
SOjsl of TEMED). Samples (2isl)  were loaded in a sharkstooth comb well and 
electrophoresis was performed at 40W constant power. Gels were fixed in 10% 
glacial acetic acid, 10% methanol for 15 minutes, dried under vacuum at 80 0C and 
autoradiographed (method 2.4.10). 
2.4.28 DNA Sequence Data Analysis 
Sequence was analysed using the university computing facilities. Compiling 
of data, analysis and manipulation was performed using the University of 
Wisconsin Genetics Computer Group Sequence Analysis Software Package 
Version 7.1 (Devereux a al., 1984). Several data bases were available for 
consultation including GenBank, BMBL and Vecbase. 
2.4.29 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction, is a powerful technique which can be used 
to amplify specific DNA sequences in vitro. The double stranded DNA is first 
denatured, then specific primers corresponding to each end of the target sequence 
annealed, and the sequence extended. This cycle is repeated as much as 40 times 
and has the potential of amplifying the target sequence as much as 10 9. Due to 
the high temperature required for the denaturation step a thermostable DNA 
polymerase is used called Taq polymerase which was isolated from Therinus 
aquaticus. 
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PCR was preformed in 0.5m1 Eppendorf tubes. Each reaction contained 
lOpi of each primer at 1RM, 2isl of 40mM dNTP solution (a mixture of 10mM 
dGTP, dATP, dTTP, dCTP), lOsl of lOx Taq polymerase buffer (500mM KC1, 
100mM Tris-HC1 pH8.3, 15mM MgC12, 0.01% gelatin), ddH20 to a total reaction 
volume of 991±1 and li.sl  of lU/pd Taq polymerase (Cetus). The reaction mixture 
was overlaid with lOOp.l of paraffin oil and the lid pierced with a syringe needle. 
The PCR was performed using a Techne PHC-2 Dri-Block according to the 
program shown (Table 2.7). 
Table 2.7: Polymerase Chain Reaction Programme. 
Cycle No. of loops Temperature ( °C) Duration 
(minutes) 
1 1 95 5 
2 1 92 5 
45 1 
70 1 
3 1 92 3 
40 .1 
70 1 
4 27 92 1 
40 1 
70 1 
5 1 70 5 
2.5 RNA METHODS 
2.5.1 Preparation of mRNA 
Total RNA, prepared from asychronous P.falciparum isolate Ki using the 
method of Chomczynski & Sacchi (1987), was provided by Robert Ridley. 
Purification of mRNA was performed using an oligo (dT)-cellulose column 
using the method described by Sambrook a aL, 1989. Oligo (dT)-cellulose (0.2g) 
(Promega) was suspended in 0.1M NaOH and the column prepared in a Pasteur 
pipette plugged with sterile glass wool. The column was washed with 3 column 
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volumes (3m1) of sterile ddH2O and then with lx column-loading buffer (20mM 
Tris-Ci pH7.6, 0.5M NaCl, 1mM EDTA pH 8.0, 0.1% sodium lauryl sarcosinate) 
until the pH of the effluent was less than 8.0. RNA (lOOsg) was dissolved in 
200pJ of sterile ddH20 and heated to 65 0C for 5 minutes. The solution was then 
quickly cooled to room temperature. An equal volume of 2x loading buffer was 
added, the solution applied to the column and the eluate collected. Once all the 
RNA solution had entered the column lml of lx loading buffer was added and the 
eluate collected. The eluates were pooled, heated to 65 0C for 5 minutes, cooled 
to room temperature and reapplied to the column. The column was then washed 
with lOml of lxloading buffer. The poly(A) RNA was eluted with 3ml of sterile 
elution buffer (10mM Tris-Cl pH 7.6, 1mM EDTA pH 8.0, 0.05% SDS) and 
collected in 0.5m1 fractions. The absorbance of each fraction at 260nm was 
measured and the fractions containing RNA pooled. In order to purify the 
po ly(A)+ further a second round of chromatography was performed similarly to 
before. The RNA solution was heated to 65 0C for 3 minutes, cooled quickly to 
room temperature, the concentration of NaCl adjusted to 0.5M and a second 
round of chromatography carried out. 
The eluted poly(A) + RNA was precipitated by the addition of 1/10 volume 
of 3M NaAc pH 5.2, 2.5 volumes of ice-cold ethanol and stored on ice for 1 hour. 
The RNA was pelleted by centrifugation at 4 0C for 15 minutes at 10,000g and 
washed with 70% ethanol. The pellet was then air-dried and resuspended in 20.sl 
of ddH20. The total yield of poly(A) RNA was approximately ljsg. 
2.5.2 Gel Electrophoresis 
RNA was fractionated in a 1.4% w/v agarose gel prepared and run in lx 
MOPS buffer (25mM MOPS, 5mM NaOAc, 1mM EDTA, pH 7.0) containing 
EtBr at 0.5sg/ml and 3% formaldehyde. The RNA in solution was mixed with an 
equal volume RNA loading buffer (2x MOPS buffer, 50% formamide, 10% 
formaldehyde) and heated to 65 0C for 5 minutes and immediately cooled on ice. 
After the addition of 0.25 volumes of normal sample buffer (0.25% Bromophenol 
Blue, 0.25% Xylene C yanol, 30% glycerol) the sample and an aliquot of RNA 
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markers were loaded. The gel was run overnight at 50V and photographed. 
2.53 RNA Molecular Weight Markers 
In order to estimate the size of RNA fragments 10kg of RNA markers 
were loaded adjacent to the RNA samples on agarose gels. The standards 
(Mannheim Boehringer consisted of the following markers (KB) 7.4, 5.3, 2.8, 1.9, 
1.6, 1.0, 0.6, 0.4, and 0.3. 
2.5.4 Northern Blotting 
The RNA gel was first rinsed .2 x 15 minutes in lOx SSC. The gel was 
placed on a paper wick connected at either end to a reservoir containing lOx SSC, 
overlaid with a HybondN+  membrane and 3 pieces of blotting paper all cut to 
size and prewetted in lOx SSC. On to this were placed 3 sheets of dry blotting 
paper, a stack of paper towels, a glass plate and a weight. Exposed areas of the 
paper wick were covered with cling-film in order to minimize evaporation and to 
ensure the flow of lOx SSC was only through the blot. After overnight transfer 
the membrane was removed, placed RNA side up on filter paper pre-wetted with 
0.05M NaOH for 5 minutes and rinsed in 2x SSC. The filter was then 
prehybridised and probed at 65 0C essentially as described in section 2.4.9.1 and 
washed 3 x 10 minutes with lx SSC, 0.1% SDS. 
2.5.5 Removal of Probes from Northern Blots 
When necessary, northern blots were stripped prior to reprobing. A 
solution of boiling 0.1% (w/v) SDS was poured over the blot and allowed to cool 
to room temperature. The filter was then autoradiographed to check complete 
removal of the probe. 
2.6 PROTEIN METHODS 
2.6.1 Indirect Immunotluorescence Assay (IFA) 
Thin blood smears were prepared by a laboratory technician. A lOOpJ 
59 
aliquot of infected blood with a parasitaemia of 5-10% was spread onto a 
microscope slide, dried overnight at room temperature and either used 
immediately or stored at -70 0C. Slides were fixed in acetone for 5 minutes, 
allowed to air thy and then divided into 12 squares using nail varnish. On each 
square was placed 20sl of the appropriately diluted antibody, in PBS. Slides were 
incubated in a moist chamber for 1 hour then aspirated; washed twice in PBS and 
once in ddH20, 5 minutes per wash. Slides were then air dried and incubated 
with 200 of the manufacturer's recommended dilution of the second conjugated 
antibody per square, either a Fluorescein isothiocyanate conjugate of preadsorbed 
polyvalent anti-mouse immunoglobulin (FITC-anti IgG Sigma) or a Rhodamine 
isothiocyanate conjugate of preadsorbed anti-rabbit immunoglobulin (RITC-anti 
IgG Sigma). In addition, parasite nuclei were counterstained with DM1. In order 
to do this, DAPI was included in the second antibody solution at a final 
concentration of 5 sgIml. Slides were then incubated and washed as before. 
When nearly dry, they were mounted in Citifluor (City University, London). The 
cells stained with FITC were counterstained, if necessary, with Evans Blue (BDH), 
0.1% in PBS, for 5 minutes prior to mounting. The slides were then examined by 
fluorescence microscopy (Leitz). 
2.6.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein extracts prepared from bacteria and parasites were fractionated by 
SDS-PAGE (Laemmli (1970)) with a discontinuous buffer system. Both large gels 
(BIORAD) 160mm x 180mm x 1mm, and mini-gels (HOEFER) 80mm x 70mm 
x 0.75mm were used in the course of this study and gel mixtures were prepared 
according the recipes given in Table 2.8. Large gels were prepared with a 160mm 
resolving gel and a 20mm stacking gel while mini-gels were cast with a 50mm 
resolving gel and a 10mm stacking gel. 
The resolving gel was poured and overlaid with a small volume of water 
saturated butanol. After gel polymerization the overlay was removed and the gel 
surface rinsed with ddH 20. The stacking gel was then poured and the 
appropriate comb inserted. Once the gel had polymerised the comb was removed 
and the wells rinsed with ddH20. The gel was then ready for loading. 
Protein samples were prepared by the addition of an equal volume of 2x 
loading buffer (125mM Tris-HC1 pH 6.8, 4% SDS, 20% glycerol, 10% 13-
mercaptoethanol) and then boiled for 5 minutes prior to loading. Gels were run 
in an electrode buffer (25mM Tris, 192mM glycine, 1% SDS), either at 70V 
overnight for large gels or at 150V for an hour for mini-gels. Separated proteins 
were then either stained with Coomassie or silver (see method 2.6.4) or 
electrophoretically transferred onto a nitrocellulose membrane (method 2.6.5). 
Table 2.8: SDS-PAGE Separating and Stacking gel recipes (sufficient for 2 large 





Final acrylamide concentration 10% 15% 4% 
Acrylamide/bis acrylamide (30:2.67) 20ml 15m1 2.6m1 
ddH20 24m1 29ml 12.2m1 
1.5M Tris-HCI, pH 8.8 15m1 15m] - 
0.5M Tris-HC1, pH 6.8 - - 5.Oml 
10% SIDS 600p.l 600pJ 200pJ 
10% ammonium persulphate 300p.l 300p1 bOOpI 
TEMED 30jsl 301sl 
Total volume j 	60m1 60m1 20ml 
2.6.3 Protein Molecular Weight Markers 
Two ranges of molecular weight markers were used to calibrate SDS-
PAGE gels. Prestained rainbow markers (Amersham) contained myosin (200,000 
blue), phosphorylase b (92,500 brown), BSA (69,000 red), ovalbumin (46,000 
yellow) carbonic anhydrase (30,000 orange), trypsin inhibitor (21,000 green) and 
lysozyme (14,300 magenta) and were used if the gel was going to be blotted. Low 
range size markers (BIORAD) consisted of phosphorylase b (97,400), BSA 
(66,200), ovalbumin (45,000), carbonic anhydrase (31,000), trypsin inhibitor 
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(21,500) and lysozyme (14,400). The markers were prepared in 2x loading buffer. 
For a small gel well, 2sg of each marker protein was loaded, 10.sg per large gel 
well, however, if the gel was silver stained 115 of this amount was used. 
2.6.4 Protein Gel Staining 
2.6.4.1 Coomassie Brilliant Blue (Fixing): Protein gels were stained, in 
order to visualise fractionated proteins, with 0.25% Coomassie brilliant blue R-250 
prepared in water:methanol:glacial acetic acid 5:5:1 for 1 hour at room 
temperature with gentle agitation. Excess stain was removed by destaining the gel 
in water:methanol: glacial acetic acid 5:5:1 until the background was clear. 
Coymassie staining can detect approximately 0.5-1sg protein per band. 
2.6.4.2 Coomassie Brilliant Blue (Non-Fixing): If the protein band was 
going to be used for immunization, the gel was stained under non-fixing 
conditions. After electrophoresis the gel was rinsed with 4 changes of ddH 20 and 
then stained in several volumes of 0.05% Coomassie brilliant blue R-250 prepared 
in water for 10 minutes at room temperature with gentle agitation. The gel was 
washed in several changes of ddH 20 until the desired band was visible. The band 
was then excised using a scalpel. 
2.6.4.3 Silver staining: This is a more sensitive staining technique and can 
detect approximately lOOng protein per band. Gels were soaked in several 
volumes, with 2 changes, of 50% methanol over a period of 1 hour then 
transferred into ddH 20, for 15 minutes and into fresh ddH20 for a further hour. 
The gel was then transferred back into 50% methanol for 15 minutes and into 
fresh 50% methanol every 30 minutes over the next 2 hours. The gel was then 
transferred into ddH20 for 30 minutes. The gel was then stained with solution 
C for 15 minutes. Solution C was prepared by adding 4m1 of solution A (20% 
AgNO3) dropwise, with constant vortexing, to 22.4ml of solution B (0.36% NaOH) 
containing 1.4m1 of 14.8M NH40H and the total volume made up to lOOthl with 
ddH20. The gel was then rinsed with ddH 20 several times, over a period of 15 
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minutes. The silver stain was developed by the addition of 500m1 of solution D 
(0.005% citric acid, 0.019% formaldehyde) until the desired intensity was achieved. 
Further staining was prevented by transferring the gel into 50% methanol. 
2.6.5 Western Transfer 
Proteins separated by SDS-PAGE were transferred onto nitrocellulose 
(Schleicher and Schuell, BASS) or Hybond-C (Amersham) by the method of 
Towbin et aL, (1979). 
The following gel 'sandwich' was assembled in a blotting cassette 
submerged in transfer buffer (25mM Tris, 0.15M glycine, 20% methanol, 0.1% 
SDS) : a Scotchbrite pad, 3 sheets of blotting paper cut to gel size, the gel, a 
nitrocellulose filter cut to size, another 3 sheets of blotting paper and another 
Scotchbrite pad. The cassette containing the gel sandwich was placed, 
nitrocellulose towards the anode, into the transfer chamber (BIORAD). Transfer 
was conducted, in transfer buffer, at 60V for 4 hours or overnight at 30V. Filters 
were then ready to be probed for bound antigen. 
2.6.6 Dot Blotting 
Partially purified protein was also bound to nitrocellulose directly without 
previous separation by SDS-PAGE. Protein solution (1-21Ll) was spotted onto 
squared nitrocellulose (Schleicher and Schuell, BA85) and dried at room 
temperature. 
2.6.7 Detection of Protein Bound to Nitrocellulose 
2.6.7.1 Ponceau S: This stain was used to check western transfer and to test 
samples of eluted fractions spotted onto nitrocellulose for the presence of protein 
after affinity chromatography. 
Ponceau S was prepared as a 0.2% solution in 3% TCA. The 
nitrocellulose filter was incubated in Ponceau S for 10 minutes at room 
temperature with agitation. The filter was then washed in ddH 20 until the 
background was clear. Since Ponceau S staining is not permanent and can be 
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removed by continued washing, filters were often subsequently tested for the 
presence of specific antigens by immunological methods. 
2.6.7.2 Immunological detection of bound antigens: This method was used 
to detect antigens bound to nitrocellulose whether after western blotting or during 
screening of genomic DNA expression libraries. All incubations and washing was 
performed at room temperature with shaking. 
The filter was first incubated in blocking solution (5% fat free milk 
(Marvel) Tris-saline (0.15M NaCI, 10mM Tris-HC1 pH 7.4)) for 30 minutes. 
During this step any bound Ponceau S stain was washed off by the milk and at 
this stage filters could be dried and stored for several months. The filter was then 
incubated in the antiserum, prepared in blocking solution, for 2 hours. Ascites 
fluid and polyclonal rabbit sera were used at dilutions between 1/250 and 1/1000, 
mouse polyclonal sera at dilutions between 1/20 and 1/100 while tissue culture 
supernatant BRIC 155 (kindly provided by M.Tanner) was used at a dilution of 
1/3. The filter was washed, 5-10 minutes per wash, once in Tris-saline then twice 
in Tris-saline plus 0.05% NP40 and again in Tris-saline. The filter was then 
incubated for 2 hours with the appropriate alkaline phosphatase conjugated anti-
IgG second antibody (PROMEGA) diluted 1/7500 in blocking solution. The filters 
were washed as before and the bound second antibody detected using the 
detection system supplied by Promega. For 5m1 of detection solution 33.0 of NBT 
(nitro blue tetrazolium) and 16.50 of BCIP (5-bromo-4-chloro-3-indolyl 
phosphate) were added to 5m1 of alkaline phosphatase buffer (100mM Tris-CI pH 
9.5, 100mM NaCl, 5mM MgCl2) and the solution used immediately. Colour 
development was continued until the desired intensity was achieved. Filters were 
then rinsed in ddH20 and dried. 
2.6.8 Expression Library Screening 
A sheared P.falciparum genomic Agtll expression library (Certa a aL, 
1988) was screened with either McAb 7.7 ascites fluid (Hall et aL, 1983) or a 7.7 
polyclonal serum (Khan, 1990) using the procedure described by Huynh a al., 
(1985). 
The library was plated out at an approximate density of 3,000 plaque 
forming units per plate and incubated for 3 1/2 hours at 420C. The plaques were 
then overlaid with a nitrocellulose filter which had previously been soaked in 
10mM IPTG and dried. The orientation of the filter was marked and incubation 
continued for 3 1/2 hours at 370C. The filters were then removed, blocked and 
probed (method 2.6.7.2) with the appropriate sera. Both the monoclonal and 
polyclonal antibody sera was used at a dilution of 1 in 100. Any identified positive 
signals were aligned with the original plate and the corresponding plaque picked 
into lml of phage buffer. Putative positives were rescreened until plaque pure. 
2.6.9 Purification of Monoclonal Antibody 7.7 
The monoclonal antibody 7.7 (Hall et al., 1983), prior to coupling to 
Sepharose, was purified from ascites fluid by ammonium sulphate precipitation 
and diethyl amino ethyl (DEAE) cellulose ion exchange chromatography. 
2.6.9.1 Ammonium Sulphate Precipitation: Aliquots (total 12m1) of murine 
ascites fluid containing the monoclonal antibody 7.7 were microcentrifuged for 5 
minutes in order to pellet any insoluble material. The supernatants were pooled, 
mixed with 2 volumes of PBS and the pH adjusted to 6.5 with 0.5M Na2HPO4. 
The proteins were precipitated with the addition dropwise of 3 volumes of 
saturated (NH42SO4 to the solution on ice. The solution was then incubated on 
ice a further hour. The solution was centrifuged at 3,000rpm for 30 minutes and 
the pellet was resuspended in enough PBS to dissolve it and then dialysed against 
starting buffer (5mM sodium phosphate pH 8.0) for 24 hours. The dialysed 
material was made up to 12 ml with starting buffer and centrifuged for 15 minutes 
at 2,500rpm prior to application to the DEAE-Cellulose column. 
2.6.9.2 DEAE-Cellulose column preparation and use: The DEAE-Cellulose 
(Whatman DE52) column was prepared as described by Hudson and Hay (1980). 
The column, 2.5cm x 40cm with a bed volume of 150m1, was extensively 
equilibrated with starting buffer (5mM NaPO 4 pH 8.0) until the pH and 
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conductivity of the buffer leaving and entering the column was identical. The 
ammonium sulphate purified antibody was applied dropwise to the column and 
elution was carried out using a convex gradient of increasing ionic strength. This 
was achieved by mixing linearly, in a mixing chamber, 150ml of starting buffer 
(5mM sodium phosphate pH 8.0) and 150m1 of limit buffer (160mM sodium 
phosphate pH 8.0). Fractions (5m1) were collected and the elution profile 
obtained by measuring the 0D280 (see figure 2.1). Samples of every second 
fraction of the IgG peak were analysed by SDS-PAGE and Coomassie staining. 
The fractions containing IgO were pooled. 
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Figure 1 	DEAE-Column Elution Profile 
2.6.10 Monoclonal Antibody 7.7 Affinity Column Preparation 
Purified TgG was coupled to CNBr-activated Sepharose 4B (Pharmacia) 
according to the manufacturer's recommendations. Prior to coupling, the IgG was 
dialysed against coupling buffer (0.1M NaHCO3 pH 8.3, 0.5M NaCl). CNBr- 
activated Sepharose 4B (ig) was swollen in several volumes of 1mM HCI for 15 
minutes and washed in 200m1 of 1mM HCI on a sintered glass G3 filter. All 
subsequent washes were performed similarly on a sintered glass filter with 200m1 
of solution. The Sepharose and dialysed IgG were then mixed at room 
temperature for 2 hours. The Sepharose beads were washed in blocking buffer 
(0.2M glycine pH 8.0) and incubated in blocking buffer for 2 hours at room 
temperature with rotation. The beads were then washed with 0.1M NaAc pH 4.0, 
0.5M NaC1 followed by a wash with coupling buffer. This step was repeated 4 
times in order to remove excess unbound protein. The coupled Sepharose was 
then poured, with a bed volume of 3 ml, at 49C, into a column prepared from a 
plastic 5 ml pipette. The column was then washed with several bed volumes of 
PBS and stored in PBS containing 0.01% azide. 
2.6.11 Preparation of Total Proteins from P.falciparum 
Parasites were released from infected RBCs by saponin lysis and washed 
in incomplete medium as described in section 2.4.2.1. The parasites were pelleted 
by centrifugation at 4,000 rpm for 10 minutes, washed in PBS and resuspended 
in SDS-PAGE loading buffer (method 2.6.2), lOOjsl per ml of original infected 
blood. Samples were boiled for 5 minutes prior to loading 10-15 VI per well. 
2.6.12 Affinity Purification of Exp-2 
Parasites were first released from approximately S x 109 infected RBCs by 
saponin lysis and washed in incomplete medium as described in section 2.4.2.1. 
The released parasites were collected by centrifugation at 4,000rpm for 10 minutes 
and resuspended in 200m1 of ice-cold extraction buffer (1% NP40, 2% sodium 
deoxycholate, 50mM Tris-CI pH 8.0, 5mM EDTA, 5mM EGTA, 5mM 
iodoacetamide, 0.2mM PMSF, protease inhibitors (Sigma) - soybean trypsin 
inhibitor, antipain, leupeptin, chymostatin, pepstatin at 25isgJml)). The mixture 
was stirred for 1 hour at 40C which allowed the protein to be extracted. 
Phenylmethylsulphonyl fluoride (PMSF) was then added to 0.2mM and the 
mixture centrifuged at 27,000rpm (Sorvall, AH627) for 3 hours at 4 0C. 
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First, several column volumes of wash buffer (1% NP40, 0.5% sodium 
deoxycholate, 50mM Tris-CI pH 8.0, 1mM EDTA, 1mM EGTA, 5mM 
iodoacetamide, 0.2mM PMSF) were passed over the column. Then the parasite 
extract was run though once at approximately lSml/hour and then, via the use of 
a pump, circulated over the column overnight. The column was then equilibrated 
with wash buffer overnight. The bound protein was eluted at 6mllhour with wash 
buffer titrated to pH 11.5 with diethylamine which was allowed to enter the 
column until the pH of the eluate was 11.5 before returning to wash buffer pH 
8.0. Samples of imI were collected in microfuge tubes containing 2.sl of 100mM 
PMSF and a small amount of powdered glycine until the pH of the eluate 
returned to 8.0. After elution the column was equilibrated with wash buffer and 
stored in PBS containing 0.01% azide. 
2.6.13 Crude Protein Preparations from igtll Lysogens 
A single colony of the lysogen was picked into 5m1 LB-amp and grown 
overnight at 300C with shaking. The following day the culture was diluted 5-fold 
in LB-amp and incubation continued at 30 0C for 2 hours with shaking. 100mM 
IPTG was then added to a final concentration of 1mM and incubation continued 
for a further 30 minutes at 30 0C. The temperature was then increased to 42 0C 
and after 1 hour the cells were collected by centrifugation at 2,000rpm for 20 
minutes at 40C. Induction was analysed by SDS-PAGE and Coomassie staining. 
2.6.14 Raising Antisera to a P.falciparum Encoded Polypeptide Expressed in pMS 
2.6.14.1 Expression of 3-galactosidase Fusion Proteins: pMS vectors were 
used to express polypeptides in E.coli as fusions with 3-galactosidase 
(Shahabuddin 1992). The chosen DNA fragment was subcloned into the unique 
EcoRI-BamHI sites of pMS1S, pMS2S and pMS3S and the resultant plasmids 
expressed E.coli JM83 (Gough and Murray, 1983). 
A single colony was picked into 5m1 of LB-amp and grown overnight at 
370C with shaking. The following day the culture was diluted 50-fold in LB-amp 
L!I 
and incubated for 1 hour. The cultures were induced by the addition of 2mM 
IPTG and grown for a further 3 hours (determined as being the optimum 
induction time). The cells were then collected by centrifugation at 2,500rpm for 
15 minutes at 40C, resuspended in 1/10 volume of PBS and then frozen at -70 0C. 
A sample of cells (30isl)  was checked for induction by SDS-PAGE and western 
blotting analysis. 
2.6.14.2 Affinity Purification of a -gaIactosidase fusion protein: Cells 
expressing the foreign polypeptide were cultured in lOOmI, collected by 
centrifugation and then lysed by freeze thaw (3 times) and by sonication with a 
5mm probe for 10 x 30 seconds. The insoluble material was removed by 
centrifugation at 15,000rpm (Sorvall, SS34) at 40C and the supernatant containing 
the soluble polypeptide was purified by affinity chromatography similar to method 
2.6.12. The McAb 7.7 affinity column was washed prior to use with 10 bed 
volumes (30ml) of 0.1M Tris-HCI pH 8.0,0.5M NaCl and 10 bed volumes of 0.1M 
NaAc pH 4.0, 0.5M NaCl. The column was then equilibrated with 20 bed 
volumes of PBS and the sample passed over the column 3 times. Prior to elution 
the column washed with 20 bed volumes of PBS. In order to elute bound protein, 
100mM triethylamine pH 11.5 was allowed to enter the column until the pH of 
the solution leaving the column was 11.5, then PBS was applied. Fractions of lml 
were collected and the pH neutralised by the addition of 1/20 volume of 1M 
phosphate pH 6.8. Samples of each fraction were analysed by dot blotting, SDS-
PAGE, silver staining and western blotting. The fractions containing the 
polypeptide were pooled, dialysed against PBS and the volume reduced by placing 
the dialysis tubing on a bed of polyethylene glycol until the volume reduced to 115 
of its original size. The solution was then removed and stored at -70 0C. 
2.6.14.3 Immunization of mice with the purified polypeptide: Two house 
bred female mice were used to raise polyclonal sera to a foreign polypeptide 
expressed in the vector pMS. 
Preparation of protein: The polypeptide was expressed in E.coli and 
purified by affinity chromatography as described in the previous section. 
Approximately 250.tl of the purified polypeptide (li.sg) was used per immunization 
emulsified with an equal volume of adjuvant. 
Immunization Regime: Prior to the first immunization a 200p1 tail bleed 
was taken from each mouse as a sample of 'pre-immune' serum. The first 
immunization was performed using protein prepared in Freund's complete 
adjuvent. The sample was applied 250pl interperitonially. The mice were boosted 
a fortnight later with the same amount of protein prepared in Freund's incomplete 
adjuvent. The boost was repeated a fortnight later and then 14 days after that a 
200 sl tail bleed was taken from each mouse. A week later the mice were given 
a further boost and bled out completely 2 weeks later. 
2:6.14.4 Preparation, purification and analysis of mouse sera: 
Preparation of sera from whole blood: In order to remove the serum from 
whole blood, the blood was left at 37 0C for 1 hour, incubated overnight at 4 0C 
and the clot pelleted by microcentrifugation. The clarified serum was transferred 
into a fresh Eppendorf tube and stored at -20 0C. 
Purification of sera: In order to remove any non-specific antibodies the 
sera were preabsorbed twice with a total protein extract prepared from an 
induced culture of E.coli transformed with the non-recombinant pMS vector. The 
E.coli culture was prepared as described in method 2.6.14.1. The cells were lysed 
by freeze thaw (3 times) and by sonication with a 5mm probe for 10 x 30 seconds. 
To an aliquot of the serum an equal volume of the lOx lysed bacterial extract was 
added and this was mixed at room temperature for one hour. Insoluble debris 
was then removed by microcentrifugation. 
Analysis of sera: Sera were analysed by IFA and western blotting analysis. 
2.6.15 Raising Antisera to Recombinant Glutathione S-transferase (GST) Fusion 
Proteins 
2.6.15.1 Expression of GST Fusion Proteins: pGEX vectors were used in 
to express polypeptides in E.coli as fusions with glutathione S-transferase (GST). 
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The basic protocol used for expressing, purifying and cleaving fusion proteins was 
that described by Smith and Corcoran (1990). 
The chosen P.falczpanim DNA fragments were subcloned into the 
appropriate pOEX vector. Since BL21 cells are not very competent for 
transformation with plasmid the initial ligation was transformed into DH5a cells 
and recombinants identified by colony hybridisation (method 2.4.21). Plasmid 
DNA was prepared from the putative positives and then transformed into BL21 
cells for the expression of fusion proteins. 
A single colony was picked into LB-amp, 5m1 for a small scale preparation, 
or lOOmI for a large scale preparation and grown overnight at 37 0C with shaking. 
The following day the culture was diluted 1:10 in LB-amp and grown at 37 0C with 
shaking. After 1 hour, lml of culture was removed, as a control before induction, 
and to the remaining culture 100mM IPTG was added to a final concentration of 
0.1mM in order to induce fusion protein expression. Cells were then grown for 
a further 3 hours. This was determined as the optimum growth conditions to give 
a consistently high yields of fusion protein. Cells were collected by centrifugation, 
at 5,500 rpm (JA-10, Beckman) for 10 minutes at 4 0C and then resuspended in 
ice-cold PBS 1/100 of the original culture volume. In order to check expression 
of the fusion protein 500 of the culture was spun down, resuspended in 10R1  of 
loading buffer and checked by SDS-PAGE and Coomassie staining. Cells were 
then frozen in 1.5ml microfuge tubes in 1 ml aliquots at -70 0C. 
2.6.15.2 Purification of GST fusion proteins: Bacterial cells, containing the 
expressed fusion protein, were thawed and then lysed using a sonicator with a 
5mm diameter probe with lysis generally occurring after 30 seconds sonication. 
To the lysed cell suspension 10% Triton X-100 was added to a final concentration 
of 1% and mixed in order to minimize any association of fusion proteins with 
bacterial ones. An aliquot of the lysed bacterial extract was then centrifuged and 
a sample of both the supernatant and pellet analysed by SDS-PAGE and 
Coomassie staining. Depending on the solubility of the fusion protein the protein 
was further purified by one of two methods. 
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Soluble GST fusion protein purification: If the GST fusion was soluble the 
lysed cells were microcentrifuged for 10 minutes in 1 ml aliquots and the 
supernatant, containing the soluble fusion protein, transferred into a clean 
microfuge tube. To each aliquot of supernatant was added iSOpI of a 50% slurry 
in PBS of pre-swelled S-linkage glutathione-agarose beads (SIGMA) and mixed 
gently for 45 minutes at room temperature. The beads were collected by 
microcentrifugation for 5 seconds and pooled. The supernatants were then 
treated with a second aliquot of beads. Each batch of pooled beads was then 
washed in 50 volumes of ice cold PBS and collected by centrifugation at 1000rpm 
for 1 minute at 40C. The wash was repeated 2 times. The beads were then 
resuspended in loading buffer and an aliquot analysed by SDS-PAGE and 
Coomassie staining in order to estimate the concentration of bound protein. 
Approximately 0.5 mg of fusion protein was loaded per preparative SDS-PAGE 
gel. The gel was then stained with Coomassie (2.6.4.2) and the appropriate band 
excised. 
Insoluble GST fusion protein purification: If the GST fusion was insoluble 
(i.e. probably present in inclusion bodies) the lysed cells were pooled then 
centrifuged at 9,500rpm (JA-20, Beckman) for 5 minutes at 40C to pellet insoluble 
fusion protein leaving the majority of bacterial proteins in the supernatant. The 
pellet was resuspended in loading buffer and approximately 0.5 mg of fusion 
loaded per preparative SDS-PAGE gel. The gel was then run, stained with 
Coomassie (2.6.4.2) and the appropriate band cut out. 
2.6.15.3 Removal of the GST carrier by protease cleavage: Fusion protein 
expressed in the vectors pGEX-2T and pGEX-3X contain an amino acid sequence 
between the GST carrier and the foreign polypeptide that is cleaved by a site 
specific protease. In pGEX-2T fusions there is a thrombin cleavage site and in 
pGEX-3X fusion proteins there is a protease blood coagulation factor Xa site. 
Fusion protein was prepared and purified on glutathione agarose beads 
as previously described. The glutathione beads, bearing the fusion, were washed 
in 20 volumes of 1% Triton X-100 in PBS. The beads were then equilibrated, by 
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washing once, in wash buffer (50mM Tris-HCI pH7.5, 150mM NaCl) and then in 
either thrombin cleavage buffer (2.5mM CaCl 2 in wash buffer) or in factor Xa 
cleavage buffer (1mM CaCl 2 in wash buffer). Washes were performed by mixing 
the beads with 20 volumes of solution and then by collecting the beads by 
centrifugation for 1 minute at 1000rpm. The beads were then resuspended in an 
equal bed volume of the appropriate cleavage buffer and transferred to an 
Eppendorf tube. The amount of fusion protein bound to the beads was estimated 
by analyzing a small aliquot of the beads by SDS-PAGE and Coomassie staining. 
To the remaining bead slurry was added either thrombin (SIGMA (0.2% to 1% 
wt/wt fusion protein)) or factor Xa (Boehringer Mannheim (1% wt/wt fusion 
protein)) and this was incubated for 1 hour at 25 0C. The beads were collected 
by microcentrifugation for 5 seconds and the supernatant, containing the cleaved 
polypeptide, recovered. The beads were then washed in one bed volume of wash 
buffer, pelleted and the supernatant recovered. The elution was repeated 3 times 
and samples of each fraction analyzed by SDS-PAGE and Coomassie staining. 
2.6.15.4 Immunization of animals with protein from pGEX constructs: 
New Zealand 4 month old male rabbits were used to raise antibodies against 
several GST fusion proteins. 
Preparation of protein: Fusion proteins were expressed in E.coli, purified 
and separated by SDS-PAGE. The gel was stained with Coomassie and the 
appropriate band excised. Approximately 0.3mg of protein contained in a gel slice 
was used per immunization emulsified with 0.7ml of adjuvant. 
A rabbit was also used to raise antibodies against a protein, expressed as 
a GST fusion but purified cleaved from the GST moiety. An aliquot (0.2mg) of 
the soluble polypeptide, in 0.5m1 of thrombin cleavage buffer, was used per 
immunization emulsified with 0.5m1 of adjuvant. 
Immunization Regime: Prior to the first immunization a lml ear bleed was 
taken from each rabbit as a sample of 'pre-immune' sera. Protein for the first 
immunization was prepared in Freund's complete adjuvant and injected 0.5 ml 
intra muscularly (i.m.) into each hind leg. Three weeks later the animals were 
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boosted with protein prepared in Incomplete Freund's adjuvant again 0.5m1 i.m. 
into each hind leg. Rabbits were boosted again 3 weeks later following an 
identical procedure. Two weeks after each boost a 20 ml ear bleed was taken. 
2.6.15.5 Preparation, purification and analysis of rabbit sera: 
Preparation of sera: To separate the serum from whole blood the blood 
sample was left for 1 hour at 37 0C, incubated at 40C overnight and the serum 
decanted into a fresh tube. In order to remove any remaining traces of blood clot 
the serum was then centrifuged for 10 minutes at 2000rpm. The clarified serum 
was then removed, aliquoted into Eppendorl tubes and stored at -20 0C. 
Purification: The sera were preadsorbed with GST in order to remove anti-
GST antibodies present. Beads bearing GST were prepared essentially as 
described for soluble fusion purification (2.6.15.2) from a induced culture of cells 
transformed with the non-reconbinant pGEX vector. A total lysed bacterial 
extract was also prepared (2.6.15.2) from cells transformed with the non-
recombinant vector. An aliquot of beads (20jsl) bearing GST plus lOOsl  of a 100x 
concentration of lysed bacteria vector were added to 500 jsl of serum and mixed 
at room temperature for 1 hour. The beads and bacterial debris were then 
pelleted by microcentrifugation for 5 seconds and the serum transferred to a fresh 
microfuge tube. 
Analysis of sera: The sera were tested by IFA and western blotting analysis. 
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CHAPTER 3 
CHARACTERIZATION OF THE PARASITE ENCODED 
PROTEIN EXP-2 
3.1 Introduction 
During their intraerythrocytic development malaria parasites induce stage-
specific changes in the ultrastructure, morphology and antigenicity of the host 
RBC (Aikawa, 1988; Sherman, 1985;). Such alterations are, at least in part, due 
to the export of lipids and proteins synthesized by the parasite into the 
erythrocyte. In order to do this the parasite must also import the necessary 
precursors (Elford et at, 1985; Hsiao et at, 1991). 
One aspect of this bidirectional transport system, of particular interest, is 
the export of parasite encoded proteins to specific locations in the host cell 
cytoplasm. Some proteins are found distributed throughout the erythrocyte 
cytoplasm (Perkins, 1988) or in membranous structures within it (Simmons a at, 
1987; Stanley et at, 1989) while others are transported to the RBC membrane 
(Taylor et al., 1987). Some proteins are found only in the PV (Knapp et at, 
1989b). This would suggest that there is a mechanism(s) which discriminates 
between proteins destined for different locations in the infected cell. In order to 
study the possible mechanisms involved, specific proteins found in defined 
locations in the host cell must be studied. 
One possible group of proteins that are useful for study are exported 
integral membrane proteins. Integral membrane proteins may act as a molecular 
marker for the polarity of a membrane. By investigating the topology of an 
integral membrane protein before and after it has crossed the various parasite 
membranes it is possible to deduce aspects of the mechanism by which the protein 
and its membrane are transported. One such protein that has been studied, in 
some detail, is the integral membrane protein exp-1. The 23kDa antigen exp-1 
was identified by a monoclonal antibody 5.1 is located in both the PVM and 
membrane bound vesicles in the RBC cytoplasm. The protein contains a 
functional N-terminal signal sequence and a hydrophobic transmembrane domain 
(Simmons et at, 1987, Gunther et at, 1991). Based on studies involving the use of 
specific monoclonal directed to segments either side of the transmembrane 
domain, antibodies its topology in parasite membranes was deduced and a 
vesicular model to describe its transport from the parasite to the cytoplasm was 
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hypothesized (Gunther et aL, 1991). In order to test the validity of this model 
other exported, parasite encoded, integral membrane proteins need to be studied. 
One candidate for such a study is the antigen defined by another McAb 7.7 
previously described in our laboratory, which is also found in the PVM and 
membranous structures in the RBC cytoplasm (Hall a aL, 1983). 
3.1.1 Previous Characterization of the 7.7 Monoclonal Antibody antigen 
Limited characterization of the protein recognised by the McAb 7.7 has 
already been carried out in our laboratory. Initial studies were carried out by Ian 
Hope (1984) who demonstrated that: 1, On a western blot of saponin lysed total 
parasite protein the McAb 7.7 detects a protein of 35kDa. 2, As with exp-1 
expression of the 35kDa protein is stage specific, they both appear during the ring 
stage, gradually accumulate throughout the erythrocytic cycle and disappear at the 
time of schizont rupture. 3, The 35kDa protein is biosynthetically labelled when 
P.falciparum cultures are grown in the presence of 35S methionine. Since the RBC 
is not biosynthetically active the 35kDa protein must be parasite encoded and not 
a modified host protein. 4, By enzymatic iodination of saponin lysed infected 
RBCs and immuno precipitation he showed that the 35kDa protein is iodinated 
and therefore is located external to the parasite membrane. 5, Total mRNA 
prepared from P.falciparum was translated in vitro. The translation products were 
analyzed by McAb 7.7 affinity chromatography, SDS-PAGE and autoradiography. 
A strong band at 36kDa was observed suggesting that the primary translation 
product is slightly larger than the mature form. This indicates that the protein, 
like exp-1, probably contains a cleavable N-terminal leader sequence to ensure 
translocation into the endoplasmic reticulum. 
The 35KDa protein is present in all the P.falciparum isolates investigated 
(McBride a at, 1982) as detected by indirect immunofluorescence assays using the 
McAb 7.7. The conservation of the proteins size and the epitope recognised by 
McAb 7.7 suggest that the protein is functionally important and indispensable to 
the parasite. The protein is also recognised by immune sera taken from adults in 
countries where malaria is endemic (Khan, 1990). 
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3.1.2 Exp-2 is an integral membrane protein 
Experiments performed by Kathrin Gunther (manuscript submitted) 
demonstrated that the 35KDa protein, recognised by McAb 7.7, is present in the 
membrane fraction of parasite extracts. Infected red blood cells were lysed by 
freeze thawing and the lysed material subjected to sequential extractions with high 
salt buffer and a high pH buffer (Gunther et aL, 1991). The material was 
separated by SDS-PAGE and the gel was silver stained. Membranes extracted 
from infected RBCs contained 6 major protein bands ranging from 23.2kDa to 
>97.4kDa in addition to the bands seen in the membrane preparations from non-
infected cells. One of these proteins, that migrating at 23kDa was identified as 
being exp-1 while another migrating at 35kDa was recognised by the McAb 7.7. 
As the 35KDa protein has similar characteristics to exp-1 i.e. it is found 
associated with the PVM and vesicle-like structures and is an integral membrane 
protein the 35KDa protein was termed exp-2 (exported protein 2). 
3.2 Exp-1 and Exp-2 co-localise to the same compartment in the infected RBC. 
It has been previously shown, by immunofluorescence analysis and by 
immunogold labelling, that exp-1 is exported to the PVM and membrane bound 
compartments of the infected RBC (Hall et aL, 1983; Simmons et aL, 1987; 
Stenzel and Kara, 1989). Also similar experiments, using McAb 7.7, indicated that 
exp-2 is also found in the PVM and membrane bound vesicles (Hall a aL, 1983, 
Khan 1990). 
A series of immunofluorescence assays (IFA) were carried out (method 
2.6.1) using monoclonal antibodies to both exp-1 and exp-2 to compare their 
reactivity (Figure 3.1). This was performed on acetone fixed thin smears of 
P.falciparuni infected RBCs. Both monoclonal antibodies were used as ascites 
fluid at a dilution of 1:500. Parasite nuclei were counterstained with DAPI and 
the bound monoclonal antibodies detected using Fluorescein anti-mouse IgG. 
All the cells which stained with Fluorescein also stained with DAPI 
indicating that the cells were parasitised and confirming the parasite origin of the 
in 
Figure 3.1 
Pattern of indirect immunofluorescence assay (IFA) staining produced by 
mononclonal antibodies 5.1 (a-f) and 7.7 (g-l) on blood films of P.falciparum. 
Acetone fixed smears of Ki P.falciparum infected RBCs were incubated with 
either McAb 5.1 or McAb 7.7 followed by anti-mouse FITC-conjugated second 
antibody. a,b and g,h are examples of ring stage parasites, c,d and i,j trophozoite 

















two proteins. Both McAb 5.1 and McAb 7.7 give a similar pattern of fluorescence 
with a distinct ring of irregular staining around the parasite, a pattern 
characteristic of the PVM. In addition some cells contain discrete areas of 
fluorescence in the RBC cytoplasm. This appeared to be only observed in cells 
containing late-ring and early trophozoite stage parasites. Since both monoclonal 
antibodies appear to recognise similar structures it seemed possible that exp-1 and 
exp-2 co-localised in the parasitised erythrocyte. To answer this question a double 
labelling IFA experiment was performed. 
Acetone fixed thin smears of P.falciparum infected RBCs were treated with 
an antibody mixture containing McAb 7.7 and rabbit polyclonal antibody (PcAb) 
5.1 raised against recombinant exp-1 (a gift from H. Matile). Both antibodies were 
used at a dilution of 1:500. Parasite nuclei were counterstained with DAPI and 
the bound murine and rabbit antibodies detected using Fluorescein anti-mouse 
IgG conjugated second antibodies which give a green fluorescence and Rhodamine 
anti-rabbit IgG conjugated second antibodies which give a red fluorescence 
respectively. The same field of infected red blood cells was analyzed, by 
fluorescence microscopy, for the presence of DAPI (data not shown), Fluorescein 
(Fig.3.2 la-3a) and Rhodamine (Fig.3.2 lb-3b). The examples shown contain 
trophozoite stage parasites in which vesicles are visible in the erythrocyte 
xdfcytoplasm. 
The appropriate control experiments were performed. There was no 
significant staining of non-infected cells and no fluorescent staining was observed 
when only the second antibodies were used (data not shown). Also the specificity 
of the conjugated second antibodies was tested, rhodamine isothiocyanate 
conjugate of preadsorbed anti-rabbit immunoglobulin (RITC-anti IgO) was tested 
with McAb 7.7 and fluorescein isothiocyanate conjugate of immunoadsorbant-
purified polyvalent anti-mouse immunoglobulin (FITC-anti IgG) was tested with 
PcAb 5.1. No signal was observed in either case (data not shown). 
Generally all the structures stained by the 5.1 PcAb were also recognised 
by the 7.7 McAb. An identical pattern of patchy staining was observed associated 




Pattern of WA staining produced by a mixture of mononclonal antibodies 5.1 and 
7.7 on blood films of P.falciparum. 
Acetone fixed smears of Ki P.falciparum infected RBCs were incubated with an 
antibody mixture containing McAb 7.7 and PcAb 5.1, followed by a mixture of 
anti-mouse FITC-conjugated and anti-rabbit RITC-conjugated second antibodies. 
The same infected cell was analysed for the presence of Fluorescein (panels la-
3a) and Rhodamine (panels lb-3b). 1, 2 and 3 are examples of three different red 
blood cells containing trophozoite stage parasites. Arrows indicate examples of 
vesicle like structures 
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recognised by both the 5.1 PcAb and the 7.7.McAb (see arrows for examples). 
These results suggest that exp-1 and exp-2 are co-localised in the PYM and also 
to some extent in structures within the RBC cytoplasm. However, examination 
of some fields suggested there may be some structures in the erythrocyte 
cytoplasm which contain only one type of antigen. 
To investigate this co-localization in finer detail immunogold electron 
microscopy using the McAb 7.7 and PcAb 5.1 was kindly performed by L. 
Bannister. The results are shown in Fig.3.3. Initial experiments indicated that the 
distribution of exp-2 was very similar to that previously described for exp-1 being 
present in low amounts in ring stages and progressively more intense in 
trophozoites and schizonts. The label followed, in discrete patches, the PVM and 
was present in many but nof all of the membranous compartments in the RBC 
cytoplasm. It was also noticed that the label was seen in areas that seemed to be 
extensions of the main PVM. In the double labelling experiment McAb7.7 and 
PcAb5.1 were found in the vicinity of each other at the PVM indicating a co-
localization there of exp-1 and exp-2 (see Fig.3.3 c-f). 
3.3 Affinity Purification of exp-2 
In order to gain more information about the protein exp-2 attempts were 
made to purify the protein from parasitised RBCs. It was hoped that N-terminal 
protein sequencing of the purified protein might provide amino acid sequence 
from which oligonucleotides could be designed to isolate the exp-2 gene from a 
suitable P. falciparum gene bank (Wallach et aL, 1984). 
An affinity column was prepared by covalently attaching purified McAb 7.7 
to Sepharose beads (method 2.6.9). Total parasite protein extracts were prepared 
by saponin lysis of infected erythrocytes in the presence of the detergents NP40 
and DOC and the protease inhibitors soybean trypsin inhibitor, antipain, 
leupeptin, chymostatin and pepstatin. The extract was applied to the McAb 7.7 
affinity column, and the bound protein eluted with triethylamine pH 11.5. A 
sample of each eluted fraction was analyzed by protein dot blotting (Fig.3.4a) 
(method 2.6.6) and SDS-PAGE (method 2.6.2). The dot blot indicates that exp-2 
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Figure 3.3 
Immunogold electromicrographs showing the localisation of exp-2 (panels A-C) 
and its co-localisation with exp-1 (panels E-F) in erythrocytes infected with 
P.falciparum isolate 1T04. 
Cells were prepared for labelling by the method of Bannister and Kent (1993). 
Sections were either immunolabelled with McAb 7.7 or double-immunolabelled 
with PcAb 7.7 and McAb 7.7. The polyclonal antibody was used at a 1:100 
dilution and the monoclonal antibody at a 1:50 dilution. The second antibodies 
were goat-anti rabbit IgG conjugated to 20nm gold particles and goat-anti mouse 
IgG conjugated to 5nm gold particles. 
A: part of a ring stage parasite showing absence of exp-2 from the parasite's 
surface or the PV. Magnification x 30,000. B: Distribution of exp-2 at the surface 
of a schizont, including some internal labelling. Magnification x 30,000. C: 
Localization of exp-2 in a membranous cleft in the cytoplasm of a parasitized 
RBC (top left) and in small amounts in the parasite cytoplasm (lower right). 
Magnification x 57,000. D: Co-localization of exp-1 and exp-2 at the parasite 
surface, presumably at the PVM. Magnification x 80,000. B: Co-localization of 
exp-1 and exp-2 at the surface of an early schizont. Note the adjacent clusters of 
particles associated with a mass of dense material (lower right). Magnification x 
80,000. F: Co-localization of exp-1 and exp-2 around a vesicular structure in the 
cytoplasm of a parasitized RBC. Magnification x 80,000. 
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is predominately eluted in fractions 3,4 and 5. The same elution profile is seen 
in the Coomassie stained gel for a protein of 35kDa (Fig.3.4b). The identity of this 
protein was confirmed as being exp-2 by western blotting and immunoprobing with 
McAb 7.7 (data not shown). Exp-2 was the major protein eluted off the column. 
However in subsequent staining of the gel with silver (Fig.3.4c) (method 2.6.4.3) 
other proteins which co-purified with exp-2 were observed. These proteins were 
not recognised by the McAb 7.7 by western blot analysis. 
This method of preparation was repeated several times with similar results 
and I was unable to obtain high yields of exp-2 of a suitable level of purity for 
protein sequencing. 
3.4 Does Band III co-purify with exp-2? 
As illustrated in Fig 3.4C there are many contaminating proteins in the 
affinity purified exp-2 preparation. Anjam Khan (1990) had previously reported 
that one of the major contaminating proteins in exp-2 preparations was the RBC 
Anion transporter Band III which he could detect with a goat polyclonal sera 
recognising human Band III. He suggested that difficulties in purification were 
due to a novel complex being formed between Band III and exp-2 and postulated 
that the two proteins interacted in some way in the infected RBC. 
I therefore attempted to discth'er whether Band III was a contaminant of 
affinity purified exp-2 preparations which I had obtained. It has been 
demonstrated that the N-terminal region of Band III and the P.falciparum antigen 
RESA share sequence homologies and that antibodies to the N-terminal region 
of Band III recognise RESA (Holmquist et aL, 1988). It was therefore possible 
that the polyclonal sera of Khan was recognising a cross-reactive epitope. In 
order to minimize any cross-reactivity which may be present between Band III 
antibodies and P.falciparum antigens I used a monoclonal antibody to the C-
terminus of Band III. The antibody, BRIC 155 (a gift from M. Tanner) recognises 
the C-terminus of Band III and reacts with both the native protein by IFA and 
denatured protein by western blotting analysis (Wainwright et al., 1990). Samples 
of saponin lysed total parasite protein extract and affinity purified exp-2 were 
Figure 3.4 
Affinity purification of exp-2. 
A detergent extract of infected red blood cells was passed over a McAb 7.7 
column. 
Immunodetection of exp-2 in the collected fractions. An aliquot of each fraction 
was spotted onto nitrocellulose and probed with McAb 7.7. 
An aliquot of each fraction was separated by SDS-PAGE on a 10% gel and 
stained with Coomassie. 
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separated by SDS-PAGE (method 2.6.2) and electrophoretically transferred onto 
Hybond-C membrane (method 2.6.5). Both preparations were immunoprobed 
with BRIC 155 tissue culture supernatant at a 1:3 dilution (data not shown). A 
broad band at 90-100KDa corresponding to the expected size of Band III was 
observed in the total cell extract, however it was not present in the affinity 
purified exp-2. Thus under the conditions of my purification exp-2 and Band III 
did not co-purify. However this does not rule out the possibility that they interact 
in the infected RBC. 
3.5 Location of the erythrocyte anion transporter Band III in the infected RBC 
Whether in fact Band III is found in the PVM of the infected RBC at all 
is of some debate. Dluzewski et al., (1989) found no evidence, of Band III and 
other components of the RBC cytoskeleton in the PVM while Mikkelson et aL, 
(1989) reports the presence of both Band III and glycophorin in the PVM. I too 
investigated the location of Band III in the infected RBC using IFA. 
Immunofluorescence assays were performed on acetone fixed thin smears 
of asynchronous P.falciparum infected RBCs using the anti-Band III BRIC 155 
tissue culture supernatant at a dilution of 1:3. The parasite nuclei were 
counterstained with DAPI and the second antibody used was conjugated to 
fluorescein. The same field was examined, by fluorescence microscopy, separately 
for DAPI (Fig.3.5 la-3a) and fluorescein staining (3.5 lb-3b). 
Anti-Band III stains the erythrocyte membrane of every cell, as expected. 
Some erythrocytes infected with parasites however show staining typical of the 
PVM (indicated by solid arrows). The small number of parasitised RBCs showing 
this pattern appeared to be early rings. The evidence for this was two-fold, firstly 
the diameter of the PVM was small which is typical of an early stage parasite, 
secondly no pigment was observed in these cells when examined under low white 
light. Unlike exp-2, the pattern of Band III staining of the PVM is very even. No 
staining of any structures which appeared to be budding off the PVM or any 
vesicle-like structures in the RBC cytoplasm was observed. The results shown are 
typical and the only parasitised cells which showed definitive staining of the PVM 
Ell 
Figure 3.5 
Pattern of IFA staining produced by anti-Band III tissue culture supernatant on 
blood films of P.falciparum. 
Acetone fixed smears of Ki P.falciparum infected RBCs were incubated with anti-
Band III tissue culture supernatant followed by anti-mouse FITC-conjugated 
second antibody. Parasite nuclei were counterstained with DAPI. The same 
infected cell was analysed for the presence of DAPI (panels la-3a) and 
Fluorescein (panels lb-3b). 1, 2 and 3 are examples of three different fields of red 











were those containing early rings. These results do not necessarily conflict with 
the electron microscopy results of Dluzewski et al., (1989). Prior to performing 
electron microscopy his sample was enriched for parasitised cells and the early 
stages (up to 6 hours post-invasion) were lost. These could be the stages 
containing Band III in the PVM. 
3.6 Discussion 
The protein exp-2, synthesized by the parasite P.falciparum, is found 
located in the PVM and membranous structures/vesicles in the host cell cytoplasm. 
It has been suggested that the vesicles located in the cytoplasm of the infected cell 
perform a role in protein and lipid trafficking between the PV and RBC 
membrane. Several types of vesicles have been described. These include 
Maurer's cleft vesicles - these are long slender vesicles with a single vesicle unit 
membrane; large circular vesicles - layered unit membrane with a whorled 
appearance and; small round vesicles - these may have an enclosing unit 
membrane with an electron dense interior. It is unclear whether the 
morphologically distinct vesicles perform different functions but the location of 
proteins to distinct types of vesicles lends support to this idea. For example HRP-
1 (Taylor et al., 1987) HRP-2 (Howard et al., 1986) and MESA (Howard et al., 1987) 
are found in whorled vesicles and electron dense spheres while the 45kDa (Hui 
& Siddiqui,1988) and 43kDa (Etzion & Perkins, 1989) proteins are found in 
Maurer's cleft vesicles. Also, the transmenibrane protein exp-1 is found in the 
PVM and exclusively in Maurer's cleft vesicles. Studies presented here show that 
exp-2, also an integral membrane protein, is found co-localised with exp-1 in both 
the PVM and Maurer's cleft vesicles suggesting that both proteins are exported 
along a common pathway. 
What determines the compartmentalization of exp-1 and exp-2 to Maurer's 
cleft vesicles? One can only speculate. Experiments performed by Kathrin 
Gunther indicate that exp-2 is an integral membrane protein. Two of the other 
four proteins which are associated with Maurer's clefts have been completely 
sequenced, exp-1 and Pf 41-2, and the predicted amino acid sequences of each 
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contain potential hydrophobic transmembrane domains (Simmons a aL,1987, 
Knapp a aL,1989a). In the case of exp-1 it has been demonstrated that this 
protein is an integral membrane protein. Pf 41-2 contains two potential 
transmembrane domains and is found not only in the PVM and Maurer's clefts 
but is also associated with the erythrocyte membrane. It may just be purely 
coincidental that these proteins contain transmembrane domains and are found 
associated with Maurer's cleft vesicles. However, two other proteins HRP-i 
(Histidine rich protein-1) and HRP-2 do not contain potential transmembrane 
domains and they are not found in Maurer's cleft vesicles. In fact both HRP-1 
and HRP-2 contain potential N-terminal signal sequences typical of secretory and 
membrane proteins (Barnwell, 1990). 
It has been suggested that the movement of Maurer's cleft vesicles is 
associated with a component of the cytoskeleton. Etzion and Perkins (1989) 
reported that actin, probably parasite derived, is found co-localised with Pf41-2 in 
Maurer's cleft vesicles and hypothesized that the movement of these vesicles may 
be dependent on actin filaments which are the major cytoskeletal elements of 
mature erythrocytes. Based on its co-purification with exp-2 Anjam Khan (1990) 
suggested that Band III, another component of the cytoskeleton may also be 
involved. Failure of anti-band III antibodies to recognise Band III in my affinity 
purified preparations of exp-2 did not rule out this possibility. However, the IFA 
results suggested that Band III is not involved since it was not present in any of 
the vesicles. The only parasite derived structure it was found associated with was 
the PVM of young ring-stage parasites a time at which there is little if any vesicle 
movement (Stanley et aL, 1989). 
Band III forms a major part of the integral membrane protein (IMP) of 
erythrocytes. Freeze fracture studies indicate that during PVM formation IMPS 
are reduced to below a tenth of their frequency in the PVM in comparison with 
the membrane of the univaded red cell indicating that RBC membrane proteins 
are degraded or hardly enter the invasion pit (Aikawa et aL,1981). Even though 
the PYM is wholly or partly derived from lipids released from the invading 
parasite (Dluzewski et aL,1992) freeze fracture results indicate that some red cell 
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components including a few IMPs are carried into the PVM during invasion. 
These could be the source of the weak immunofluorescence associated with Band 
III which was observed. 
RE 
CHAPTER 4 
ATTEMPTS TO CLONE EXP-2 AND THE 
IDENTIFICATION 
OF ANOTHER ANTIGEN LOCALISED TO THE PVM 
4.1 Introduction 
Cloning the gene encoding exp-2 would enhance our understanding of exp-
2. It's sequence may shed light on the protein's structure and possible function. 
Apart from comparing its sequence to sequences of other known proteins, it 
would also be possible to examine whether the sequence contained features such 
as a membrane spanning domain or a signal sequence such as occurs in exp-1. 
Also, the cloning of the gene encoding exp-2 would provide the basis for the 
production of segment-specific antibodies which in turn could be used to study its 
transport from its site of synthesis in the parasite to its destination in the host cell. 
A method has been successfully devised to isolate genes from Agti 1 DNA 
expression libraries by probing for in situ expression of the cloned gene with sera 
specific for the antigen of interest. The gene encoding exp-1 was isolated from 
a Agtli cDNA expression library by probing with polyclonal sera raised against 
affinity purified exp-1 (Hope et. al., 1985). Several other genes in our laboratory 
have also been isolated in a similar manner including MSP-1 (Hall et aL, 1984) 
and RAP-1 (Ridley et aL, 1990). It was therefore decided to use this technique 
in an attempt to identify the gene encoding exp-2. 
Prior to explaining the screening procedure a brief explanation of the 
essential features of the vector Xgtil will be given. The structure of the 
expression vector Agtil (lacS, cI857, nin5, S100) is shown in Fig.4.1. The Agtli 
expression vector contains a unique EcoRl site within the lacZ gene, which is 53 
base pairs upstream from the -galactosidase translation termination codon. Up 
to 7.2 kb of foreign DNA can be inserted into this site and may then be expressed 
as part of a -galactosidase fusion protein under the control of the lacZ repressor. 
During the initial hours of phage growth the product of the lacl gene, the lac 
repressor, prevents lacZ-directed expression of the fusion protein. Expression of 
the fusion can be induced however by inactivating the repressor with isopropyl f3-
D-thiogalactopyranoside (IPTG). 
Normally the product of the ci gene is a repressor which acts on the 
operators °L  and  °R•  This prevents expression of potentially lethal genes and 
results in turbid plaques i.e. there are many surviving bacterial cells. However, the 
Xgtll vector produces a temperature sensitive repressor (cI857) so that lysogens 
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Figure 4.1: Map of Agtll indicating EcoRI and KpnI restriction sites. 
of this phage can only be propagated at low temperatures (32-340C). When the 
temperature is raised (420C) the phage are induced into the lytic cycle. 
The wild-type A vector contains t, a transcription termination site 
between genes P and Q. In order for the phage to grow lytically the product of 
the phage N gene allows transcription to continue past the transcription sites tp 
and tL2  but in its absence transcription termination occurs. The deletion nin5 
removes tp and allows the phage to form plaques on bacteria in which the N 
gene product is ineffective. The Agtll vector also contains an amber mutation 
(S 100) which renders it lysis defective in hosts which lack the amber suppressor 
supF and therefore recombinant proteins can be retained in the cells which lack 
the supF mutation. 
The expression library was screened • using the procedure described by 
Huynh et al., (1985) (see method 2.6.8). Essentially the phage were plated out as 
plaques and grown in the absence of IPTG at 420C for 3 1/2 hours. The plaques 
were then overlaid with a nitrocellulose filter which had previously been soaked 
in 10mM IPTG and incubation continued for 3 1/2 hours at 370C. The filters were 
then removed, blocked with 5% non-fat milk and probed (method 2.6.7.2) with the 
appropriate sera. Two sera were available for screening McAb 7.7 (Hall et al., 
1983) and PcAb 7.7 (Khan, 1990) raised in rabbits against affinity purified exp-2. 
The filters were incubated with the primary antibody, either McAb7.7 or PcAb7.7, 
washed and then incubated with the appropriate second antibody. The second 
antibodies used were either anti-mouse or anti-rabbit IgG conjugated to the 
enzyme alkaline phosphatase (Promega). The binding of the second antibody was 
detected by testing for the presence of alkaline phosphatase using two substrates 
NBT and BCIP, which produce a purple colour in the presence of the enzyme. 
4.2 Isolation and identification of a Clone 
In order to identify a clone encoding a specific gene from an expression 
library you need: 1) a good library i.e. a large number of recombinants in a 
suitable vector and 2) high titre sera specific for the gene of interest. In this case 
the expression library used contained randomly sheared genomic DNA of the Thai 
(KI) isolate of P.falciparutn and was constructed by U. Certa (Certa a aL, 1988) 
in the vector Agtll. Both a monoclonal antibody McAb 7.7 and a polyclonal 
PcAb 7.7, were available for screening the library. Ascites fluid containing McAb 
7.7 was specific for exp-2. The polyclonal antibody was not as specific and 
recognised other malarial proteins. However, in theory it had an advantage over 
the monoclonal antibodies as it probably recognised multiple epitopes on exp-2. 
The expression library was initially screened with the polyclonal sera, 
however no reproducibly positive clones were identified. The mouse McAb 7.7 
was then used, at a working dilution of 1/100, to screen the expression library 
(method 2.6.8). Extensive screening yielded one positive clone SL13 which was 
weakly but consistently reactive with McAb 7.7 ascites fluid (Fig.4.2a). This clone 
was also reactive with both the PcAb 7.7 sera and pooled human immune sera. 
DNA was prepared from this clone using the procedure of Grossberger 
(1987) (method 2.4.2.4). Digestion of the DNA with the restriction enzyme EcoRI 
did not release an insert yet it did cut the DNA thus indicating that one of the 
Figure 4.2 
Isolation and characterization of a positive clone recognised by McAb 7.7. 
Clone SL13 secondary screen filter probed with McAb 7.7 at a dilution of 
1:100. A mixture of positive (arrowhead) and negative (arrow) plaques are 
shown. 
Western blot of Agtll lysates prepared from a non-recombinant control (Track 
1) and the positive clone SL13 (Track 2), probed with McAb 7.7 at a dilution of 
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EcoRI sites had been lost from the cloned DNA. EcoRIIKpnI digestion of the 
cloned A DNA yielded a fragment of 2.8kb suggesting that the clone had an insert 
of 1.8kb and that the 3' EcoRI site had been lost. Further restriction analysis 
showed a unique ScaT site at the 3' end of the insert. ScaT is a blunt end cutter 
and the EcoRT/ScaT fragment was used for subsequent subcloning experiments 
(see later). 
4.3 Analysis of crude lysates prepared from Agtll lysogens. 
In order to characterize further the antigens expressed by the putative 
positive clone the phage were lysogenized in E.coli Y1089 (method 2.6.1). Y1089 
is used rather than Y1090 for this work as it contains not only the lac repressor 
which prevents lacZ gene expression until the addition of TPTG and a deficiency 
in the ion protease which increases the stability of recombinant fusion protein, but 
also the mutation hfiA 150 which enhances the frequency of phage lysogeny. 
The lysogens plus a non-recombinant control were grown to a high cell 
density at 300C and the lacZ-directed fusion production induced by the addition 
of IPTG. The cells were collected and the lysates prepared for SDS-PAGE and 
western blotting analysis with McAb 7.7 (Fig.4.2b). 
It is expected that clones isolated from a Agtll expression library express 
a lacZ fusion protein greater than 1 l6kDa in size. Analysis of clone SL13, 
surprisingly, did not indicate expression of a fusion protein containing an epitope 
for the McAb 7.7. Instead, in comparison to the control (Track 1), it expressed 
a protein migrating at approximately 60kDa which was recognised by McAb 7.7 
(Track 2). Interestingly this size of protein corresponds to an open reading frame 
(ORF) of approximately 1.8kb, the size of the insert in clone SL13. 
Several explanations were suggested to explain why the Agt11SL13 lysogen 
expressed a protein of 60kDa. They included the possibility that it was a 
breakdown product of a -galactosidase fusion protein, however no proteins larger 
than 114kDa were ever observed despite numerous repeat experiments. 
Alternatively the 60kDa protein may be the product of an independent translation 
initiation event within the insert DNA. Indeed this was previously observed in the 
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cloning of the &xp-1 gene (Hope et aL, 1985). Prokaryotic ribosomes can find 
initiation sites in any region of the mRNA and polycistronic messengers are 
possible whereas'in eukaryotic mRNAs only the most S'site(s) is utilized (Kozak, 
1983). In prokaryotes the most frequently used initiator codon is AUG and the 
initiating AUG is preceded by a purine-rich stretch of 5-10 residues 7±2 bases 
upstream (Shine and Dalgarno, 1974) which mediates ribosome binding by virtue 
of its complementarity to a highly conserved region near the 3' end of the 16S 
rRNA (Steitz and Jakes, 1975). Also the upstream region to this is usually rich 
in A residues and lacking in G residues (Rodier et al, 1982). However, eukaryotic 
ribosomes recognise a capped S'mRNA end i.e. a terminal G methylated in 
position 7 and linked via a 5'-5' triphosphate bond to RNA. This increases the 
stability of the transcript and enhances the binding on the 40S ribosomal subunits 
to the mRNA. Translation initiation then starts at the first downstream AUG. 
Considering the differences between the two systems it would seem likely 
that mRNA from eukaryotic genes may contain sequences which would be 
recognised as a translation initiation sites by prokaryotic ribosomes which would 
not be recognised as initiating sites by the eukaiyote ribosomes. Thus when 
fragments of eukaryotic genes are expressed in prokaryotic systems anomalous 
expression of the eukaryotic sequences may occur. 
Several lines of investigation were used to test whether the 60kDa was the 
result of a breakdown of a -galactosidase fusion protein or the result of an 
independent translation event and to investigate whether the clone encoded exp-2. 
These were 1) cloning of the 1.8kb fragment in all three frames of an expression 
plasmid to test whether expression of the ôOkDa polypeptide occurred in all three 
frames, 2) sequencing of the 1.8kb fragment to identify possible open reading 
frames and 3) raising antisera to the polypeptide in order to determine whether 
the clone encoded exp-2. 
4.4 Analysis of proteins expressed by pMS SL13 constructs 
In order to test for independent initiation of translation within the insert 
the 1.8kb EcoRl/Scal fragment described previously was subcloned into an 
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expression plasmid pMS. Like Agtll the pMS plasmid family contain a unique 
EcoRI site within the lacZ gene (see Fig.4.3). Foreign DNA can be inserted into 
this site and has the potential to be expressed as a 3-gaIactosidase fusion protein 
under the control of the lacZ repressor. Three different forms of the plasmid 
were available with the EcoRI site in a different frame in each and the insert was 
subcloned into all three reading frames. In theory if the 60kDa protein is the 
result of an independent translation initiation event all three constructs should 
express the 60kDa protein. Also, if the insert contains a continuous open reading 
frame throughout its length one pMS construct should give a high molecular 
weight lacZ fusion protein. 
4.4.1 Subeloning Strategy 
The 1.8kb EcoRl/Scal fragment was subcloned into an EcoRI/blunt ended 
site of pMS (see Fig.4.4 for strategy). In order to prepare the vector for 
subcloning the vector was first digested with BamMI, since after this site there is 
a translation stop region, and then blunt-ended using Klenow to end-fill the DNA. 
The vector was then cut with EcoRI, a ligation reaction performed with the 
EcoRIIScaI fragment and the mixture transformed into E.coli JM83 cells. Positive 
colonies were identified by hybridisation to the 1.8kb insert (see method 2.5.21). 
4.4.2 Sequence analysis of the three pMS SL13 constructs 
DNA was prepared from positive clones pMS1SL13/A, pMS2SL13/C and 
pMS3SL13/F each representing the insert in a different reading frame. In order 
to confirm that the insert in each were in the correct frame the constructs were 
sequenced across the lacZ/insert junction (see Fig.4.5). Interestingly sequence 
analysis indicated that the origin of the 5' EcoRI site was genomic and not the 
result of linker addition since the sequence of the linker is GGAATTCC and the 
three clones contained just GAATIFC at the junction. Preliminary sequence 
analysis also indicated that only construct pMS2SL13/C contained the insert in 
frame with the lacZ gene and therefore it was predicted that this construct could 
express a lacZ fusion protein. Also, as indicated in the figure, this potential ORF 
is not in frame with the lacZ gene of Agtll and therefore as observed no fusion 
protein would be expressed in the Agtll SL13 clone. 
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Polylinker sequence of pMS1 S, pMS2S, pMS3S. 
LacZ1023 	Xhol 	/nI 	factor Xa-site 	KpnI 
5'-CM AAA cm GAG GTh CCG ATC GM CGI AG GTA CCA 
He 	Glu Gly Mg I 
EcoR I 
Hind I II 	Bg1Il pMS1S AGAAUC 
AGUACAAIGTGAG pMS2S GMTTCT GM OCT 
pMS3S AAUCTA 
stop- region 	 Sinai 
AGT MT TM TAG ATA ATA GC 0(3(1 GCT TC MA TCG AGT-3' 
Figure 4.3: The pMS plasmid expression vector family. 
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1, Cut with EaRI 
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2, Cut with Seal. 
pMSIS, pMS2S, PMS3S 
Cut with BaxnHl. 
End-Fill.  
I 
3' 	 5' 
1.8kb 
Hililfil - LacZ gone 





- 	 —Direction of 
LacZ 
transcription 
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Figure 4.4: Outline of the strategy used to subclone the SL13 1.8kb insert 
into the three pMS vectors. 
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Figure 4.5 
DNA sequence and predicted ORF across the fritZ/insert junction of the three 
pMS constructs. 
Using the 'universal' oligonucleotide primer the DNA sequence across the 
lacZlinsert junction of the three pMS constructs pMS1SL13/A, pMS2SL13/C and 
pMS3SL13/F was determined. The figure indicates the predicted amino acid 
translation and stop sites. It also shows the predicted DNA sequence and amino 
acid sequence of the isolated 1gt11SL13 clone across the lacZ/insert junction. 




GQ GAA flC flT AGA AGA GAC ACA AGA CAA 
AGT11SL13 	 A E F F R R D T R Q 
ATT Afl AGA ACT ATA TGA AAA Tn' TAA GAA AGA 
I 	I 	ft T 	I STOP 
EcoR I 
I 
TGC MiA GM TTC TTT AGA AGA GAC ACA AGA CAA 
R 	E 	F 	F 	ft 	ft 	P 	T 	ft 
pMS1 SLI 31A 
Afl An AGA ACT ATA TGA AAA Tn' TAA GAA AGA 
I 	I 	ft T 	I STOP 
EcoR I 
I 
A<G AAT TCr TTA GAA GAG ACA CAA GAC MA 
pMS2SL13/C 	C ft N S L E E T 0 P K 
flA flA GAA CTA TAT GAA AAT Tn' AAG AM GM 
L L E L Y E N F K K E 
EcOR I 
I 
TGG AGA Afl Cfl TAG AAG AGA CAC AAG ACA AAT 
C 	ft 	I 	L STOP 
pMS3SL1 3/F 	
TAT TAG MC TAT ATG AM Afi TTA AGA AAG AAA 
IM 
4.4.3 Expression analysis 
In order to test for expression of the insert, the three recombinant plasmids 
plus a control pMS vector containing no insert were grown in the absence and 
presence of IPTG. Total protein from each was separated by SDS-PAGE and 
electrophoretically transferred onto nitrocellulose. The blot was then probed with 
McAb 7.7 (Fig 4.6a). As expected only one construct, pMS2SL13/C, in which the 
insert is in the correct reading frame with the lacZ gene, expressed a high 
molecular weight fusion protein recognised by the McAb 7.7. However, all three 
constructs express a protein migrating at 60KDa which is recognised McAb 7.7. 
This protein was only present upon induction with JPTG and was not seen in the 
pMS control. Thus the 60kDa polypeptide is the result of a independent 
translation initiation event since it was expressed regardless of the frame. Blots 
prepared from total protein expressed by construct pMS2SL13/C were also probed 
with PcAb 7.7 (Fig 4.6b) and anti-3-galactosidase antibodies (Fig 4.6c) which 
demonstrated that the 60kDa protein was also recognised by the polyclonal 7.7 
serum and confirmed that the 180kDa protein was indeed a 3-galactosidase fusion 
protein. 
4.5 Sequence analysis of the 1.8kb insert 
To assess further the idea of an internal initiation site near the 5' end of 
the insert, the insert was completely sequenced (method 2.4.26) (see next chapter 
for sequence data). This was achieved by walking along the gene using synthetic 
oligonucleotides as primers. Computer prediction from the sequence indicated 
that the insert contained a continuous ORF with the potential of encoding a 
70kDa polypeptide and a full analysis of this amino acid sequence will be given 
in the next chapter. For the purposes of the present discussion however the 
sequence data was also analyzed to see if there was a potential Shine-Dalgarno 
sequence followed by an ORF capable of encoding a 60kDa protein. At a 
position 318bp downstream from the EcoRI site there is an ATG codon in frame 
with the ORF which if it acted as a translation start site, would encode a 
polypeptide of approximately 60kDa. Five bases upstream from this AUG there 
11119 
Figure 4.6 
Western blot analysis of the proteins expressed by the pMS SL13 contructs; 
The 3 recombinant plasmids pMS1SL13/A, pMS2SL13/C and pMS3SL13/F plus 
a non-recombinant control pMS vector were grown in the absence (U) and 
presence (I) of IPTG. 
Total protein from each was separated by SDS-PAGE, electrophoretically 
transferred onto nitrocellulose and probed with McAb 7.7 at a dilution of 1:500. 
Blots prepared from pMS2SL13/C and a non-recombinant control were probed 
with McAb 7.7 at a dilution of 1:500 (Panel 1) and PcAb 7.7 at a dilution of 
1:250 (Panel 2). 
Blots prepared the plasmid pMS2SL13/C and a non-recombinant control were 
probed with McAb 7.7 at a dilution of 1:500 (Panel 1) and anti--galactosidase 
antibodies at a dilution of 1:500 (Panel 2). 
Molecular weight standards (M) are in kDa. 
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is a potential Shine-Dalgarno sequence (3 out of 5 bases of the consensus) with 
an upstream region rich in A residues and lacking in G residues. 
These results are summarized in Figure 4.7. The sequencing data confirm 
the conclusions of the expression studies that when constructs Agt11SL13, 
pMS1SL13/A, pMS2SL13/C and pMS3SL13/F are expressed in E.coli an 
independent internal initiation of translation generates a 60kDa polypeptide. 
Since this is only observed upon induction with IPTG it indicates that expression 
is under the control of the lacZ repressor. This suggests that there is only one 
transcription product of the lacZ fusion and that this functions as a polycistronic 
message (i.e. the bacterial ribosomes recognise not only an initiation site 
corresponding to the beginning of the -galactosidase gene but also a second 
AUG within the mRNA corresponding to the beginning of the 60kDa protein). 
In constructs Agt11SL13, pMS1SL13/A and pMS3SL13IF the ribosomes reach a 
stop codon shortly after the lacZIl.8kb junction and soon after the end of the 
1.8kb insert. Thus they produce a truncated -galactosidase fusion protein and 
a 60kDa protein from the internal initiation. In construct pMS2SL13/C the 
ribosome does not reach a stop codon until soon after the end of the 1.8kb insert. 
Hence a 180kD fusion protein is expressed from the first initiating methionine and 
once again a 60kDa protein is expressed from the internal initiation. 
4.6 Characterization and subcellular localization of the antigen encoded by clone 
SL13 
As discussed earlier the 1.8kb insert of SL13 contained a potential ORF 
encoding a polypeptide of 70kDa, despite the fact that exp-2 is only 35kDa in size. 
There are two possible explanations for this discrepancy: 1) SL13 encodes exp-2 
but exp-2 is initially synthesized as a large precursor which is subsequently 
processed to 35kDa or 2) Clone SL13 does not encode exp-2 but encodes a 
protein with a cross-reactive epitope. In order to determine which of these 
explanations is correct it was decided to raise antibodies to the affinity purified 
60kDa protein and test for reactivity against exp-2. 
Levels of expression of the 60kDa protein were very poor so conditions 
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Figure 4.7 
Model describing expression of the 1.8kb insert in the pMS SL13 contructs 
Summary of AgtllSL13, pMS1SL13/A, pMS2SL13/C and pMS3SL13/F 
expression. In all four constructs there is a single transcription product of the lacZ 
fusion which functions as a polycistronic message in the bacterial expression 
system. When translation occurs in this system in constructs Agtl.1SL13, 
pMS1SL13/A and pMS3SL13IF the ribosomes reach a stop codon shortly after the 
lacZlinsert junction and soon after the end of the 1.8kb insert. They produce a 
truncated fusion protein and a 60kDa protein from the internal initiation. 
Whereas in construct pMS2SL13/C the ribosome only reaches a stop codon 
shortly after the end of the 1.8kb insert and therefore a 180kDa fusion protein is 
expressed from the first initiating methionine and a 60kDa protein from the 
internal initiation. 
Sequence data indicating the predicted internal initiating methionine and the 
potential upstream Shine-Dalgarno sequence. 
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were optimized to enhance expression. Time course studies indicated that the 
60kDa protein was observed from one hour after induction with IPTO and the 
relative amount as a percentage of total cell protein increased steadily up to four 
hours post-induction (data not shown). The protein was purified from cell lysates 
by using the McAb 7.7 affinity column described earlier (method 2.6.14.2). The 
bound protein was eluted with 100mM diethylamine pH 11.5, dialysed against 
PBS, concentrated and used to immunize two mice (method 2.6.14.3). 
The antibodies raised against affinity purified 60kDa protein were tested 
by western blotting analysis and IFA. The results of the western blot analysis 
against total parasite proteins are shown in (Fig.4.8). Control strips were probed 
with McAb 7.7 (Track 1) and PcAb 7.7 (Track 2). The mouse anti-60kDa protein 
sera were tested before (Tracks 3 and 4) and after absortion with an E.coli cell 
lysate (Tracks 5 and 6). As expected both the McAb 7.7 and PcAb 7.7 sera 
recognized the 35kDa protein exp-2. The mouse anti-60kDa sera failed to 
recognise this protein indicating that they had been generated against another 
antigen not exp-2. The sera did however recognise several large proteins with a 
molecular weight greater than 200kDa. 
In order to assess the localization of the antigen encoded by SL13 an IFA 
was performed on acetone fixed thin smears of asynchronous P.falcipanun infected 
RBCs. The mouse sera were used at a dilution of 1:3 (method 2.6.1) and the 
parasite nuclei were counterstained with DAPI (Fig.4.9). All the cells which 
stained with fluorescein also stained with DAPI indicating that the antibody 
recognised parasitised cells and confirming the parasite origin of the protein(s) 
- recognised by the mouse sera. The pattern of fluorescence had similarities to that 
of exp-1 and exp-2 in that 1) there is a distinct ring of irregular staining around 
the parasite, a pattern characteristic of the PV.M and 2) it is present in ring, 
trophozoite and schizont stage parasites. There was however, no evidence of 
staining of vesicular structures. These results taken together with the western 
analysis suggest that the sera do not recognise either exp-1 or exp-2 but another 
protein which is localized to the PVM. This antigen, due to similar localization 
as exp-1 and exp-2 in the parasitized RBC, was termed exp-3. 
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Figure 4.8 
Western blotting analysis 
A western blot of saponin lysed total parasite protein extracts were probed with 
McAb 7.7 (1:500) (Track 1), PcAb 7.7 (1:500) (Track 2), mouse 1 anti-60kDa 
antigen serum (1:50) (Track 3) and mouse 2 anti-60kDa antigen serum (1:50) 
(Track 4), pre-absorbed mouse 1 anti-60kDa antigen serum (1:50) (Track 5) and 
pre-absorbed mouse 2 anti-60kDa antigen serum (1:50) (Track 6). 
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Pattern of indirect immunofluorescence assay (IFA) staining produced by the 
mouse anti-60kDa antigen serum on blood films of P.falciparum. 
Acetone fixed smears of Ki P.falciparum infected RBCs were incubated with 
mouse 1 anti-60kDa antigen serum followed by anti-mouse FITC-conjugated 
second antibody. Parasite nuclei were counterstained with DAPI. The same 
infected cell was analyzed for the presence of DAFT (panels la-3a) and 
fluorescein (panels lb-3b). Three fields of infected RBCs are shown, panel 1 
shows a RBC containing a ring-stage parasite, panel 2 RBCs containing 
trophozoite stage parasites and panel 3 a RBC containing a schizont stage 
parasite. 
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4.7 Discussion 
The McAb 7.7 is a relatively specific antibody which recognises a protein 
of 35kDa termed exp-2. This antibody was used to extensively screen expression 
libraries and a clone reacting positively with the antibody was identified. 
However, further analysis indicated that the clone contained a 1.8kb insert 
containing a continuous ORF encoding a protein of at least 70kDa. It was 
determined that the 60kDa protein expressed by the Agtll clone resulted from an 
internal initiation of translation at a cryptic Shine-Dalgarno sequence within the 
insert. Antibodies raised against this 60kDa protein encoded by clone SL13 failed 
to recognise the 35kDa exp-2 protein but recognised instead parasite proteins 
greater than 200kDa in size. Thus it appeared that the clone encoded a large 
protein which contained an exp-2 cross-reacting epitope. One option available at 
this point was to abandon this clone and further attempt to isolate the exp-2 gene 
by library screening and other methods. However, as previously discussed, the 
purification of large quantities of exp-2 for protein sequencing had proved difficult 
and extensive screening of libraries with both monoclonal and polyclonal 7.7 sera 
had failed to produce other candidate clones. Since IFA indicated the parasite 
protein, partly encoded by clone SL13, had a similar distribution to both exp-1 and 
exp-2 in the parasitised RBC, i.e. it was also localized to the PVM, and since the 
original aim of the project was'to characterize proteins exported by the parasite 
to the PVM, it was decided to proceed with further characterization of the exp3 
gene identified by clone SL13 and its gene product. 
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CHAPTER 5 
IDENTIFICATION OF TWO MEMBERS OF A GENE 
FAMILY 
5.1 Introduction 
In the previous chapter a clone (SL13) selected by screening, was 
characterized in terms of the size and localization of its gene product. Its DNA 
sequence was analyzed to explain the bacterial expression of a 60kDa protein 
rather than a lSOkDa Lac Z-fusion protein. 
In the course of further characterizing this clone it became apparent that 
the clone encoded one member of a two gene family. This chapter initially 
describes the analysis that leads to this conclusion and finally discusses the 
deduced protein sequences of the two respective genes. 
5.2 Identification of two genomic EcoRI fragments related to the clone SL13. 
The SL13 clone contained a 1.8kb fragment which encoded part of an 
antigen termed exp-3. To characterize further the gene encoding exp-3 a 
Southern blot of EcoRI digested P.falciparum isolate K1 genomic DNA was 
probed with the 1.8kb fragment. This DNA was digested with EcoRI, separated 
by electrophoresis, transferred onto Hybond-N (method 2.4.7) and probed with 
the 1.8kb insert at 65 0C (method 2.4.9). The filter was then washed stringently 
(0.1x SSC, 0.1% SDS at 650C (4 x 15 minutes)) and autoradiographed. The result 
is shown in Figure 5. la. The 1.8kb probe hybridised to two EcoRI fragments of 
approximately 6kb and 4.3kb. Subsequently genomic DNA of the two P.falcipansin 
clones 3D7 and H133 was hybridised to probes specific for these two EcoRI 
fragments. The DNA of both these clones hybridised to both fragments. (See 
Appendix 1, p.247  for further details and discussion). 
Since the 1.8kb insert did not contain an internal EcoRI restriction site, it 
indicated that there were two sequences in the P.falcipamm genome related to the 
probe sequence. Furthermore, since the hybridisation and subsequent washing 
was performed at high stringency it suggested that both fragments shared a high 
degree of homology to the probe. This led to a hypothesis that two members of 
a two gene family had been identified. 
5.2 PCR analysis 
A formal possibility existed that the insert in the original SL13 clone, 
isolated from the sheared library, was the result of two sheared DNA fragments 
122 
Figure 5.1 
Characterization of the SL13 clone 
Identification of two genomic EcoR.1 fragments related to clone SL13 
An aliquot (3 pg) of EcoRI digested genomic P.falciparum isolate Ki DNA was 
separated by electrophoresis in a 0.7% agarose gel and transferred onto Hybond-
N. The blot was probed with the 1.8kb insert from clone SL13 at 650C, washed 
stringently and autoradiographed. Molecular weight markers (M) are in kb. 
and c) PCR analysis 
DNA was amplified from genomic P.falczparum isolate Ki DNA (Track 1) and 
from the plasmid construct pMS2SL13/C (Track 2) using oligonucleotide primers 
286G and 534H. SpA of each reaction was separated by gel electrophoresis and 
stained with ethidium bromide (panel b). The DNA was transferred onto 
Hybond-N, probed with an internal oligonucleotide 980H at 37 0C, washed and 
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which had been ligated together in the same phage vector. Such an insert would 
hybridise to two genomic DNA fragments. To test this possibility PCR analysis 
was used to discover whether an identically sized fragment, corresponding to the 
1.8kb insert, could be amplified from genomic P.falciparum DNA and from the 
clone. The expression construct pMS2SL13/C was used for this experiment. Two 
reactions were performed, one using genomic DNA as the template and the other 
pMS2SL13/C DNA (method 2.4.29). The oligonucleotide primers used were 286G 
(5'-TATTAGAACTATATGTG-3') which maps to nucleotides 30-47 and 534H (5'-
ATATCATGAYITGTTG-3') which maps to nucleotides 1612-1595 of the 1.8kb 
fragment (see Fig.5. 13a) From the sequence data it was predicted that the PCR 
should amplify a fragment of approximately 1.6kb. An aliquot of each reaction 
was separated by gel electrophoresis (Fig 5.1 b), blotted onto Hybond-N and 
probed with an internal oligomer 980H which maps to position 1346-1329 (Fig 
5.1c). Both reactions amplified an identically sized fragment of the predicted size 
which was recognised by the internal oligomer. This confirms that the SL13 1.8kb 
insert was a single genomic fragment. 
5.4 Isolation and analysis of a 4.3kb EcoRI fragment 
The genomic blot probed with the 1.8kb insert indicated that the two 
related genes contained EcoRI fragments of 6kb and 4.3kb. The next stage in 
analysis of this potential two gene family was to further investigate the relationship 
between the two genomic EcoRI fragments and the 1.8kb insert. To do this the 
fragments needed to be isolated and cloned. In theory the EcoRI ANM1149 
(Goman et al., 1982) library should contain both fragments, though the larger of 
the two fragments is close to the insert upper size limit of the library. This library 
was probed with the 1.8kb insert (method 2.4.25). The library was plated out as 
plaques in the bacterial strain Y1090 and incubated overnight at 37 0C. The 
following day DNA from the plaques was transferred onto Hybond-N filters 
denatured, neutralised and fixed. A random labelled probe was prepared from 
the 1.8kb fragment (method 2.4.8) and the filters were allowed to hybridize to the 
probe overnight at 65 0C. Filters were then washed at high stringency and 
autoradiographed. A total of 15 positive plaques were identified and subsequently 
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plated out and rescreened until plaque pure. DNA was prepared from all the 
positive clones (method 2.4.2.4) and digested with EcoRI. All 15 clones contained 
an EcoRI fragment of 4.3kb. 
For further genetic manipulation and sequencing of the 4.3kb fragment it 
had to be subcloned into a suitable plasmid. Attempts were made to subclone the 
4.3 EcoRI fragment into pUC19 and pUBS but this was unsuccessful. Attempts 
were also made to subclone the fragment into the sequencing vectors ml3mp18 
and m13mp19. However, the insert proved to be unstable in these vectors and 
deletions frequently occurred. Because of these problems it was decided to 
attempt subcloning of a smaller fragment of the EcoRl 4.3kb insert. In order to 
identify a suitable fragment aliquots of the 4.3kb insert DNA were digested with 
a range of restriction enzymes. The digested DNA was then separated by gel 
electrophoresis, blotted onto Hybond-N and probed with the 1.8kb insert from 
clone SL13. Digestion with HindIII yielded two fragments of 2.2kb and 2.1kb and 
the EcoRIIHin dIll 2.2kb fragment was recognised by the 1.8kb probe. Both these 
fragments were suitable for subcloning but since the larger EcoRI/HindIII 
fragment was recognised by the 1.8kb probe, and therefore may contain 
overlapping sequence to the 1.8kb it was decided to subclone this fragment first. 
This 2.2kb EcoRIIHindIII fragment was subcloned into the EcoRI/HindIII site of 
the plasmid vector PUC19, construct pUC2.2R/H for sequence analysis. 
5.4.1 Preliminary sequence analysis of the 2.2kb EcoPJIHindIII fragment. 
The 2.2kb EcoRIIHindIII fragment in construct pUC2.2R/H was sequenced. 
The 5' end of it was identical to the 5' end of the 1.8kb clone and both clones 
begin at an identical position i.e at an EcoRI site. However, after 1300bp of 
identical sequence the two sequences diverged considerably. This result suggested 
that the 1.8kb fragment and the 2.2kb EcoRIIHindIII fragment were not 
overlapping fragments but mapped to the two different EcoRI genomic fragments 
previously demonstrated in Figure 5. 1a. This result is the basis of the model for 
the two genes shown in Fig 5.2. In the model the gene containing the pMSL13 
1.8kb fragment is termed exp-3a and the gene containing the pUC2.2R/H 2.2kb 
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EcoRl/Hindlil fragment is termed exp-3b. 
0 	 2 	 4 	 6 
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Figure 5.2: Model showing a partial restriction map of the two members of the 
exp-3 gene family indicating where the 1.8kb pMSL13 and 2.2kb pUC2.2R/H 
inserts map and the sequence common and unique to each. 
5.5 Confirmation that there are two related sequences 
In summary the previous results indicated that two members of a gene 
family have been identified which contained a common sequence. This required 
confirmation and also further investigation was needed to determine the 
relationship between the two genes. If there are two related genes with a 
common sequence a probe from the common sequence should hybridise to two 
genomic EcoRI fragments while a probe from either of the unique regions should 
hybridise to only one genomic EcoRI fragment. 
Total genomic P.falciparum DNA was digested with either EcoRI, Hin dill 
or double digested with both EcoRI and Hin dill and separated by electrophoresis. 
The DNA was then transferred onto Hybond-N and either probed with a common 
sequence probe or with either of the two divergent unique sequence probes. The 
three probes were generated by PCR (method 2.4.29). A 600bp common probe 
was amplified from the Agtll SL13 clone using oligonucleotide primers 286G (5'-
TATTAGAACTATATGTG-3') which maps to nucleotides 30-47 and 285K (5'-
CAGATTTCCCCGTATTC-3') which maps to 648-631 of exp-3a. The 350bp 
unique exp-3a probe was also amplified from the ).gt11 SL13 clone but using 
127 
oligonucleotide primer 150M (5 '-GTTAGTATGGATAATAC-3') which maps to 
nucleotides 1477-1494 of exp-3a and primer 380A (5'-TAGCGACCGGCGCTC-3') 
which maps to a region adjacent to the EcoRI in the gt1 1 vector. The 800bp 
unique exp-3b probe was amplified up from pUC2.2R/H using the oligonucleotide 
primer 219M (5'-CAAGAAAGACAAGAACA-3') which maps to nucleotides 
5085-5102 of exp-3b and the pUC19 polylinker 'reverse' primer. The results are 
shown in Figure 5.3 and summarized in Table 5.1. 
Table 5.1: Summary of the Southern blot result shown in Fig.5.3. 
Size of genomic DNA fragment 
Probe 
EcoRI Hindlil EcoRI/HzndIII 
6.1kb 8.0kb 5.9kb 
Common sequence 
4.3kb 4.9kb 2.2kb 
Unique sequence 
from 1.8kb insert 6.1kb 8.0kb 5.9kb 
Unique sequence 
from 2.2kb 4.3kb 4.9kb 2.2kb 
EcoRI/HindIII insert 
As expected the blot probed with the common sequence fragment 
recognised two fragments in each genomic digest (panel a), whereas the unique 
probes recognised only one each of these, confirming the two gene family 
hypothesis previously outlined (panels b and c). Using these results a provisional 




Genomic Southern blots probed with fragments of exp-3a and exp-3b. 
P.falciparum isolate Ki genomic DNA was digested with either EcoRI (Al), 
HindJII (1-13) or double digested with both EcoRI and HindIII (RI/1-13). Aliquots 
(3isg) of each digest were separated by gel electrophoresis and transferred onto 
Hybond-N. Blots were probed with either a 600bp common region probe (panel 
a), a 350bp unique exp-3a probe (panel b) or a 800bp unique exp-3b probe (panel 
c) at 650C, washed stringently and autoradiographed. Molecular weight markers 
(M) are in kb. 
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igure 5.4: Provisional restriction map of exp-3a and exp-3b showing the location 
f EcoRI (RI) and HindIII (H3) restriction sites based on the blot shown in Fig. 
..:'. 
5.6 Identifying further genomic clones from a sheared library. 
Sequencing to this point had indicated that both the 1.8kb fragment of exp-
3a and the 2.2kb EcoRIIHindIII fragment of exp-3b both contained continuous 
ORFs. In order to continue sequencing studies overlapping clones to each needed 
to be isolated. Initially, efforts were concentrated on continuing the downstream 
sequence where the two sequences were known to differ. 
Probing genomic blots with the 1.8kb insert had indicated that overlapping 
EcoRI and Hindlil fragments to it were 6.1kb and 8kb respectively. However, 
attempts to isolate the 6kb EcoRI fragment from a library had been unsuccessful 
and it seemed unlikely that the larger 8kb HindIII fragment would be present in 
a Hindill library. Therefore in order to isolate overlapping clones a sheared 
genomic library in Agtll (Certa et al., 1988) was screened using the 1.8kb insert 
as a probe by a procedure similar to that previously described for screening the 
EcoRI library. 
A total of 13 clones were identified on the primary screen which were 
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subsequently plated out and rescreened until plaque pure. DNA was prepared 
from 12 of the positive clones (method 2.4.2.4). The DNA was initially 
characterized by restriction analysis which revealed that there were in fact only 9 
different types of clones. None of these contained an internal EcoRI restriction 
site suggesting none overlapped the 5' end of the clones so far obtained. Since 
the probe would have isolated DNA fragments which would overlap genes 
encoding both exp-3a and exp-3b the clones were further distinguished. This was 
achieved by probing the digested DNA with the 1.3kb common sequence and an 
oligonucleotide 607L (5'-GATGYTAATGATTATAG-3') specific for exp-3a 
encoding part of the 3' end of the original 1.8kb insert isolated from clone 13. A 
summary of the results is shown in Table 5.2. 











1 2.2kb x x x 
2, 5, 8, 11 1.5kb / / x 
3 3.0kb / x pUCSL3 
4 1.6kb / x x 
6 1.65kb / / x 
7 1.7kb / x pUCSL7 
10 1.8kb / / x 
12 2.9kb / / pUBSLL 
13 2.6kb V pUBSLM 
The results indicated that clones 2, 5, 8, 11, 6, 10, 12 and 13 contained 
sequence overlapping the 1.8kb, the gene designated exp-3a, while clones 3, 4 and 
7 contained sequence overlapping either exp-3a or exp-3b. 
It was decided to subclone some of these inserts for further sequencing 
analysis. The clones containing the largest inserts hopefully representing both 
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exp-3a and exp-3b were subcloned into pUC 19 or pUBS as indicated. The 
inserts from clones 3, 7, 12 and 13 were subcloned into either the plasmid vector 
pUC19 or pUBS. 
The inserts of the four clones were sequenced. Three of the clones, 
pUCSL7, pUBSLM and pUBSLL contained inserts which overlapped the exp-3a 
while the fourth construct pUCSL3 contained an insert which overlapped exp-3b 
(summarized in Figure 5.5). For both genes the overlapping sequence was at the 
3' ends. In both cases TAA stop codons were identified which occurred at the 
onset of A+T rich DNA. This is typical of malarial stop codons (Pollack et al., 
1982) and suggested that the 3'-end of the coding region of both genes had been 
identified. (The details of the sequence will be presented at the end of this 
chapter). However further analysis of the 5' region of the gene was also required. 
5.7 Identifying a 5' HindlIl overlapping clone 
From the previous screening result it seemed unlikely that the sheared 
library would yield overlapping 5' clones because several of the clones identified 
terminated at the identical genomic EcoRI site. This indicated that perhaps 
during construction of the sheared library the genomic DNA had not been 
methylated and genomic EcoRI sites had been cut. Therefore in order to obtain 
5' overlapping sequence across the EcoRI site a HindIII library was screened. The 
expected size of the overlapping Hindlil fragment for exp-3a was 8kb and for exp-
3b it was 5kb (see Fig.5.3). It was unlikely that the library contained the larger 
HindIII fragment. However the smaller fragment was likely to be present. 
The HindIII library was screened for the HindlIl 4.9kb fragment using the 
2.2kb EcoRI/HindIII fragment from the exp-3b gene as a probe. DNA was 
prepared from 6 positive clones and digested with Hindlil. All 6 clones contained 
a Hindill fragment of approximately 5kb. The fragment was subcloned into the 
Hindill site of the vector pUC19, construct pUC5H3, and sequenced. As 
expected the sequence overlapped the 5' end of the exp-3b sequence (see Fig.5.6). 
Complete sequencing showed a continuous ORF but there was no obvious 
initiating methionine. 
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Figure 5.5: Model of the 3' ends of exp-3a and exp-3b indicating the putative 
stop sites and where the isolated sheared library clones map. 
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2.2kb probe used to screen Hind III library 
e 5.6: Model showing an extended restriction map of the exp-3b gene 
Iting the EcoRI (RI) and HindIII (1-13) restriction sites and the fragmen 
to screen the Hin dill library. 
5.8 Identifying a 5' EcoRI overlapping clone 
In order to continue walking along the exp-3b gene fragments overlapping 
the 5' of the 4.8kb HindIll fragment had to be identified and isolated. To 
determine the size of the next 5' overlapping EcoRI fragment a genomic blot 
similar to that previously probed was probed with the 5' 2.6kb HindIIIIEcoRI 
fragment from construct pUC5H3. It hybridised to a single EcoRI fragment of 
3.8kb. 
The EcoRI library was screened for this 3.8kb fragment with the 2.6kb 
HindIIIIEcoRI fragment using a standard procedure. DNA was prepared from 
6 of the positive clones and digested with EcoRI. All 6 clones yielded a 3.8kb 
EcoRI fragment as expected. The 3.8kb EcoRI insert was subcloned into pUBS, 
construct pUB3.8R, and sequenced. The 3.8kb EcoRI fragment was also digested 
with HindIII and the 1.2kb EcoRi/Hindill fragment subcloned into pUBS, 
construct pUB1.2RH. The 3.8kb EcoRI sequence overlapped with the 5' end of 
the 5kb HindlIl fragment as expected. Once again the ORF was continuous and 
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no initiating methionine was identified (see Fig.5.7 for summary). 
RI 	H3 	 RI 	 RI 





2.6kb HIridIII/EcRi probe 
ire 5.7: Model showing the extended restriction map of exp-3b indicating 
RI (RI) and Hindu! (H3) restriction sites and the fragment used to screen 
RI library. 
In order to continue walking along the exp-3b gene the size of the 
overlapping Hindlil fragment needed to be identified. In addition the relationship 
of the 3.8kb EcoRI fragment from pUC3.8R to the other gene exp-3a needed to 
be assessed i.e is this region of the gene highly conserved between both exp-3a 
and exp-3b? Both these questions could be answered by probing a genomic blot 
with the insert from pUC3.8R to assess if multiple bands are present or not in the 
EcoRI track. 
The 3.8kb EcoRI fragment was used to probe a genomic blot, similar to 




Genomic Southern blot probed with the 3.8kb EcoRI fragment 
P.falciparum isolate Ki total genomic DNA was digested with either EcoRI (RI), 
HindIII (1-13) or double digested with both EcoRI and HindlIl (RII1-13). An 
aliquot (3 vg) of each digest. was separated by gel electrophoresis and transferred 
onto Hybond-N. The blot was probed with the exp-3b 3.8kb EcoRI fragment at 
650C, washed stringently and autoradiographed. Molecular weight markers (M) 
are in kb. 
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Table 53: Summary of the Southern blot shown in Fig.5.8 
probed with the 3.8kb EcoRI fragment. 
Size of genomic DNA fragment 
EcoRI Hindill EcoRI/HindIII 
3.8kb 12kb 2.5kb 
8.0kb 1.2kb 
4.8kb 
The 3.8kb fragment hybridises to a single 3.8kb EcoRI fragment. It also 
hybridises to 3 different Hindlil fragments of 4.8kb, 8kb and 12kb. These data 
strongly suggest that the 3.8kb EcoRI fragment is present and strongly conserved 
in both genes. An updated restriction map of the two genes is presented below. 
STOP 


















3.8kb EPI probe 
re 5.9: Model showing the extended restriction map of exp-3a and exi 
ating the EcoRI (RI) and HindITI ( 1-13) restriction sites and summarizing 
shown in Fig 5.8. 
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Based on previous results and the restriction map the 12kb fragment must 
be the next 5' overlapping Hindill fragment of the 3.8kb EcoRI fragment. It is 
unlikely that the large 12kb HindlIl fragment would be present in a Hindill 
library and no attempts were made to isolate it. 
At this point in the analysis of exp-3a and exp-3b it was decided to 
discontinue the seque,ncing studies and to confirm the model outlined in Figure 
5.9 by investigating whether the 3.8kb EcoRI fragment is common to both genes. 
It was also thought essential to invest more time and effort into characterizing the 
gene products of the exp-3a and exp-3b genes. 
5.9 Copy number analysis of the 3.8kb EcoPJ fragment 
As described in the previous section it was believed that the 3.8kb EcoRI 
fragment from clone pUB3.8R is related to both the exp-3a and exp-3b gene 
sequences. If this is true there should be twice as many copies of the 3.8kb EcoRI 
fragment in the genome relative to any of the unique sequences found at the 3' 
ends of the exp-3a and exp-3b genes. In order to test this an experiment was 
devised to compare the relative number of copies of a piece of the EcoRI 
fragment and a piece one of the unique sequences in the P. falciparum genome. 
The outline of the theory of this experiment and the analysis of the results 
is as follows. Total P. falczparum DNA was serially diluted and spotted in 
duplicate on to a nylon membrane. It was then probed with either a part of the 
3.8kb EcoRI fragment or part of the unique region of exp-3b. Since the probes 
will vary in their incorporation of counts a control plasmid pUC5H3 containing 
a single copy of each of the target sequences per plasmid was also spotted on the 
same filters as a control. The ratio of signal strength between genomic DNA and 
the plasmid DNA are compared for each probe to determine their relative 
frequency in the genome. The level of hybridisation was measured by two indirect 
methods 1) scanning the autoradiograph and 2) scintillation. 
A map showing the relationship of the probes relative to the conserved and 
unique regions of the 5kb Hind III fragment of exp-3b are shown in Fig.5.10. The 
results of the dot blot analysis is shown in Fig. 5.11 and the intensity of the signals 
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and the relevant conclusions are illustrated in Table 5.4. 
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5.10: Map showing the relationship of the probes, used for the 
experiment, relative to the conserved and unique regions of the 
fragment of exp-3b. 
The results shown in table 5.4 indicate that the relative number of copies 
of a fragment of the 3.8kb EcoRI fragment to a portion of the unique sequence 
of the exp-3b gene is 2:1. Therefore this result supports the hypothesis that both 




Copy Number Analysis to examine whether the 3.8kb EcoRl fragment is related 
to both the exp-3a and exp-3b gene sequences. 
Total P.falciparum isolate Ki genomic DNA and the plasmid construct pUC5H3 
were serially diluted and spotted in duplicate on to HybondN+.  The filters were 
probed at 650C with either part of the 3.8kb EcoRI fragment (panel a) or part 
of the unique region of exp-3b (panel b), washed stringently and 
autoradiographed. 
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a 	 Relative Amount of DNA 
16 	8 	4 	2 
P.falciparurn DNA 	• • 
pUC5H3 DNA 
Relative Amount of DNA 
168  
P.falciparurn DNA 
pUC 5113 DNA 
Table 5.4: 	Summary of the copy number analysis shown in Fig.5.11 (results 
shown in bold are from scintillation analysis and the others from densitometry) 
spot 
Relative amount of DNA 
16 8 1 	4 1 	2 1 




1230.83 920.28 571.55 / I 




502.81 188.45 13732  
20881.3 9523.9  
ratio of 
counts 
2.4 4.9 4.2 / I 
1.9 3.7 / 
Unique sequence probe  
Plasmodium 1035.67 574.75 325.15 I / 
falciparum 
DNA 22403.0 12551.4  
plasmid 962.41 256.65 158.65 I / 
construct 
pUC5H3 20059.9 6178.4 
ratio of 
counts 
1.1 2.2 2.0  
1.7 1.9  
Therefore ratio of a part of the 3.8kb EcoRI fragment to a part of the unique 










5.10 Sequence analysis of the exp-3a and exp-3b genes 
The sequence of both genes was determined using synthetic 
oligonucleotides to prime reactions on overlapping clones isolated and 
characterized as previously described (see Fig.5.12 for a summary). This section 
of the chapter will described further analysis of the two genes and examine their 
DNA and predicted amino acid sequences. The sequence determination of both 
genes is given in Figs 5.13a and Fig 5.13b with the predicted amino acid 
translation. The oligonucleotides used as primers are also given. The sequence 
from the 3.8kb EcoRI fragment described above has been presented with the 
sequence data of the exp-3b gene even though Southern blot and copy number 
analysis suggest it is present in both genes. 
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Figure 5.12 
Partial restriction maps of the exp-3a and exp-3b genes. 
Partial restriction maps of the exp-3a and exp-3b genes indicating the putative 
stop sites and the overlapping clones isolated. The 3.8kb EcoRI fragment is 
presented with the exp-3b gene but is probably common to both. Arrows indicate 
the direction Of sequencing. 
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Fig 5.13a: Exp-3a DNA sequence and predicted translation. ([] indicate the 
oligonucleotides used) 
EcoRI 
I 	 [ 	286G 
2 GAATTCTTTAGAAGAGACACAAGACAAATTATTAGAACTATATGAAAATTTTAAGAAAG 60 
CTTAAGAAATCTTCTCTGTGTTCTGTTTAATAATCTTGATATACTTTTAAAATTCTTTC 
	
[ 	650L 	] 
1 N S L E E T Q D K L L E L Y E N F K K E 20 
61 AAAAAAATATTATAAATAATAATTATAAAATAGTACATTTTAATAAATTAAAAGAAATAC 120 
TTTTTTTATAATATTTATTATTAATATTTTATCATGTAAAATTATTTAATTTTCTTTATC 
21 K N I I N N N Y K I V H F N K L K E I E 40 
121 AAAATAGTTTAGAGACATATAATTCAATATCAACAAACTTTAATAAAATAAATGAAACAC 180 
TTTTATCAAATCTCTGTATATTAAGTTATAGTTGTTTGAAATTATTTTATTTACTTTGTG 
41 	N S L E T Y N S I S T N F N K I N E T Q 	60 
181 AAAATATAGATATTTTAAAAAATGAATTTAATAATATCAAAACAAAAATTAATGATAAAG 240 
TTTTATATCTATAAAATTTTTTACTTAAATTATTATAGTTTTGTTTTTAATTACTATTTC 
61 	N I D I L K N E F N N I K T K I N D K V 70 
[ 	524G 	 ] 
241 TAAAAGAATTAGTTCATGTTGATAGTACATTAACACTTGAATCAATTCAAACGTTTAATA 300 
ATTTTCTTAATCAAGTACAACTATCATGTAATTGTGAACTTAGTTAAGTTTCCAAATTAT 
81 	K E L V H V D S T L T L E S I Q T F N N 100 
301 ATTTATATGGTGACTTGATGTCTAATATACAAGATGTATATMLATAflAAGATATTAATA 360 
TAAATATACCACTGAACTACAGATTATATGTTCTACATATATTTATACTTCTATAATTAT 
101 	LYGDLMSN I Q DVYKYE D IN N 120 
361 ATCTTGAATTGAAAAAGGTGAAATTATATATAGAAAATATTACAA-ATTTATTAGGMAA 420 
TACAACTTAACTTTTTCCACTTTAATATATATCTTTTATAATGTTTAAATAATCCTTCTT 
121 	V E L K K V K L Y I F N I T N L L G R I 140 
852G 
421 TAAACACATTCATAAAGGAGTTAGACAAATATCAGGATGAMATAATGGTATAGATAAGT 480 
ATTTGTGTAAGTATTTCCTCAATCTGTTTATAGTCCTACTTTTATTACCATATCTATTCA 
141 N T F I K E L D K Y Q D F N N G I D K Y 160 
) 
481 ATATAGAAATCAATAAGGAAAATAATAGTTATATAATAAAATTGAAAGAAAAAGCCAATA 540 
TATATCTTTAGTTATTCCTTTTATTATCAATATATTATTTTAACTTTCTTTTTCGGTTAT 
161 	1 F I N K F N N S Y I I K L K F K A N N 180 
Om 
541 ATCTAAAGGAAAATTTCTCAAAATTATTACAAAATATAAAAAGAAATGAAACTGAATTAT 600 
TAGATTTCCTTTTAAAGAGTTTTAATAATGTTTTATATTTTTCTTTACTTTGACTTAATA 
181 L K E N F S K L L Q N I K R N E T E L Y 200 
601 ATAATATAAATAACATAAAGGATGATATTATGAATACGGGGAAATCTGTAAATAATATAA 660 
TATTATATTTATTGTATTTCCTACTATAATACTTATGCCCCTTTAGACATTTATTATATT 
285K 
201 	N I N N I K ID ID I M N T G K S V N N I K 220 
535H 
661 AACAAAAATTTTCTAGTAATTTGCCACTAAAAGAAAAATTATTTCAAATGGAAGAGATGT 720 
TTGTTTTTAAAAGATCATTAAACGGTCATTTTCTTTTTAATAAAGTTTACCTTCTCTACA 
221 Q K F S S N L P L K E K L F Q H E E H L 240 
721 TACTTAATATAAATAATATTATGAATGAAACGAAAAGAATATCAAACACGGATGCATATA 780 
ATGAATTATATTTATTATAATACTTACTTTGCTTTTCTTATAGTTTGTGCCTACGTATAT 
241 L N I N N I M N E T K R I S N T D A Y T 260 
781 CTAATATAACTCTCCAGGATATTGAAAATAATAAAAATAAAGAAAATAATAATATGAATA 840 
GATTATATTGAGACGTCCTATAACTTTTATTATTTTTATTTCTTTTATTATTATACTTAT 
261 N I T L Q D I E N N K N K E N N N H N I 280 
841 TTGAAACAATTGATAAATTAATAGATCATATAAAAATACATAATGAAAAAATACAAGCAG 900 
AACTTTGTTAACTATTTAATTATCTAGTATATTTTTATGTATTACTTTTTTATGTTCGTC 
281 	E T I ID K L I ID H I K I H N E K I Q A E 300 
824H 
901 AAATATTAATAATTGATGATGCCAAAAGAAAAGTAAAGGAAATAACAGATAATATTAACA 960 
TTTATAATTATTAACTACTACGGTTTTCTTTTCATTTCCTTTATTGTCTATTATAATTGT 
[ 
301 	I L I I ID ID A K R K V K E I T D N I N K 320 
961 AGGCTTTTAATGAAATTACAGAAAATTATAATAATGAAAATAATGGGGTAATTAAATCTG 1020 
TCCGAAAATTACTTTAATGTCTTTTAATATTATTACTTTTATTACCCCATTAATTTACAC 
9851 
321 A F N E I T E N Y N N E N N G V I K S A 340 
1021 CAAAAAATATTGTCGATGAAGCTACTTATTTAAATAATGAATTAGATAAATTTTTATTCA 1080 
GTTTTTTATAACAGCTACTTCGATGAATAAATTTATTACTTAATCTATTTAAAAATAACT 
341 	K N I V ID E A T Y L N N E L ID K F L L K 360 
1081 AATTGAATGAATTATTAAGTCATAATAATAATGATATAAAGGATCTTGGTGATGAAAAAT 114 
TTAACTTACTTAATAATTCAGTATTATTATTACTATATTTCCTAGAACCACTACTTTTTA 




1141 TAATATTAAAAGAAGAAGAAGAAAGAAAAGAAAGAGAAAGATTGGAAAAAGCGAAACAAG 1200 
ATTATAATTTTCTTCTTCTTCTTTCTTTTCTTTCTCTTTCTAACCTTTTTCGCTTTGTTC 
381 I 	L 	K 	E 	E 	E 	E 	R 	K 	E 	R 	E 	R 	L 	E 	K 	A 	K 	Q 	E 400 
1201 AAGAAGAAAGAAAAGAGAGAGAAAGAATAGAAAAAGAAAAACAAGAGAAAGAAAGACTGG 1260 
TTCTTCTTTCTTTTCTCTCTCTTTCTTATCTTTTTCTTTTTGTTCTCTTTCTTTCTGACC 
401 E 	E 	R 	K 	E 	R 	E 	R 	I 	E 	K 	E 	K 	Q 	E 	K 	E 	R 	L 	E 420 
1261 AAAGAGAGAAACAAGAACAACTACAAAAAGAAGAAGAATTAAGAAGACAAGAGCAGCAAA 1320 
TTTCTCTCTTTGTTCTTGTTGATGTTTTTCTTCTTCTTAATTCTTCTGTTCTCGTCCTTT 
421 R 	E 	K 	Q 	E 	Q 	L 	Q 	K 	E 	E 	E 	L 	R 	R 	Q 	E 	Q 	E 	K 440 




441 Q 	Q Q R 	N1 	Q 	E 	L 	E 	E 	Q 	K 	K 	P 	E 	I 	I 	N 	E 460 
1381 AAGCATTGGTGAAGGGGCATAAAATACTAGAAGGAAGTGATCAGAGAAATATGGAATTAA 1440 
TTCGTAACCACTTCCCCCTATTTTATGATCTTCCTTCACTAGTCTCTTTATACCTTAATT 
461 A 	L 	V 	K 	G 	D 	K 	I 	L 	E 	G 	S 	D 	Q 	R 	N 	M 	E 	L 	S 480 
[ 	1SOM 
1441 GCAAACCTAACGTTAGTATGGATAATACTAATAATAGTCCAATTACTAACAGTGAAATTA 1500 
CGTTTGGATTGCAATCATACCTATTATGATTATTATCAGGTTAATCATTGTCACTTTAAT 
481 	K P N V S M D N T N N S P I S N S E I T 500 
1501 CAGAAAGCGATGATATTCATAACAGTGAAAATATACATACTAGTCATATGAGTGACATGC 1560 
GTCTTTCGCTACTATAAGTATTGTCACTTTTATATGTATGATCAGTATACTCACTGTACG 
501 	E S D D I H N S E N I H T S H N S D M Q 520 
1561 AAAGTACACAAACTAGTCATAGAAGTAACACCCATGGGCAACAAATCAGTGATATTGTTG 1620 
TTTCATGTGTTTGATCAGTATCTTCATTGTGGGTACCCGTTGTTTACTCACTATAACAAC 
[ 	534H 
521 	S T Q T S H R S N T H G Q Q I S D I V E 540 
1621 AAGATCAAATTACACATCCTAGTAATATTGGAGGAGAAAAAATTACTCATAATGATGAAA 1680 
TTCTAGTTTAATGTGTAGGATCATTATAACCTCCTCTTTTTTAATGACTATTACTACTTT 
541 	D Q I T H P S N I C C E K I T H N D E I 560 
[ 	607L 
1681 TTTCAATCACTGGTGAAAGAAATAACATTAGCCATCTTAATGATTATAGTGAAAGTAGCA 1740 
AAAGTTAGTGACCACTTTCTTTATTGTAATCGCTACAATTACTAATATCACTTTCATCGT 
561 	S I T G E R N N I S D V N D Y S E S S N 580 
150 
1741 ACATATTTGAAAATGGTGACAGTACTATAAATACCAGTACAAGAAACACGTCTAGTACAC 1800 
TGTATAAACTTTTACCACTGTCATGATATTTATGGTCATGTTCTTTGTGCAGATCATGTG 
581 	I F E N G D S T I N T S T R N T S S T H 600 
1801 ATGATGAATCCCATATAAGTCCTATCAGCAATGCGTATGATCATGTTGTTTCAGATAATA 1860 
TACTACTTAGGGTATATTCACGATAGTCGTTACGCATACTAGTACAACAAAGTCTATTAT 
601 	D E S H -I S P I S N A Y ID H V V S D N K 620 
1861 AAAAAAGTATGGATGAAAACATAAAAGATAAATTAAAGATAGATGAAAGTATAACTACAG 1920 
TTTTTTCATACCTACTTTTGTATTTTCTATTTAATTTCTATCTACTTTCATATTGATGTC 
621 	K S M ID E N I K ID K L K I ID E S I T T ID 640 
[ 	562M 
1921 ATGAACAAATAAGATTAGATGATAATTCTAATATTGTTAGAATTGATAGTACTGACCAAC 1980 
TACTTGTTTATTCTAATCTACTATTAAGATTATAACAATCTTAACTATCATGACTGGTTG 
641 	E Q  I R L ID ID N S N I V R I ID S T ID Q R 660 
1981 GTGATGCTAGTAGTCATGGTAGTAGTAATAGGGATCATGATGAAATAAGTCATGTTGGTA 2040 
CACTACGATCATCAGTACCATCATCATTATCCCTACTACTACTTTATTCAGTACAACCAT 
661 	ID A S S H G S S N R ID D ID E I S H V C S 680 
2041 GCCACATTCATATCGCACGTCTTCATATTCATGATAGTATTGACACTGATCAAAATGCTG 2100 
CGCTGTAAGTATACCGTGCACAACTATAACTACTATCATAACTGTGACTACTTTTACGAC 
681 	D I H M A R V ID I H D S I D T D E N A D 700 
2101 ATCACAGACATAATGTTAACTCTGTTGATACTCTTAGTTCTAGTGATTACACTGATACAC 2260 
TAGTGTCTGTATTACAATTGAGACAACTATCAGAATCAAGATCACTAATGTGACTATGTG 
701 	H R H N V N S V D S L S S S ID Y T D T Q 720 
325N 
2161 ACAAAGACTTTAGTACTATTATTAAACATCCCGCAAATAAAGAAGGACATGCTCAGAATG 2200 
TCTTTCTGAAATCATCATAATAATTTCTACCCCCTTTATTTCTTCCTGTACGACTCTTAC 
721 	K ID F S S I I K D C C N K E C H A E N E 740 
2221 AATCTAAAGAATATGAATCCCAAACAGAACAAACACATCAACAAGCAATTATGAATCCAA 2280 
TTAGATTTCTTATACTTACCGTTTCTCTTGTTTGTGTACTTCTTCCTTAATACTTAGCTT 
741 	5 K E Y E S Q T E Q T H E E C I N N P N 760 
2281 ATAAATATTCAATTACTGAACTTGATGGTATTAAATTAAATCAACAAGCTAAACATAAAA 2340 
TATTTATAACTTAATCACTTCAACTACCATAATTTAATTTACTTCTTCGATTTCTATTTT 
761 	K Y S I S E V D G I K L N E E A K H K I 780 
151 
692M 
2341 TTACAGAAAAACTGGTAGATATCTATCCTTCTACATATAGAACACTTGATGAACCTATGG 2400 
AATGTCTTTTTGACCATCTATAGATAGGAAGATGTATATCTTGTGAACTACTTGGATACC 
781 T E K L V D I Y P S T Y R T L D E P N E 800 
2401 AAACACATGGTCCAAATGAAAAATTTCATATGTTTGGTAGTCCATATGTAACAGAAGAAG 2460 
TTTGTGTACCAGGTTTACTTTTTAAAGTATACAAACCATCAGCTATACATTGTCTTCTTC 
801 T H C P N E K F H M F C S P Y V T E E D 820 
2461 ATTACACGCAAAAACATGATTATGATAACCATGAAGATTTCAATAATGAAAGGTATTCAA 2520 
TAATGTGCCTTTTTGTACTAATACTATTCGTACTTCTAAAGTTATTACTTTCCATAAGTT 
821 Y T E K H D Y D K H E D F N N E R Y S N 840 
2521 ACCATAACAAAATGGATGATTTCCTATATACTGCTGGAGCACTTCTTTGTTGTGTATTAT 2580 
TCGTATTGTTTTACCTACTAAAGCATATATGACCACCTCCTCAACAAACAACACATAATA 
841 H N K N D D F V Y T A C C V V C C V L F 860 
2581 TTTTTGCAACTATTACTTTCTTTTCTATGCACACATCWTAAGGATGAATCCCATTTTG 2640 
AAAAJkCCTTCATAATCAAAGAAAACATACCTGTCTAGTTTATTCCTACTTACGCTAAAAC 
861 F A S I T F F S M D R S N K D E C D F D 880 
2641 ATATGTGTCAACAAGTATATAATAATGATCACTTATCCAATTATGCTGATAAAGAAGAAA 2700 
TATACACACTTCTTCATATATTATTACTAGTGAATAGCTTAATACCACTATTTCTTCTTT 
759M 
881 M C E E V Y N N D H L S N Y A D K E E I 900 
2701 TTATTGAAATTCTGTTTGATCAAAATGAACAAAAATATTTTtaaCtattacataQtttaa 2760 
AATAACTTTAACACAAACTACTTTTACTTCTTTTTATAAAAattg8taatgtatCaaatt 
901 	I E I V F D E N E E K Y F * 	 913 
2761 taatgaatatataacaaaaapacataatattattagataagtaattaattgttgttaata 2820 
attacttatatattctttttctgtattataataatctattcattaattaacaacaattat 
2821 taattttttatcttgtttaaatatttataaaaaaaaaaaaaaaaaaaaagtpataa 2873 
attaaaaaatagaacaaatttataaatatttttttttttttttttttttCaCtatt 
152 
Fig 5.13b 	Sequence of exp-3b and deduced amino acid 
translation 
EcoRI 
1 GCAATTCGTATGACCATACAAAGCAAAATATAGAAAGCAATCTTAAAATAAATTTACATT 60 
CCTTAAGCATACTGGTATGTTTCGTTTTATATCTTTCGTTAGAATTTTATTTAAATCTAA 
1 	N S Y ID H T K Q N I E S N L K I N L D S 	20 
61 CTTTCGAAAAGGAAAAAGATACTTGGGTTCATTTTAAAAGTACTATAGATAGTTTATATG 120 
GAAAGCTTTTCCTTTTTCTATCAACCCAAGTAAAATTTTCATGATATCTATCAAATATAC 
21 F E K E K D S W V H F K S T I D S L Y V 40 
212 TGGAATATAACATATGTAATCAAAAGACTCATAATACTATCAAACAACAAAAAAATGATA 180 
ACCTTATATTGTATACATTAGTTTTCTGAGTATTATGATAGTTTGTTGTTTTTTTACTAT 
41 	E Y NI!  C N Q K TM N TI K Q Q K N DI 	60 
Li3 
181 TCATAGAACTTATTTATAAACGTATAAAAGATATAAATCAAGAAATAATCGAAAAGGTAG 240 
AGTATCTTGAATAAATATTTGCATATTTTCTATATTTAGTTCTTTATTAGCTTTTCCATC 
61 	I E L I Y K R I K ID I N Q E I I E K V ID 	80 
241 ATAATTATTATTCCCTGTCAGATAAAGCCTTAACTAAACTTAAATGTATTCATTTTAATA 300 
TATTAATAATAAGGGACAGTCTATTTCGGAATTGATTTGAATTTACATAAGTAAAATTAT 
81 N Y Y S L S D K A L T K L K C I H F N I 100 
301 TTGATAAGGAAAAATATAAAAATCCCAAAAGTCAAGAAAATATTAAATTATTAGAAGATA 360 
AACTATTCCTTTTTATATTTTTAGGGTTTTCAGTTCTTTTATAATTTAATAATCTTC TAT 
101 	D K E K Y K N P K S Q E N I K L L E ID R 120 
361 GAGTTATGATACTTGAGAAAAAGATTAAGGAAGATAAAGATGCTTTAATACAAATTAAGA 420 
CTCAATACTATGAACTCTTTTTCTAATTCCTTCTATTTCTACGAAATTATGTTTAATTCT 
121 - V M I L E K K I K E ID K D A L I Q I K N 140 
421 ATTTATCACATGATCATTTTGTAAATGCTGATAATGAGAAAAAAAAGCAGAACGAGAAGG 480 
TAAATAGTGTACTAGTAAAACATTTACGACTATTACTCTTTTTTTTCGTCTTCCTCTTCC 
141 	L S H D H F V N A ID N E K K K Q K E K E 160 
341S 	) 
481 AGGAGGACGACGAACAAACACACTATAGTAAAAAAAGAAAAGTAATGGGAGATATATATA 540 
TCCTCCTGCTGCTTGTTTGTGTGATATCATTTTTTTCTTTTCATTACCCTCTATATATAT 
161 E D D E Q T H Y S K K R K V M G D I Y K 180 
153 
541 AGGATATTAAAAAAAACCTAGATGAGTTAAATAATAAAAATTTGATAGATATTACTTTAA 600 
TCCTATAATTTTTTTTGGATCTACTCAATTTATTATTTTTAAACTATCTATAATGAAATT 
181 D I K K N L D E L N N K N L I 0 I T L N 200 
601 ATGAAGCAAATAAAATAGAATCAGAATATGAAAAAATATTAATTGATGATATTTGTGAAC 660 
TACTTCGTTTATTTTATCTTAGTCTTATACTTTTTTATAATTAACTACTATAAACACTTG 
201 E A N K I E S E Y E K I L I 0 D I C E Q 220 
661 AAATTACAAATGAAGCAAAAAAAAGTGATACTATTAAGGAAAAAATCGAATCATATAAAA 720 
TTTAATGTTTACTTCGTTTTTTTTCACTATGATAATTCCTTTTTTAGCTTAGTATATTTT 
221 	I T N E A K K S 0 T I K E K I E S Y K K 240 
721 AACATATTGATTATGTAGATGTGGACGTTTCCAAAACGAGGAACGATCATCATTTGAATG 780 
TTCTATAACTAATACATCTACACCTGCAAAGGTTTTGCTCCTTGCTAGTAGTAAACTTAC 
241 0 I 0 Y V 0 V D V S K T R N D H H L N C 260 
781 CTCATAAAATACATGATTCTTTTTTTTATGAAGATACATTAAATTATAAAGCATATTTTC 840 
CACTATTTTATGTACTAAGAAAAAAAATACTTCTATGTAATTTAATATTTCGTATAAAAC 
261 D K I H D S F F Y E 0 T L N Y K A Y F D 280 
841 ATAAATTAAAAGATTTATATGAAAATATAAACAAGTTAACAAATGAATCAAATGGATTAA 900 
TATTTAATTTTCTAAATATACTTTTATATTTCTTCAATTGTTTACTTAGTTTACCTAATT 
281 K L K 0 L Y E N I N K L T N E S N C L K 300 
901 AAAGTCATCCTCATAATAACAACACACAACTTGATAAACTAAAAGAAATTAATTTACAAG 960 
TTTCACTACGACTATTATTGTTCTCTCTTCAACTATTTGATTTTCTTTAATTAAATGTTC 
301 S D A H N N N T Q V D K L K E I N L Q V 320 
961 TATTCACCAATTTAGGAAATATAATTAAATATGTTCAAAAACTTGAGAATACATTACATG 1020 
ATAAGTCGTTAAATCCTTTATATTAATTTATACAACTTTTTGAACTCTTATCTAATCTAC 
556T 
321 F S N L G N I I K Y V E K L E N T L H E 340 
1021 AACTTAAACATATGTACGAATTTCTAGAAACGATCCATATTAATAAAATATTAAAA-ACTA 1080 
TTCAATTTCTATACATCCTTAAAGATCTTTGCTAGCTATAATTATTTTATAATTTTTCAT 
341 L K 	M Y E F L E T I 0 I N K I L K S I 360 
1081 TTCATAATACCATGAAGGAATCAGAAGAATATAGTAATCAAACCAAAAAAATATTTGAAC 1140 
AAGTATTATCGTACTTCCTTAGTCTTCTTATATCATTACTTTGCTTTTTTTATAAACTTG 
361 	H N S H K E S E E Y S N E T K K I F E Q 380 
1141 AATCAGTAAATATAACTAATCAATTTATAGAAGATGTTGAAATATTGAAAACCTCTATTA 1200 
TTAGTCATTTATATTGATTAGTTAAATATCTTCTACAACTTTATAACTTTTGCAGATAAT 
381 	S V N I T N Q F I E 0 V E I L K T S I N 40 
154 
Hindill 
1201 ACCCAAACTATGAAAGCTTAAATGATGATCAAATTGATGATAATATAAATCTAAAGAAAG 1260 
TGGGTTTGATACTTTCGAATTTACTACTAGTTTAACTACTATTATATTTAGATTTCTTTC 
401 	P N Y E S L N D ID Q I ID D N I N L K 	E 420 
1261 AGGAAATATCCGAAAAAAGAAAACAAGTGAATAAATACATAACAGATATTGAATCTAATA 1320 
TCCTTTATAGGCTTTTTTCTTTTGTTCACTTATTTATGTATTGTCTATAACTTAGATTAT 
319P 
421 	E I S E K R K Q V N K Y I T D I E S N K 440 
1321 AAGAACAATCAGATTTACATTTACGATATGCATCTAGAAGTATATATGTTATTGATCTTT 1380 
TTCTTCTTAGTCTAAATGTAAATGCTATACGTAGATCTTCATATATACAATAACTAGAAA 
441 E Q S D L H L R Y A S R S I Y V I D L F 460 
241P 
1381 TTATACATGAAATAATAAATCCTACCGATGGAAAAAATTTTGATATTATAAAGGTTAAAG 1440 
AATATGTACTTTATTATTTAGGATCGCTACCTTTTTTAAAACTATAATATTTCCAATTTC 
461 	1 II E I I N P S ID G K N F D I I K V K E 480 
1441 AAATGATAAATAAAACCAAACAAGTTTCAAATGAAGCTATGGAATATGCTAATAAAATGC 1500 
TTTACTATTTATTTTGGTTTGTTCAAAGTTTACTTCGATACCTTATACGATTATTTTACC 
481 M I N K T K Q V S N E A M E Y A N K M D 500 
1501 ATGAAAAAAATAAGGACATTATAAAAATAGAAAATCAACTTTATAATTTAATTAATAATA 1560 
TACTTTTTTTATTCCTGTAATATTTTTATCTTTTACTTGAAATATTAAATTAATTATTAT 
501 E K N K D I I K I E N E L Y N L I N N N 520 
318P 
1561 ACATCCGTTCATTAAAAGGGGTAAAATATCAAAAAGTTAGGAAACAAGCAAGAAATGCAA 1620 
TGTAGGCAAGTAATTTTCCCCATTTTATACTTTTTCAATCCTTTGTTCGTTCTTTACGTT 
521 	I R S L K G V K Y E K V R K Q A R N A I 540 
1621 TTGATCATATAAATAATATACATTCTAATATTAAAACGATTTTAACCAAATCTAAAGAAC 1680 
AACTACTATATTTATTATATGTAAGATTATAATTTTGCTAAAATTGGTTTAGATTTCTTG 
541 	ID ID I N N I H S N I K T I L T K S K E R 560 
1681 GATTAGATGAGATTAAGAAACAACCTAACATTAAAAGAGAAGGTGATGTTTTAAATAATG 1740 
CTAATCTACTCTAATTCTTTGTTGGATTGTAATTTTCTCTTCCACTACAAAATTTATTAC 
561 	L D E I K K Q P N I K R E C ID V L N N ID 580 
1741 ATAAAAACAAAATAGCTTATATTACAAATACAATAAATAACCCAAGAAGACAATCTAATT 1800 
TATTTTTGTTTTATCGAATATAATGTTTATGTTATTTATTGCCTTCTTCTCTTACATTAA 
581 K N K I A Y I T N T I N N C R R E S N L 600 
155 
1801 TATTAAATATATTAAATATGAAACATAACATAGATACTATCTTGAATAAAGCTATGGATT 1860 
ATAATTTATATAATTTATACTTTGTATTGTATCTATGATAGAACTTATTTCGATACCTAA 
601 L N I L N M K H N I D T I L N K A N D Y 620 
Lii 
1861 ATATGAATGATGTATCAAAATCTGACCAGATTGTTATTAATATAGATTCTTTGAATATGA 1920 
TATACTTACTACATAGTTTTAGACTGGTCTAACAATAATTATATCTAAGAAACTTATACT 
621 N N D V S K S D Q I V I N I D S L N N N 640 
1921 ACCATATATATAATAAGGATAAAGATCTTTTAATAAATATTTTAAAAGAAAAACAGAATA 1980 
TGCTATATATATTATTCCTATTTCTAGAAAATTATTTATAAAATTTTCTTTTTGTCTTAT 
641 D I Y N K D K D L L I N I L K E K Q N M 660 
1981 TGGAGGCAGAATATAAAAAAATGAATGAAATGTATAATTACGTTAATGAAACAGAAAAAG 2040 
ACCTCCGTCTTATATTTTTTTACTTACTTTACATATTAATGCAATTACTTTGTCTTTTTC 
661 E A E Y K K M N E N Y N Y V N E T E K E 680 
2041 AAATAATAAAACATAAAAAAAATTATGAAATAAGAATTATGGAACATATAAAAAAAGAAA 2100 
TTTATTATTTTGTATTTTTTTTAATACTTTATTCTTAATACCTTGTATATTTTTTTCTTT 
681 	I I K H K K N Y E I R I N E H I K K E T 700 
2101 CAAATGAAAAAAAAAAAAAATTTATGGAATCTAATAACAAATCATTAACTACTTTAATGG 2160 
GTTTACTTTTTTTTTTTTTTAAATACCTTAGATTATTGTTTAGTAATTGATGAAATTACC 
701 N F K K K K F M E S N N K S L T T L N ID 720 
554T 
2161 ATTCATTCAGATCTATGTTTTATAATGAATATATAAATGATTATAATATAAATCAAAATT 2220 
TAAGTAAGTCTAGATACAAAATATTACTTATATATTTACTAATATTATATTTACTTTTAA 
721 	S F R S M F Y N E Y I N D Y N I N E N F 740 
2221 TTGAAAAACATCAAAATATATTGAATGAAATATATAATGGATTTAATGAATCATATAATA 2280 
AACTTTTTGTAGTTTTATATAACTTACTTTATATATTACCTAAATTACTTAGTATATTAT 
Li2 
741 F K H Q N I L N E I Y N G F N E S Y N I 760 
2281 TTATTAATACAAAAATGACTGAAATTATAAATGATAATTTAGATTATAATGAAATAAAAG 2340 
AATAATTATGTTTTTACTGACTTTAATATTTACTATTAAATCTAATATTACTTTATTTTC 
761 	I N T K N T E I I N D N L ID Y N F I K F 780 
2341 AAATTAAAGAAGTAGCACAAACAGAATATGATAAACTTAATAAAAAAGTTGATGAATTAA 2400 
TTTAATTTCTTCATCGTGTTTGTCTTATACTATTTGAATTATTTTTTCAACTACTTAATT 
781 	I K E V A Q T F Y D K L N K K V ID F L K 800 
156 
- 	 ( 	555T 
2401 AAAATTATTTGAATAATATTAAAGAACAAGAAGGACATCGATTAATTGATTATATAAAAG 2460 
TTTTAATWCTTATTATAATTTCTTGTTCTTCCTGTACCTAATTAACTAATATATTTTC 
801 N Y L N N I K E Q E G H R L I D Y I K E 820 
2461 AAAAAATATTTAACTTATATATAAAATGTTCAGAACAACAAAATATAATAGATGATTCTT 2520 
TTTTTTATAAATTGAATATATATTTTACAAGTCTTGTTGTTTTATATTATCTACTAAGAA 
240P 
821 	K I F N L Y I K C S E Q Q N I I D D S Y 840 
2521 ATAATTATATTACAGTTAAAAAACAGTATATTAAAACTATTGAAGATGTGAAATTTTTAT 2580 
TATTAATATAATGTCAATTTTTTGTCATATAATTTTGATAACTTCTACACTTTAAAAATA 
841 N Y I T V K K Q Y I K T I E D V K F L L 860 
2581 TAGATTCATTGAACACAATAGAAGAAAAAAATAAATCAGTAGCAAATCTAGAAATTTGTA 2640 
ATCTAAGTAACTTGTGTTATCTTCTTTTTTTATTTAGTCATCGTTTAGATCTTTAAACAT 
861 D S L N T I E E K N K S V A N L E I C T 880 
2641 CTAGTAAAGAAGATATAAAAAATTTACTTAAACATGTTATAAAGTTGGCAAATTTTTCAG 2700 
GATCATTTCTTCTATATTTTTTAAATGAATTTGTACAATATTTCAACCGTTTA-AAAAGTC 
881 	S K E D I K N L L K H V I K L A N F S G 900 
2701 GTATTATTGTAATGTCTGATACAAATACGGAAATAACTCCAGATCCTTTAGAACATAATG 2760 
CATAATAACATTACAGACTATGTTTATGCCTTTATTGAGGTCTAGGAAATCTTCTATTAC 
996N 
901 	I I V M S D T N T E I T P D P L E D N D 920 
2761 ATTTATTAAATTTACAATTATATTTTGAAAGAAAACATGAAATACCATCAACATTGGAAA 2820 
TAAATAATTTAAATGTTAATATAAAACTTTCTTTTGTACTTTATGGTAGTTGTAACCTTT 
921 L L N L Q L Y F F R K H E I P S T L E N 940 
2821 ATGATTCTGATTTAGAGTTAGATCATTTAGCTAGTAATTCGGATGAATCTATAGATAATT 2880 
TACTAAGACTAAATCTCAATCTAGTAAATCCATCATTAAGCCTACTTAGATATCTATTAA 
941 	D S D L E L D H L C S N S D E S I D N L 960 
2881 TAAAGGTTTATAATGATATTATAGAATTACACACATATTCAACACAAATTCTTAAATATT 2940 
ATTTCCAAATATTACTATAATATCTTAATCTGTGTATAAGTTCTCTTTAAGAATTTATAA 
961 	K V Y N D I I F L H T Y S T Q I L 	Y L 980 
2941 TAGATAATATTCAAAAACTTAAAGGAGATTCCAATGATTTAGTAAAGGATTGTAAAGAAT 3000 
ATCTATTATAAGTTTTTGAATTTCCTCTAACCTTACTAAATCATTTCCTAACATTTCTTA 
981 D N I Q K L K C D C N D L V K D C K F L 1000 
157 
3001 TACGTGAA'TTCTCTACGCCATTATATGATTTAAAAATACAAATTACTAGTGTAATTAATA 3060 
ATGCACTTAACAGATGCCGTAATATACTAAATTTTTATGTTTAATGATCACATTAATTAT 
744N 
1001 	R E L S T A L Y D L K I Q I T S V I N R1020 
3061 GAGAAAATGATATTTCAAATAATATTGATATTGTATCTAATAAATTAAATGAAATAGATG 3120 
CTCTTTTACTATAAAGTTTATTATAACTATAACATAGATTATTTAATTTACTTTATCTAC 
1021 	E N D I S N N I D I V S N K L N E I D A 1040 
3121 CTATACAATATAATTTTGAAAAATATAAAGAAATTTTTGATAATGTAGAAGAATATAAAA 3180 
GATATGTTATATTAAAACTTTTTATATTTCTTTAAAAACTATTACATCTTCTTATATTTT 
1041 	I Q Y N F E K Y K E I F D N V E E Y K T 1060 
3181 CATTAGATGATACAAAAAATGCATATATTGTAAAAAAGGCTGAAATTTTAAAAAATGTAG 3240 
GTAATCTACTATGTTTTTTACGTATATAACATTTTTTCCGACTTTAAAATTTTTTACATC 
1061 L D D T K N A Y I V K K A E I L K N V D 1080 
3241 ATATAAATAAAPSCAAAAGAAGATTTAGATATATATTTTAATGACTTAGACGAATTAGAA-A 3300 
TATATTTATTTTGTTTTCTTCTAAATCTATATATAAAATTACTGAATCTGCTTAATCTTT 
1081 	I N K T K E ID L D I Y F N D L ID E L E K 1100 
3301 AATCTCTTACATTATCATCTAATGAAATGGAAATTAAAACAATAGTACAGAACTCATATA 3360 
TTAGAGAATGTAATAGTAGATTACTTTACCTTTAATTTTGTTATCATGTCTTGAGTATAT 
493N 
1101 	S L T L S S N E M E I K T I V Q N S Y N 1120 
3361 ATTCCTTTTCTGATATTAATAAGAACATTAATGATATTGATAAAGAAATGAAAACACTGA 3420 
TAACGAAAAGACTATAATTATTCTTGTAATTACTATAACTATTTCTTTACTTTTGTGACT 
1121 	S F S D I N K N I N D I ID K F M K T L I 1140 
3421 TCCCTATGCTTGATGAATTATTAAATGAAGGACATAATATTGATATATCATTATATAATT 3480 
ACGGATACGAACTACTTAATAATTTACTTCCTGTATTATAACTATATAGTAATATATTAA 
1141 	PM L D E L L N E G H N I D I S L Y N F1160 
3481 TTATAATTAGAAATATTCAGATTAAAATAGGTAATGATATAAAAAATATAAGAGAACAGG 3540 
AATATTAATCTTTATAAGTCTAATTTTATCCATTACTATATTTTTTATATTCTCTTGTCC 
1161 	I I R N I Q I K I G N ID I K N I R E Q E 1180 
3541 AAAATGATACTAATATATGTTTTGAGTATATTCAAAATAATTATAATTTTATAAAGAGTG 3600 
TTTTACTATGATTATATACAAAACTCATATAAGTTTTATTAATATTAAAATATTTCTCAC 
1181 	N ID T N I C F E Y I Q N N Y N F I KS D1200 
3601 ATATAACTATCTTCAATAAATATGATGATCATATAAAAGTAGATAATTATATATCTAATA 3660 
TATATTCATAGAAGTTATTTATACTACTAGTATATTTTCATCTATTAATATATAGATTAT 
360N 	] 
1201 	I S I F N K Y D D H I K V ID N Y I S N N1220 
158 
3661 ATATTGATGTTGTCAATAAACATAATAGTTTATTAAGTGAACATGTTATAAATGCTACAA 3720 
TATAACTACAACAGTTATTTGTATTATCAAATAATTCACTTGTACAATATTTACGATGTT 
1221 	I D V V N K H N S L L S E H V I N A T N 1240 
EcoRI 
3721 ATATTATAGTGAATATTATGACAAGTATTGTCGAAATAAATGAAGATACAGAAATGAATT 3780 
TATAATATCACTTATAATACTGTTCATAACAGCTTTATTTACTTCTATGTCTTTACTTAA 
1241 	I I V N I M T S I V E I N E D T E N N S 1260 
[ 	286G 	] 
3781 CTTTAGAAGAGACACAAGACAAATTATTAGAACTATATGAAA&flTTAAGAAAGAAAAAA 3840 
GAAATCTTCTCTGTGTTCTGTTTAATAATCTTATATACTTTTAAAATTCTTTCTTTTTT 
650L 
1261 L E E T Q D K L L E L Y E N F K K E K N1280 
3841 ATATTATAAATAATAATTATAAAATAGTACATTTTAATAAATTAAAAGAAATAGAAAATA 3900 
TATAATATTTATTATTAATATTTTATCATGTAAAATTATTTAATTTTCTTTATCTTTTAT 
1281 	I I N N N Y K I V H F N K L K E I E N S 1300 
3901 GTTTAGAGACATATAATTCAATATCAACAAACTTTAATAAAATAAATGAAACACAAAATA 3960 
CAAATCTCTGT.ATATTAAGTTATAGTTGTTTGAAATTATTTTATTTACTTTGTGTTTTAT 
1301 	L E 1 Y N S I S T N F N K I N E T Q N I 1320 
3961 TAGATATTTTAAAAAATGAATTTAATAATATCAAAACAAAAATTAATGATAAAGTAAAAG 4021 
ATCTATAAAATTTTTTACTTAAATTATTATAGTTTTGTTTTTAATTACTATTTCATTTTC 
1321 D I L K N E F N N I K T K I N D K V K E 1340 
5240 
4021 AATTAGTTCATGTTGATAGTACATTAACACTTCAATCAATTGAAACGTTTAATAATTTAT 4080 
TTAATCAAGTACAACTATCATGTAATTGTGAAGTTAGTTAACTTTGCAAATTATTAAATA 
1341 L V H V D S T L T L Q S I E T F N N L Y 1360 
4081 ATGGTGACTTGATGTCTAATATACAAGATGTATATAAATATGAAGATATTAATAATGTTG 4140 
TACCACTGAACTACAGATTATATGTTCTACATATATTTATACTTCTATAATTATTACAAC 
1361 G D L N S N I Q D V Y K Y E D I N N V E 1380 
4141 AATTGAAAAAGGTGAAATTATATATAGAAAATATTACAAATTTATTAGGAAGAATAAACA 4200 
TTAACTTTTTCCACTTTAATATATATCTTTTATAATGTTTAAATAATCCTTCTTATTTGT 
1381 L K K V K L Y I EN IT N L L GRIN T1400 
[ 	8520 
4201 CATTCATAAAGGAGTTAGACAAATATCAGGATGAAAATAATGGTATAGATAAGTATATAG 4260 
GTAAGTATTTCCTCAATCTGTTTATAGTCCTACTTTTATTACCATATCTATTCATATATC 
1401 	F I K E L D K Y Q D E N N C I D K Y I E 1420 
159 
4261 AAATCAATAAGGAAAATAATAGTTATATAATAAAATTGAAAGAAAAAGCCAATAATCTAA 4320 
TTTAGTTATTCCTTTTATTATCAATATATTATTTTAACTTTCTTTTTCGGTTATTAGATT 
1421 	I N K E N N S Y I I K L K F K A N N L K1440 
4321 AGGAAAATTTCTCAAAATTATTACAAAATATAAAAAGAAATGAAACTGAATTATATAATA 4380 
TCCTTTTAAAGAGTTTTAATAATGTTTTATATTTTTCTTTACTTTGACTTAATATATTAT 
1441 E N F S K L L Q N I K R N F T F L Y N I 1460 
4381 TAAATAACATAAAGGATGATATTATGAATACGCGGAAATCTGTAAATAATATAAAACAAA 4440 
ATTTATTGTATTTCCTACTATAATACTTATGCCCCTTTAGACATTTATTATATTTTGTTT 
285K 
1461 N N I K D 0 I M N T G K S V N N I K Q K1480 
535H 	] 
4441 AATTTTCTAGTAATTTGCCACTAAAAGAAAAATTATTTCAAATGGAAGAGATGTTACTTA 4500 
TTAAAAGATCATTAAACGGTGATTTTCTTTTTAATAAAGTTTACCTTCTCTACAATGAAT 
1481 F S S N L P L K F K L F Q M E E M L L N 1500 
4501 ATATAAATAATATTATGAATGAAACGAAAAGAATATCAAACACGCATGCATATACTAATA 4560 
TATATTTATTATAATACTTACTTTGCTTTTCTTATAGTTTGTGCCTACGTATATGATTAT 
1501 	I N N I M N E T K R I S N T D A Y T N I 1520 
4561 TAACTCTCCAGGATATTGAAAATAATAAAAATAAAGAAI\ATAATAATATGAATATTGAAA 4620 
ATTGAGAGGTCCTATAACTTTTATTATTTTTATTTCTTTTATTATTATACTTATAACTTT 
1521 T L Q D I E N N K N K E N N N M N I F T 1540 
4621 CAATTGATAAATTAATAGATCATATAAAAATACATAATGAAAAAATACAAGCAGAA-ATAT 4680 
GTTAACTATTTAATTATCTAGTATATTTTTATGTATTACTTTTTTATGTTCGTCTTTATA 
1541 	I D K L I D H I K I H N E K I Q A E I L 1560 
824H 
4681 TAATAATTGATGATGCCAAAAGAAAAGTAAAGGAAATAACAGATAATATTAACAAGGCTT 4740 
ATTATTAACTACTACGGTTTTCTTTTCATTTCCTTTATTGTCTATTATAATTGTTCCGAA 
985J 
1561 	I I D D A K R K V K F I T D N I N K A F 1580 
4741 TTAATGAAATTACAGAAAATTATAATAATGAAAATAATGGGGTAATTAAATCTGCAAAAA 4800 
AATTACTTTAATGTCTTTTAATATTATTACTTTTATTACCCCATTAATTTAGACGTTTTT 
1581 N F I 	F N Y N N F N N G V I K S A K N1600 
4801 ATATTGTCGATGAAGCTACTTATTTAAATAATGAATTAGATAAATTTTTATTGAAATTGA 4860 
TATAACAGCTACTTCGATGAATAAATTTATTACTTAATCTATTTAAAAATAACTTTAACT 
1601 	I V D E A T Y L N N F L D K F L L K L N 1620 
160 
4861 ATGAATTATTAAGTCATAATAATAATGATATAAAGGATCTTGGTGATGAAAAATTAATAT 4920 
TACTTAATAATTCAGTATTATTATTACTATATTTCCTAGAACCACTACTTTTTAATTATA 
1621 E 	L 	L 	S 	H 	N 	N 	N 	D 	I 	K 	D 	L 	C 	ID 	E 	K 	L 	I 	L1640 
4933 
4921 TAAAAGAAGAAGAAGAAAGAAAAGAAAGAGAAAGATTGGAAAAAGCCAAACAAGAAGAAG 4980 
ATTTTCTTCTTCTTCTTTCTTTTCTTTCTCTTTCTAACCTTTTTCGCTTTGTTCTTCTTC 
1641 K 	E 	E 	E 	E 	R 	K 	E 	R 	E 	R 	L 	E 	K 	A 	K 	Q 	E 	E 	E 1660 
4981 AAAGAAAAGAGAGAGAAAGAATAGAAAAAGAAAAACAAGAGAAAGAAAGAC TGGAAAGAG 5040 
TTTCTTTTCTCTCTCTTTCTTATCTTTTTCTTTTTGTTCTCTTTCTTTCTGACCTTTCTC 
1661 R 	K 	E 	R 	E 	R 	I 	E 	K 	E 	K 	Q 	E 	K 	E 	R 	L 	E 	R 	E 1680 
219M 
5041 AGAAACAAGAACAACTAAAAAAAGAAGCATTAAAAAAACAAGAGCAAGAAAGACAAGAAC 5100 
TCTTTGTTCTTGTTGATTTTTTTCTTCGTAATTTTTTTGTTCTCGTTCTTTCTGTTCTTC 
1681 K 	Q 	E 	Q 	L 	K 	K 	E 	A 	L 	K 	K 	Q 	E 	Q 	F 	R 	Q 	E 	Q 1700 
5101 AACAACAAAAAGAAGAACCATTAAAAAGACAAGAACAAGA 5140 [SEQUENCE MISSING] 
TTGTTGTTTTTCTTCTTCGTAATTTTTCTGTTCTTGTTCT 
1701 Q 	Q 	K 	F 	E 	A 	L 	K 	R 	Q 	F 	Q 
5141 GGCTGGAAACAGAGAAACAAGAACAACTACAAAAAGAAGAAGAATTAAAAAGACAAGAAC 5200 
CCGACCTTTCTCTCTTTGTTCTTGTTGATCTTTTTCTTCTTCTTAATTTTTCTGTTCTTG 
1714 L 	E 	R 	E 	K 	Q 	F 	Q 	L 	Q 	K 	F 	F 	E 	L 	K 	R 	Q 	E 	Q 1733 
5201 AAGAACGACTACAAAAAGAAGAAGCATTAAAAAGACAAGAACAAGAACGACTACAAAAAG 5260 
TTCTTGCTGATGTTTTTCTTCTTCGTAATTTTTCTGTTCTTGTTCTTGCTCATGTTTTTC 
1734 F 	R 	L 	Q 	K 	F 	E 	A 	L 	K 	R 	Q 	F 	Q 	F 	R 	L 	Q 	K 	F 1753 
5261 AAGAAGAATTAAAAAGACAAGAGCAAGAAAGACTGGAAAGAAAGAAAATCGAGTTAGCAG 5380 
TTCTTCTTAaTTTTTCTGTTCTCGTTCTTTCTGACCTTTCTTTCTTTTAGCTCAATCGTC 
1754 E 	F 	L 	K 	R 	Q 	F 	Q 	F 	R 	L 	F 	R 	K 	K 	I 	F 	L 	A 	F 1773 




1774 R 	F 	Q 	H 	I 	K 	S 	K 	L F 	S 	ID 	M 	V 	K 	I 	I 	K 	D 	F 1793 
5381 AACTAACAAAAGAAAAAGATGAAATAATAAAAAACAAAGATATAAAACTTAGACATAGTT 5440 
TTGATTGTTTTCTTTTTCTACTTTATTATTTTTTGTTTCTATATTTTGAATCTGTATCAA 
1794 L 	T 	K 	F 	K 	D 	F 	I 	I 	K 	N 	K 	D 	I 	K 	L 	R 	H 	S 	L 1813 
161 
5441 TGGAACAGAAATGGTTAAAACATTTACAAAATATATTATCGTTAAAAATAGATAGTCTAT 5500 
ACCTTGTCTTTACCAATTTTGTAAATGTTTTATATAATAGCAATTTTTATCTATCAGATA 
1814 	E Q K W L K H L Q N I L S L K I D S L L 1833 
5501 TAAATAAAAATGATGAGGTCATAAAAGATAATGAGACACAATTGAAAACAAATATATTGA 5560 
ATTTATTTTTACTACTCCAGTATTTTCTATTACTCTGTGTTAACTTTTGTTTATATAACT 
1834 N K ND E VI K D NET Q L K TN IL N1853 
5561 ACTCATTAAAAAATCAATTATATCTTAATTTGAAACGTGAACTTAATGAAATTATAAAGG 5620 
TGAGTAATTTTTTAGTTAATATAGAATTAAACTTTGCACTTGAATTACTTTAATATTTCC 
492N 
1854 	S L K N Q L Y L N L K R E L N E I I K E 1873 
5621 AATACGAAGAAAACCAGAAAAAAATATTGCATTCAAATCAACTTGTTAACGATAGTTTAG 5680 
TTATGCTTCTTTTGGTCTTTTTTTATAACGTAAGTTTACTTCAACAATTGCTATCAAATC 
1874 	Y E E N Q K K I L H S N Q L V N D S L E 1893 
5681 AGCAAAAAACTAATAGACTCGTCGATATTAAACCTACAAAGCATGGTGATATATATACTA 5740 
TCGTTTTTTGATTATCTGAGCAGCTATAATTTGGATGTTTCCTACCACTATATATATGAT 
1894 Q K T N R L V D I K P T K H C D I Y T N1913 
5741 ATAAACTTTCTGATAATGAAACTGAAATGCTGATAACATCTAI½-AGAAAAAAAACATGAAA 5800 
TATTTCAAAGACTATTACTTTGACTTTACGACTATTGTAGATTTCTTTTTTTTCTACTTT 
4 
1914 K L S D N E T E M L I T S K E K K D E T 1933 
5801 CAGAATCAACTAAAAGATCAGGAACAGATCATACTAATACTTCCGAAAGTACTACTGATG 5860 
GTCTTAGTTCATTTTCTAGTCCTTGTCTACTATGATTATCAAGCCTTTCATCATGACTAC 
374N 
1934 	E S T K R S C T D H T N S S E S T T D D 1953 
5861 ATAATACCAATGATACAAATTTTTCTCCATCAAAGAATTTGAGTGTTCCTATATACACAC 5920 
TATTATCGTTACTATCTTTAAAAACACCTACTTTCTTAAACTCACAACCATATATGTCTC 
1954 N T N D R N F S R S K N L S V A I Y T A 1973 
5921 CAGGAAGTGTAGCTTTATGTGTGTTAATATTTTCTAGTATAGGATTATTACTTATAAACA 5980 
GTCCTTCACATCCAAATACACACAATTATAAAAGATCATATCCTAATAATGAATATTTCT 
1974 G S V A L C V L I F S S I C L L L I K A 1993 
Hi n dill 
844N 	 I 	 I 
5981 CTAATAGTGGAGATAACAATTCTAATGAAATTAATCAACCTTTTGAACCGAATGATGATG 6040 
CATTATCACCTCTATTGTTAAGATTACTTTAATTACTTCGAAAACTTGGCTTACTACTAC 
1994 N S C D N N S N E I N E A F E P N D D V2013 
162 
6041 TTCTCTTTAAGGAGAAGGATGAAATCATTGAPSATCACTTTTAATGATAATGATAGTACAA 6100 
AAGAGAAATTCCTCTTCCTACTTTAGTAACTTTAGTGAAAATTACTATTACTATCATGTT 
2014 	L F K E K D E I I E I T F N D N D S T I 2033 
6101 TTtaaaatgtatgagataaCatattatgtatapaaaatatgatgaQCcgaoattotoCCa 6160 
AAattttacatactctattgtataatacatatcttttatactaCtcggctCtaacaCggt 
* 
6161 ctpcctccagtctaootciacaaaataagaccctgtctaaaaaaaaaaaaaaaaaaaaaaa 6221 
gacggaggtcagacccactgtctcattctgggacagattttttttttttttttttttttt 
6221 aaa 6223 
ttt 
Irom 
5.10.1 Sequence Comparison 
A protein sequence comparison was performed between the exp-3a and 
exp-3b sequences from the EcoRI site to the C-terminus of both genes i.e. it did 
not include the 3.8kb EcoRI fragment thought to be common to both. The 
comparison is presented as a dot-plot shown Figure 5.14. The dot-plot was 
performed using a window size of 30 and a stringency of 22 i.e. the program 
compares the sequences in 30 residue blocks plots a dot if within a 30 residue 
comparison window there are at least 22 identical or similar residues. The plot 
clearly shows that the sequences diverge within a repeat region and that their C-
termini are similar. 
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Fig.5.14: Dot-plot of a protein sequence comparison between exp-3a and 
exp-3b, plotted from the EcoRl site to the C-terminus. 
The sequence divergence within the repeat region is illustrated at the 
amino acid level in Fig.5.15. Due to the highly repetitive nature of this region at 
164 
both the DNA and amino acid level it proved impossible to completely sequence 
through this region of the exp-3b gene. However, an approximation of the 
number of repeats has been given based on the size of the fragment and 
sequencing analysis. 
Fig. 5.15: Highly charged region of exp-3a and exp-3b (sequences are 
presented to indicate the repeats, the sequence common to both is in bold 
and the arrow .-. indicates where the divergence between the sequences 
starts): 
exp-3a: 	383 K E E E E R K E R E R L E K A 397 
398 K Q E E E R K E R E R I E K E 412 
413 K Q  E K E R L E R E R Q E Q  L 427 
428 --Q  K E E E L R R Q E Q E K Q Q Q R 	445 
exp-3b: 	1641KEEEERKERERLEKA 1655 
1656 K Q  E E E K K E K E K I E K E 1670 
1671 K Q  E K E K L E K E K Q E Q  L 1685 
1686 - - K K E AL K K Q E  ER Q E  	Q  1701 
1702 - Q K E E A L K R Q E Q E 1/ 1713 
1714 //LEREKQEQL 1722 
1723 - Q K E E E L K R Q E Q E R L 1736 
1737 - Q K E E A L K R Q E Q E R L 1750 
1751 - Q K E E E L K R Q E Q E R L 1764 
sequence missing (estimated 3 more complete 14-mer repeats here) 
The 3' unique regions vary in length with exp-3a being 250bp longer. 
Bestfit analysis indicates only 52% similarity between the two genes at the amino-
acid level over this unique sequence. The dot-plot indicated that the protein 
sequences are similar near the C-termini. Closer examination of this sequence 
indicates that this is a potential transmembrane region i.e. a region rich in 
hydrophobic residues (see Fig.5.16) which interestingly is very similar at the amino 
acid level in both genes (64% identity, 86% similarity). Thi s is consistent with the 
proteins being potential parasitophorous vacuole membrane proteins. The 
parasitophorous vacuole membrane exp-1 gene product also has a membrane 
spanning domain (Gunther et al., 1991). 
165 
Fig. 5.16: Symbol comparison of the last 100 residues of both genes (region 
in bold is a potential transmembrane domain): 
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5.11 Protein secondary structure prediction 
The basic structural units of proteins are the a-helix and the 0-sheet. 
Based on the X-ray analysis of globular proteins the statistical probability of an 
amino acid being found as part of a particular structure such as an a-helix or 13-
sheet has been calculated and rules predicting the conformational preference of 
amino acids devised (Gamier et aL, 1978). The accuracy of such predications is 
debated but it is generally accepted that between 55% and 66% of all residues are 
correctly assigned. 
Using computer analysis the secondary structure of the two proteins exp-3a 
and exp-3b was predicted from the primary amino acid sequence. The programs 
used utilized the prediction schemes of both Chou-Fasman (Chou and Fasman, 
1978) and Gamier-Robson (Gamier et aL, 1978). However, for the squiggly plots 
only the prediction scheme of Garnier-Robson was used which essentially differs 
from that of Chou-Fasman in that the conformational state of a given residue is 
determined not only by the residue itself but also by the neighbouring ones. 
The secondary structure predications of the two proteins are shown in 
Figure 5.17 as panel graphs. Based on these graphs some general comments can 
be made about both putative gene products. Both sequences are very hydrophilic 
particularly the charged amino acid repeats which are predicted to form a-helices. 
Indeed the majority of both proteins is predicted to form a-helices. Hydrophilic 
166 
Figure 5.17 
Secondary Structure Predictions. Panel Graphs. 
Secondary structure prediction of the 3.8kb EcoRI fragment thought to be 
common to both genes. 
Secondary structure prediction of the exp-3a gene from the 3' EcoR! site to the 
C-terminus. 
Secondary structure prediction of the exp-3b gene from the 3' EcoRI site to the 
C-terminus. 
Fig.5.17a 	 PLOTSTRUCTURZ of: exp-3.p2s January 19, 1993 13:55 
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areas of the protein also have a high probability of being found on the surface of 
the protein and are therefore potential antigenic sites. At the C-terminus of both 
proteins there is a hydrophobic region which is typical of a membrane spanning 
domain as defined by Kyte and Doolittle (1982) i.e. the mean hydrophobicity is 
higher than + 1.6. The 'squiggly' plots also show the predicted secondary structure 
of both proteins. These plots highlight the a-helical charged repeat regions and 
the potential transmembrane domains of both proteins (Figure 5.18). 
5.12 Data Base Searches 
In order to get a further clue as to the function of the two proteins data 
bases were searched for possible homologies. The protein database Swissprot22 
(Bairoch and Boeckmann, 1991) was searched with both predicted amino acid 
sequences. The search scored for both identity and conserved changes. There 
was no striking similarity with any proteins in the data base, however some general 
comments can be made about the result of the search. Both proteins had 
similarities to two malarial antigens 1) the precursor P101 (Acidic basic repeat 
antigen) which contains a region rich in glutamic acid and lysine residues (Stahl 
et aL, 1986) and 2) glutamic acid rich protein (Triglia a aL, 1988). However,, the 
scores were low and appeared to be solely due to the presence of the charged 
residues. 
The highest scoring protein with similarity to exp-3b, in fact it gave the top 
8 scores was the sheep protein Trichohyalin, a wool follicle protein (Fietz et aL, 
1990). This also scored 10th with exp-3a. Primarily the similarity was between 
the repeat region in Trichohyalin and the charged repeat region of exp-3b. Both 
regions contain glutamine and lysine residues surrounded by charged amino acids. 
In Trichohyalin this region is thought to be a-helical in structure and the 
glutamine residues are thought to the site of post-translational modification by 
transglutaminases. Transglutaminases catalyse post-translational modification by 
inducing an isopeptide bond between internal glutamine residues and an amine 
donor, usually lysine (Folk, 1980). The resultant product is two proteins 
crosslinked by an e-(y-glutamyl) lysine isopeptide bond. It has been suggested 
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Figure 5.18 
Secondary Structure Predictions. 'Squiggly' Plots. 
Secondary structure prediction of the 3.8kb EcoRI fragment thought to be 
common to both genes. 
Secondary structure prediction of the exp-3a gene from the 3' EcoRI site to the 
end. 
e) Secondary structure prediction of the exp-3b gene from the 3' EcoRI site to the 
end. 
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that transglutaminase in filarial parasites is responsible for crosslinking of 
host/parasite proteins (Mehta et aL, 1992). 
Other proteins identified as having similarities, also to the charged repeat 
region to exp-3a and exp-3b included pig and human membrane-organizing 
extension spike protein (moesin) and mouse ezrin. These are all structural 
proteins. They are distributed diffusely on or near the cell membrane with 
significant preference for retraction fibres, microspikes, fililodia and lamellopodia. 
Moesin binds spectrin/actin complex to protein 4.1. Interestingly several malarial 
proteins have been shown to bind proteins of the RBC skeleton including RESA 
a malarial protein which binds spectrin which is thought to increase rigidity of the 
red blood cell membrane (Foley a al., 1991). 
5.13 Chromosome mapping 
Southern blot analysis indicated that are two related sequences in the 
genome and which potentially encode two proteins exp-3a and exp-3b. To 
characterize further the two genes the chromosome location of them was 
identified. This was achieved by blotting pulsed field gradient electrophoresis gels 
of malarial chromosomes with sequences from the unique region of both genes. 
The pulse field gel electrophoresis of P.falciparum Ki DNA was performed by M. 
Goman as described in Ridley et aL, (1991). The blot was probed with a unique 
sequence probe from the exp-3a gene, washed and autoradiographed (Fig.19a). 
The blot was then stripped and reprobed with a unique sequence probe from the 
exp-3b gene washed and autoradiographed (Fig.19b). Both probes hybridised to 
chromosome 13 indicating that both related sequences were present on the same 
chromosome. In order to confirm that this was chromosome 13 as defined by 
Triglia a aL, (1992) the blot was stripped and probed with a marker for 




Pulsed field gel electrophoresis of P.falciparum Ki DNA and transferring on to 
Hybond-N was performed by M. Goman as described by Ridley et al., (1991). 
The blot was probed with part of the unique region of the exp-3a gene (panel a) 
at 650C, washed and autoradiographed. The blot was then stripped and probed 
with part of the unique region of the exp-3b gene (panel b) The blot was then 
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5.14 Northern blot analysis 
In order to determine if either of the genes is transcribed a northern blot 
was probed with the common sequence probe. Total RNA, prepared from 
asynchronous P.falciparurn isolate Ki using the method of Chomczynski & Sacchi 
(1987), was provided by Robert Ridley. Purification of mRNA was then 
performed using an oligo (dT)-cellulose column using the method described by 
Sambrook et aL, (1989) (see method 2.5.1). The purified poly A RNA was 
separated by gel electrophoresis (method 2.5.2), blotted on to H ybondN+ 
(method 2.5.3) and probed with the óOObp (see section 5.5) common sequence 
probe, washed and autoradiographed (method 2.5.4) (see Fig. 5.20). The probed 
hybridised to one major band of approximately 8.5kb indicating that an 8.5kb 
message is generated by at least One of the exp-3 genes in asexual stage parasites. 
Two faint bands of approximately 3.3kb and 4.5kb were also observed. 
Since the blot was probed with a region common to both genes and since 
I do not know if the genes are significantly different in size the 8.5kb message 
observed may correspond to one or other or both of the exp-3 genes. The mRNA 
is large enough to encode for proteins of 200-23OkDa, which were observed by 
western blot analysis using antisera raised against the 60kDa recombinant antigen 
(see chapter 4). 
Discussion 
Here I have described the isolation of two very similar genes, located on 
chromosome 13 which appear highly conserved at their amino terminus and 
diverge in a repeat region towards their C-terminus. Northern blot analysis 
coupled to the antibody results of chapter 4 indicates that at least one of the 
genes is expressed in asexual stage parasites. In recent years several malarial gene 
families have been described. Histidine rich proteins II and III are very similar 
to each other with the major differences occurring in the repeat region (Wellems 
and Howard, 1986). Outside the repeat region there is 85-90% homology. The 
authors suggest that "the tandem repeats are relatively labile elements within the 
genome that may provide the parasite with a means of rapid evolutionary change'. 
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Figure 5.20 
Northern blotting analysis 
Poly A+  RNA was prepared from total P.falciparwn isolate Ki RNA on a oligo 
(dT)-cellulose column. The purified poly A RNA (1sg) was separated by gel 
electrophoresis and transferred onto HybondN+.  The blot was probed at 65 C 
with the 600bp common sequence probe, washed and autoradiographed. The 
RNA molecular weight markers (M) are in kb. 
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They also suggest that the sequences originated by duplication and diverged from 
a common ancestral sequence. It is unclear what the functional differences are 
in these two genes both of which are expressed. 
Two actin genes have also been identified Pf-actin-I and Pf-actin-II. Pf-
actin-I contains no introns however Pf-actin-TI contains 1 intron. They share 79% 
similarity at the amino acid level (Wesseling, 1989). Northern blot analysis 
indicated that Pf-actin-I is expressed in both asexual and sexual stage parasites 
whereas Pf-actin-II is solely expressed in sexual stage parasites. Interestingly the 
amino-acid sequence of Pf-actin II is the most muscle-like actin ever found in a 
non-muscle tissue or single cell and they suggested that it may be used in the 
motile apparatus of the ookinete. There also appear to be two a-tubulin genes, 
a-tubulin I and a-tubulin II, which are similarly differentially expressed (Holloway 
et aL, 1990, Delves et aL, 1990). a-Tubulin II shares 94.2% identity at the amino-
acid level with ft-tubulin I yet a-tubulin I is transcribed at high levels in both 
asexual and sexual blood stages while the a-tubulin II gene is predominately 
transcribed during the sexual forms. It has been suggested that both a-tubulins 
are functionally equivalent and represent the products of duplicated genes which 
have evolved to contain different regulatory sequences which activate transcription 
during alternative programmes of differentiation (Cleveland, 1987). 
More recently a second RESA gene termed RESA-2 has been identified 
(Cappai et aL, 1992). It has high homology to exon 1 and exon 2 of RESA at 
both the nucleotide and amino acid level but lacks both blocks of tandem repeats 
present in RESA. The lack of an RESA-2 RNA transcript in either asexual of 
sexual stage parasites and the presence of an in frame stop codon which would 
result in a truncated polypeptide suggests that RESA-2 is a pseudogene. RESA-2 
is found on chromosome 11 whereas RESA is located on chromosome 1. 
The similarity observed between the DNA sequences of exp-3a and exp-3b 
and the fact both genes are located on chromosome 13 supports the hypothesis 
that the two sequences originated by duplication from a common ancestor as 
suggested for the origin of the HRP genes (Wellems and Howard, 1986). Also, 
like HRP II and HRP III, exp-3a and exp-3b vary within repeat sequences which 
'RI.] 
in the case of the HRP genes, are labile and may play a role in the generation of 
antigenic diversity in the parasite population as previously discussed. 
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CHAPTER 6 
FURTHER CHARACTERIZATION OF 
EXP-3A AND EXP-313 
6.1 Introduction 
The previous two chapters have described the identification and initial 
characterization of the exp-3 gene family. Chapter 4 reports the isolation of the 
original clone and describes the preliminary localization studies, while chapter 5 
discusses the analysis that led to the conclusion that there are two exp-3 genes and 
describes their DNA and predicted amino acid sequences. This chapter takes the 
characterization a stage further by investigating if both genes are expressed and 
the localization of their gene products in the malaria infected erythrocyte. 
The murine antibodies generated against the recombinant 60kDa antigen 
expressed by the clone described in chapter 4 suggested that exp-3 is over 200kDa 
in size and localized to the PVM. Further work indicated that there are two 
copies of the exp-3 gene which diverge in a repeat region towards their C-
terminus. Since half of the fragment encoding the original 60kDa antigen was 
DNA sequence common to both genes it suggests that the murine antibodies 
raised to this polypeptide potentially recognised both gene products by western 
blot and IFA. In order to determine (i) if both exp-3 proteins are expressed and 
(ii) to localise both proteins in the parasitised cell further localization studies and 
blotting analysis were required. 
Furthermore these studies were required in order to investigate if the exp-3 
genes have an expression pattern similar to that found amongst members of other 
P.falciparum gene families. For example, is one of the exp-3 genes a pseudogene 
like RESA-2 (Cappai et at, 1992)? Alternatively, are the exp-3 genes 
differentially expressed in asexual and sexual stage parasites like the Pf-actin genes 
and the a-tubulin genes (Wesseling et at, 1989, Holloway et at, 1990)? 
To answer these questions antibodies were raised to common and unique 
regions of both proteins. DNA fragments were subcloned into the expression 
vector pGEX (Smith and Johnson 1988), the expressed polypeptides purified and 
used to immunize rabbits. The resulting sera were then tested by western blotting 
and IFA. Prior to describing the results a brief description of the pGEX vector 
and the methods used will be given. 
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6.1.1 The pGEX vector expression system 
The structure of the pGEX plasmid expression family is shown Fig 6.1. 
pGEX is an expression vector that expresses a piece of cloned DNA as a fusion 
with Glutathione-S-Transferase (GST), a 26kDa cytoplasmic protein of eukaryotes 
(Smith and Johnson 1988). The plasmid contains a mutant Lacl gene (LacS) 
which produces high levels of the lac repressor (lOx more than lad). The lac 
repressor binds to the P tac promoter, repressing expression of the OST fusion 
protein. This enhances our control over expression, for example the synthesis of 
potentially toxic fusion proteins is minimized when the system is not induced. The 
'tac promoter contains the consensus sequences of the -35 and -10 promoter 
regions and is a hybrid of the trp and lacUV5 promoters (Amann a aL, 1983). 
This engineered P tac promoter is lix stronger than the lac promoter. Expression 
of the fusion protein can be induced by inactivating the repressor with IPTO. 
Fusion proteins expressed in this system often remain soluble within bacteria and 
can be easily purified because of the affinity of the GST moiety for glutathione. 
DNA of interest can be inserted into the polylinker located at the 3' end 
of the GST gene. The polylinkers of pGEX2T and pGEX3X contain protease 
cleavage sites so the cloned protein can be released from the GST moiety. 
6.2 Strategies used for subcloning fragments of exp-3a and exp-3b into pGEX 
In order to answer the questions posed in the introduction of this chapter 
a strategy was devised to generate antibodies to both common and unique regions 
of the proteins encoded by the exp-3a and exp-3b genes. Firstly regions which 
were suitable for subcloning, expressing and raising antisera had to be identified. 
It was decided not to generate more antibodies to the region corresponding to the 
original 5L13 clone since sera had already been raised to the 60kDa exp-3a 
antigen. Candidate restriction fragments were therefore identified within the 
3.8kb EcoRl fragment which is common to both genes. In deciding which unique 
regions to subclone, it was thought unwise to generate antibodies to portions of 
the repeats because it seemed likely that the antibodies would cross-react with 
other malarial antigens containing a charged repeat region e.g Glutamic acid rich 
IM 




The pGEX polylinker sequences 
pGEX1 CC). AAA TCC CAT CCC CCC GAIL rrc ATC GTC ACT CAC TCA CGA TCT 
thrombin 
pCEX2T CCA AAA TCG GILT Cit GTF CCC CGT GGA TCC CCC GGA Afl CAT CCT GAC TGA Cit 
BamHI Sinai ERI 
factor Xe 
pGEX3X CCA AAA TCG CAT CM Alt GAIL GGT CGT CCC ATC CCC CCC ANT TCA TCG ltA Cit 
I_I ______ 
Figure 6.1: The pGEX expression vector family. 
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protein (GARP) (Triglia et aL, 1988) and p101 (Stahl a aL, 1986). Fragments 
were therefore identified near the 3' ends of both genes. 
The main determinant for successful purification of foreign polypeptides 
using the pGEX system is solubility of the fusion protein. The fusion protein is 
more likely to be insoluble if much larger than 50kDa or when the protein 
contains regions that are strongly hydrophobic or charged (Smith and Corcoran, 
1990). Since the size of the GST moiety is 26kDa the size of the foreign 
polypeptide should be no more than 15-25kDa (encoded by an ORF of 
approximately 450-750bp). 
DNA fragments which would yield approximately the ideal size GST fusion 
were identified in the exp-3a and exp-3b genes. In total four pGEX constructs 
were made, two contained fragments from 5' common region, pGEX8SH and 
pGEX4HH, while the other two, pGEX21 and pGEX76, contained sequences 
from the 3' end of both genes (see Fig 6.2). The construct pGEX8SH was made 
by subcloning a 800bp SmaIlHindll fragment from the construct pUB1.2RH 
(section 5.9), utilizing the SmaT site present in the pUBS vector, into the Smal site 
of pGEX2-T. This fragment corresponds to nucleotide numbers 1 to 740 in 
Fig.5.13b. While the construct pGEX4HH was made by subcloning the adjacent 
400bp HindIl/HindIl also into the Smal site of pGEX2-T utilizing the HindlI site 
in the pUBS vector. This fragment corresponds to nucleotide numbers 741 to 
1214 in Fig.5.13b. Positive clones were identified by restriction analysis of DNA 
prepared from putative clones. These constructs contained an additional 2/3 
amino acids encoded by the pUBS polylinker but this was thought unlikely to 
compromise the antigenicity of the polypeptides. 
The constructs containing the two unique fragments were made by 
subcloning I) the exp-3a 3' 760bp HindII/EcoRI fragment from clone pUBSLL, 
which maps to nucleotides 2118 to 2873 in Fig.5.13a, into the SmaI/EcoRI site of 
pGEX3X and ii) the exp-3b 2.1kb Hindil/EcoRl fragment, from clone pUCSL3 
which maps to nucleotide 5668 (Fig.5.13b) to the end of the pUCSL3 insert, into 
the Smal/EcoRl site of pGEX3X. Both the fragments included stop codons. 
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Figure 6.2: Partial restriction maps of the exp-3a and exp-3b 
genes, indicating the location of fragments subcloned into 
pGEX vectors. 
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63 Expression, Purification and Raising antisera to GST fusion proteins 
All four pGEX constructs were transformed in E.coli strain BL21 and 
induced with IPTG. The results are shown in Fig.6.3a and6.3e. As shown in the 
Figure, upon induction with IPTG all four constructs expressed GST fusion 
proteins. Each fusion protein was of the expected size. 
The GST system has been designed so that soluble fusion proteins can be 
easily purified using glutathione attached to agarose beads. In order to assess if 
the expressed fusion proteins were soluble, lysed bacterial extracts containing the 
expressed fusion proteins were centrifuged and an aliquot of the pellet and 
supernatant analyzed by SDS-PAGE and coomassie staining. The results are 
shown in Figure 6.3b, c, f and g. 
Only the pGEX4HH construct (Fig.6.3c) expressed a completely soluble 
fusion protein. The pGEX21 and pGEX76 fusions proteins were partially soluble 
(Fig.6.3f and g) while the pGEXSH fusion protein was insoluble (Fig6.3b). 
Further attempts were made to the get the pGEX8SH fusion protein into solution 
using detergents (1% triton, 0.03% SDS) and 10mM DTT, all of which are 
conditions in which GST binds glutathione, but were unsuccessful (Fig.6.3b). 
Therefore this protein was not further purified using glutathione attached to 
agarose beads but was purified for immunization by excising the appropriate band 
from a preparative SDS-PAGE gel (method 2.6.15.2) 
All the other fusion proteins, expressed by constructs pGEX4HH, pGEX21 
and pGEX76, were at least partially soluble. Therefore these fusion proteins were 
purified on S-linked glutathione-agarose beads (Sigma) (method 2.6.15.2). The 
results are shown in Fig.6.3c, f and g. Aliquots of each of the fusion proteins 
bound to agarose beads were then separated by SDS-PAGE and the appropriate 
bands excised for rabbit immunizations. 
It was also decided to immunize a rabbit with just the cleaved soluble 
portion of one of the fusion proteins. This was done in order to assess whether 
cleaner and higher titre serum was obtained from rabbits immunized with soluble 
protein cleaved from the GST moiety rather than fusion protein present in 
acrylamide gel. The pGEX4HH fusion protein was chosen since it was the most 
Figure 6.3 
Analysis of proteins expressed by the pGEX constructs 
In all lanes the equivalent of 50i.sl of original culture was loaded unless otherwise 
stated. 
Panels a and e: The 4 recombinant plasmids pGEX4HH (common region), 
pGEX8SH (common region), pGEX21 (exp-3b) and pGEX76 (exp-3a) plus a 
non-recombinant control pGEX2T vector were grown in the absence (U) and 
presence (1) of IPTG. Total proteins were separated and analyzed by SDS-
PAGE. Dashes indicate the migration of the Glutathione-S-Transferase (GST), 
and the fusion proteins (FP). 
Panel b: Analysis of the proteins expressed by pGEXSSH. Samples of total 
expressed protein (Lane To), Soluble protein (5) and proteins present in the 
insoluble pellet (F) were separated by SDS-PAGE. Solubility of the fusion 
protein was also tested in 1% Triton, 0.03% SDS and 10mM DTT. 
Panel C: Analysis of the proteins expressed by pGEX4HH. Samples of total 
expressed protein (Lane To), Soluble protein (5) and proteins present in the 
insoluble pellet (P) were separated by SDS-PAGE. Samples were of the fusion 
protein bound to glutathione beads were also loaded (Bxl - fusion protein bound 
to beads from 50pl of original culture and BxlO - fusion protein bound to beads 
from 500pl of original culture) and also a sample of the supernatant after the 
removal of the beads bearing the fusion protein (S2). 
Panel d: Analysis of cleavage of the GST moiety from the pGEX4HH fusion 
protein. Samples of total expressed protein (Lane To), Soluble protein (5) and 
proteins present in the insoluble pellet (P) were separated by SDS-PAGE. After 
cleavage of the fusion protein with thrombin, samples supernatant containing the 
cleaved protein (CP) were analyzed (Cxl - cleaved protein 50pl of original culture, 
CxlO - cleaved protein 500R1  and CxlOO - cleaved protein 5ml of original culture) 
and the beads bearing the GST moiety (Bxl, BxlO, BxlOO). 
Panel f: Analysis of the proteins expressed by pGEX21 and Panel g: Analysis of 
proteins expressed by pGEX76: Samples of total expressed protein (Lane To), 
Soluble protein (5) and proteins present in the insoluble pellet (P) were separated 
by SDS-PAGE. Samples were of the fusion protein bound to glutathione beads 
were also loaded (Bxl - fusion protein bound to beads from 50R1  of original 
culture and BxlO - fusion protein bound to beads from SOOpI of original culture) 
and also a sample of the supernatant after the removal of the beads bearing the 
fusion protein (S2). 
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soluble fusion protein and because the GST moiety could be removed using 
thrombin (see Fig. 6.4d) (method 2.6.15.3). The l5kDa cleaved protein was 
termed pGEX4HS. 
In total 5 New Zealand 4 month old male rabbits were immunized. Four 
rabbits were immunized with GST fusion proteins, expressed by constructs 
pGEX8SH (contained fragment common to both genes), pGEX4HH (common 
fragment), pGEX76 (unique to exp-3a) and pGEX21 (unique to exp-3b). The 
fusion proteins were prepared for immunization by separating an aliquot of the 
beads bearing the fusion protein or an aliquot of the pellet containing the fusion 
protein on a SDS-PAGE preparative gel. The gel was then stained and the 
appropriate band excised. Approximately 0.3mg of protein contained in a gel slice 
was used per immunization emulsified with 0.7m1 of adjuvant. A rabbit was also 
used to raise antibodies against the pGEX4HH cleaved polypeptide termed 
pGEX4HS. Approximately 0.2mg of the cleaved soluble polypeptide, in 0.5m1 of 
thrombin cleavage buffer, was used per immunization emulsified with 0.5m1 of 
adjuvant. All immunization procedures were performed by R. MacKenzie at the 
Moredun Institute, Edinburgh. 
6.4 Initial characterization of the antisera 
Sera from each rabbit were tested by western blotting analysis in order to 
assess whether antibodies had been raised against the immunizing fusion proteins. 
Preliminary analysis of the sera indicated that they all contained antibodies against 
the appropriate fusion proteins. In addition they contained antibodies to the GST 
moiety and E.coli proteins (data not shown). In order to minimize this the serum 
was preabsorbed with both GST and an E.coli cell lysate extract (method 2.6.15.5). 
In addition the two sera raised against the unique C' termini, anti-pGEX76 (exp-
3a) and anti-pGEX21 (exp-3b) sera, were also pre-absorbed with beads bearing 
the other polypeptide i.e. pGEX21 antisera were preabsorbed with agarose beads 
bearing the pGEX76 GST fusion protein and vice versa, in order to remove cross-
reactive antibodies. 
The pre-bleed serum from each rabbit (P-bleed), and the serum from the 
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two subsequent bleeds before (bleed 1 and 2) and after absorption (bleed 1A and 
2A) were tested by western blot (methods 2.6.5 and 2.6.7) (Figure 6.4). Blots 
probed with the anti-pGEX8SH (common region) sera are shown in Fig.6.4a, the 
anti-pGEX4HH (common region) sera in Fig.6.4b, the anti-pGEX4HS (common 
region) sera in Fig.6.4c, the anti-pGEX21 (exp-3b) sera in Fig.6.43 and the anti-
pGEX76 (exp-3a) serum in Fig.6.4e. Each serum was tested against i) total cell 
extract containing the expressed fusion protein (Lane 1), ii) purified fusion protein 
(Lane 2) and iii) GST (Fig.6.4a Lane 3, and Figs.6.4b, c, d, e Lane 4). In addition 
the anti-pGEX4HH sera and the anti-pGEX4HS sera were tested against purified 
pGEX4HH cleaved protein (Fig.6.4b and c Lane 3). Also, the anti-pGEX21 sera 
(exp-3b) and the anti-pGEX76 sera (exp-3a) were tested for cross-reactivity 
(Fig.6.4d Lane 3 and Fig.6.4e Lane 2). 
None of the pre-bleed sera recognised the fusion proteins used for 
immunization. All the sera recognised the GST fusion proteins they were raised 
against, both before and after absorbtion with GST-agarose beads indicating that 
the sera contained antibodies against the foreign polypeptide. Pre-absorption was 
more successful with the first bleed than the second. 
The two sera raised to the pGEX4HH polypeptide, both recognise the 
fusion protein and the cleaved polypeptide. The sera raised against the cleaved 
soluble polypeptide (Fig.6.4c) gave much cleaner results with less background than 
the sera raised against the fusion protein (Fig.6.4b). 
In order to remove cross-reactive antibodies pGEX21 antisera were 
preabsorbed with agarose beads bearing the pGEX76 GST fusion protein and vice 
versa. However, this had limited success (see Figs 6.4d and 6.4e). The absorbed 
pGEX76 (exp-3a) sera was specific but the absorb,ed pGEX21 (exp-3b) sera 
recognised both proteins albeit the pGEX76 polypeptide weakly. The cross-
reactivity is probably due to conserved regions in the potential transmembrane 
domains of both proteins (see previous chapter). 
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Figure 6.4 
Initial characterization, by western blot, of the antisera raised against the pCEX 
fusion proteins. 
The pre-bleed serum from each rabbit (P-bleed), and the serum from the two 
subsequent bleeds before (bleed 1 and 2) and after absorption (bleed 1A and 2A) 
were tested. 
a Blots probed with anti-pGEX8SH (common region) sera 
b Blots probed with anti-pGEX4HH (common region) sera 
c Blots probed with anti-pGEX4HS (common region) sera 
d Blots probed with anti-pGEX21 (exp-3b) sera 
e Blots probed with anti-pGEX76 (exp-3a) sera 
Each serum was used at a dilution of 1:100. They were tested against; 
total cell extract containing the expressed fusion protein (Lane 1) 
purified fusion protein (Lane 2) 
Glutathione-S-transferase (a Lane 3, and b, c, d, e Lane 4). 
the anti-pGEX4HH sera and the anti-pGEX4HS sera were tested against 
purified pGEX4HH cleaved protein (b and c Lane 3). 
The GEX21 sera and the anti-pGEX76 sera were tested for cross-reactivity (d 
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6.5 Western blotting analysis 
In order to identify the proteins recognised by the immune sera and 
determine if both forms of exp-3 are expressed, western blots prepared from total 
parasite extracts were probed. The blots were prepared from both asexual and 
sexual stage parasites in order to investigate the possibility of stage specific 
expression the exp-3 proteins. From the previous western blotting studies 
(chapter 4), the northern analysis and the deduced exp-3 open reading frames 
(chapter 5), the predicted size of the expressed proteins must be in the order of 
200-25OkDa. It was expected that if both forms of the protein are expressed the 
sera raised to the common region, i.e. pGEX4HH, pGEX4HS and pGEX8SH 
antisera, should recognise both proteins, while the sera raised to the specific ends 
of the two forms should recognise just one protein i.e. the pGEX76 antisera 
should recognise exp-3a and the pGEX21 antisera exp-3b. 
Total protein extracts were prepared from asexual Ki parasites (Fig.6.5a) 
and from 3D7 parasites enriched for sexual stages (kindly provided by R. Carter) 
(Fig.6.5b). The protein extracts were separated by SDS-PAGE under reducing 
conditions and electrophoretically transferred onto Hybond-C. Strips of the blot 
were probed with the five different rabbit immune sera obtained from the second 
bleed which had been pre-absorbed (see section 6.5). Control strips were probed 
with the five pre-immune sera, McAb 7.7, PcAb 7.7 and sera raised against the 
proliferating cell nuclear antigen fusion protein (PCNA-GST) (Kilbey eat aL, 1993, 
in press). Anti-PCNA serum was used as a control in order to distinguish any 
bands that were due to the pGEX expression system and the immunization 
protocol used. This serum was obtained in exactly the same way as 5 exp-3 sera, 
i.e a portion of a P. falciparum gene, PCNA, was expressed in pGEX as a GST 
fusion, purified from a gel and used to immunize New Zealand white rabbits. 
All the preimmune sera failed to recognise any malarial proteins as 
expected (data not shown). The McAb 7.7 recognises one major band of 35kDa 
which is exp-2 in both the Ki and 3137 extracts (Fig.6.5 al, a2, bi and b2). The 
PcAb7.7 serum recognises exp-2 and several other bands including one greater 
than 200kDa (Fig.6.5 a3, a4, b3 and b4). The PCNA sera recognises bands 
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Figure 6.5 
Western blot analysis of the pGEX sera 
Total protein extracts prepared from asexual Ki parasites (panel a) and 3D7 
parasites enriched for sexual stages (panel b), were separated by SDS-PAGE and 
electrophoretically transferred onto Hybond-N. Strips of the blots were probed 
with: 
lane 1: McAb 7.7 at 1:1000 
lane 2: McAb 7.7 at 1:100 
lane 3: PcAb 7.7 at 1:1000 
lane 4: PcAb 7.7 at 1:100 
lane 5: anti-PCNA GST fusion protein serum at 1:100 (arrow indicates PCNA 
band) 
lane 6: anti-pGEX8SH fusion protein serum, bleed 2A, at 1:100 
lane 7: anti-pGEX4HH fusion protein serum, bleed 2A, at 1:100 
lane 8: anti-pGEX4HS cleaved protein serum, bleed 2A, at 1:100 
lane 9: anti-pGEX76 fusion protein serum, bleed 2k at 1:100 
lane 10: anti-pGEX21 fusion protein serum, bleed 2A, at 1:100 
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migrating at 3lkDa (PCNA) and 61kDa, and does not recognise any bands greater 
than 200kDa (Fig.6.5 aS and b5). The observation that exp-2 is present in the 
3D7 extract (Fig.6.5 bl-4) indicates that asexual stage proteins are present. Exp-2 
is known to be expressed in asexual erythrocytic stages and not in erythrocytic 
sexual stages (3.1.1). 
The pGEX8SH serum, raised to part of the exp-3 common region, 
recognises a series of 5 bands greater than 200kDa in size in the Ki extract 
(Fig.6.5 a6) and these plus several others in the 3D7 extract (Fig.6.5 b6). The 
other two sera, pGEX4HH and pGEX4HS, raised to another piece of the exp-3 
common region also recognise the same bands, however, this has unfortunately 
not reproduced well in the Figure (Fig.6.5 a7, a8, b7 and b8). The serum raised 
to part of the unique region of exp-3a, pGEX76, also recognises in both extracts 
a series of bands greater than 200kDa and in addition recognises several bands 
between lOOkDa and 150kDa (Fig.6.5 a9 and b9). The serum raised to part of 
the unique region of exp-3b, pGEX21, weakly recognises several bands greater 
than 200kDa in the Ki extract (Fig.6.5 alO) and recognises the same bands more 
strongly in the 3D7 extract (Fig.6.5 blO). Closer examination of the results 
indicate that the pGEX76 (exp-3a unique) and pGEX21 sera (exp-3b unique) are 
each recognising a different subset of the bands recognised by the pGEX4HH, 
pGEX4HS and pGEX4HH sera. Noticeably the pGEX21 and pGEX76 sera 
clearly do not recognise the same series of bands greater than 200kDa in the 3D7 
extract i.e. both sera are specific for different proteins. Both sera however, 
recognise a band migrating at approximately 73kDa which is not recognised by the 
other three sera. The significance of this is unknown but is possibly just a cross-
reactive epitope. 
Two main conclusions can be drawn from the results presented above: 
1) As the sera raised to the unique C-termini of the two forms exp-3 recognise 
two different sets of bands and since these bands are also recognised by the 
antibodies raised to regions common to both proteins, and not by the pre-immune 
sera and the PCNA control sera, the results suggest that these bands represent the 
products of the two exp-3 genes. 2) From the results obtained from the enriched 
gametocyte extract and the asexual Ki blots it can be concluded that both forms 
of exp-3 are present in asexual stage parasite extracts. Neither form of exp-3 is 
solely expressed in gametocytes and it is unclear whether either of them are 
expressed in gametocytes at all. 
6.6 Immunolocalization of exp-3a and exp-3b 
In order to assess the localization of the exp-3 antigens 
immunofluorescence assays were performed on acetone fixed thin smears of 
asynchronous P.falctparum Ki and 3D7 infected RBCs. The Ki slides contained 
RBCs infected with just asexual stage parasites. While the 3137 slides contained 
a mixture of RBCs, infected with both asexual and gametocyte stage parasites. 
The rabbit antisera, pGEX8SH, pGEX4HH, pGEX4HS, pGEX76 and 
pGEX21 were used at a dilution of 1:50 and the McAb 7.7 ascites fluid at a 
dilution of 1:100 (method 2.6.1). The parasite nuclei were counterstained with 
DAPI. The bound rabbit antibodies were detected using either Fluorescein anti-
rabbit IgG conjugated second antibodies which give a green fluorescence or 
Rhodamine anti-rabbit IgG conjugated second antibodies which give a red 
fluorescence. The bound murine antibodies were detected using Fluorescein anti-
mouse IgU conjugated second antibodies. The results are shown in Figures 6.6, 
6.7 and 6.8. The appropriate control experiments were performed. No staining 
of infected or non-infected cells was observed when any of the five pre-immune 
sera were used (data not shown). Also, there was no significant staining of non-
infected cells and no fluorescent staining was observed when only the second 
antibodies were used (data not shown). 
Before a more detailed discussion some general comments can be made 
concerning the IFA results shown. Firstly the examples shown are representative 
of a series of many experiments which consistently gave the same fluorescence 
patterns. Secondly all the cells which stained with Fluorescein or Rhodamine also 
stained with DAPI indicating that all the antibodies recognised parasitised cells 




Pattern of IK%. staining produced by McAb 7.7 and the pGEXSSH, pGEX4HH 
and pGEX4IIS antisera on blood films of F.falciparum isolate Ki. 
Acetone fixed smears of P.falcipanun infected RBCs were incubated with McAb 
7.7 (panels 1 and 2), pGEX8SH bleed 2A antiserum (panels 3 and 4), pGEX4HH 
bleed 2A antiserum (panels 5 and 6) and pGEX4HS bleed 2A antiserum (panels 
7 and 8) followed by anti-rabbit FITC-conjugated second antibodies. Parasite 
nuclei were counterstained with DAPI. The same infected cell was analyzed for 
the presence of DAFT (panels la-8a) and fluorescein (panels lb-8b). Panels 1, 
2, 4, 6 and 8 show RBCs containing schizonts while panels 3, 5 and 7 show RBCs 









Pattern of IFA staining produced by pGEX76 (exp-3a) and pGIEX21 (exp-3b) 
antisera on blood films of P.falciparum isolate Ki. 
Acetone fixed smears of P.falciparum infected RBCs were incubated with pGEX76 
bleed 1A antiserum (panels 1, 2, 3, 4) and pGEX21 bleed 1A antiserum (panels 
5 and 6) followed by anti-rabbit FITC-conjugated second antibodies. Parasite 
nuclei were counterstained with DAPL The same infected cell was analyzed for 
the presence of DAPI (panels la-6a) and fluorescein (panels lb-6b). 
Also, acetone fixed smears of P.falcipamm infected RBCs were incubated with a 
mixture of the pGEX21 bleed 2A antiserum (panels 7c-10c) and McAb 7.7 
(panels 7b-10b) followed by a mixture of anti-mouse FITC-conjugated and anti-
rabbit RITC-conjugated second antibodies. Parasite nuclei were counterstained 
with DAPI (panels 7a-10a). 
Panels 1, 2, 3, 7, 8, 9 and 10 show RBCs containing ring or trophozoite stage 
parasites while panels 4, 5 and 6 show RBCs containing schizont stage parasites. 
202 
5a 	 Sb 	 (,a 	 61) 
3a 	 31) 	 -Ia 	 41) 
la 	 21) 
7:1 	 71) 	 7c 	 Sa 	 II) 	 Sc 
m mmm . 
9:1 	 91) ic 	 I 	 1(11) 	 IOu 	 S 
Figure 6.8 
Pattern of IFA staining produced by McAb 7.7, pGrEX8SII, pGEX4HH, pGEX76 
and pGEX21 antisera on blood films of Ffalciparum. 
Acetone fixed smears of 3D7 P.falciparum infected RBCs, containing both asexual 
and sexual stage parasites were incubated with pGEX8SH bleed 2A antiserum 
(panel 1), pGEX4HH bleed 2A antiserum (panel 2), pGEX76 bleed 1A antiserum 
(panel 3) and pGEX21 bleed 1A antiserum (panel 4) followed by anti-rabbit 
FITC-conjugated second antibodies. A blood smear was also incubated with a 
mixture of MeAb 7.7 (panel 5a) and pGEX21 bleed 1A antiserum (panel 5b) 
followed by a mixture of anti-rabbit RITC-conjugated and anti-mouse FITC-




The three antisera pGEX8SH, pGEX4HH and pGEX4HS, raised to 
polypeptides common to çxp-3a and exp-3b give a very diffuse pattern of staining 
in ring, trophozoite and early schizont stage parasites (Fig.6.6 3b-8b). However, 
the pattern of fluorescence even though diffuse is localised to the intracellular 
parasite and there appears to some hint, particularly with the pGEX4HS serum 
(Fig.6.6 7b), of fluorescence associated with the PVM or parasite membrane. In 
the late-schizont, segmenter stage parasite the fluorescence is clearly not 
associated with the nucleus but appears to be localised in the gaps between the 
developing merozoites (Fig. 6.6 4b and 6b). This diffuse fluorescence pattern 
observed in rings, trophozoites and early schizonts is different to that observed 
with the mouse sera raised to the 60kDa antigen (Fig. 4.9) and McAb 7.7 (Fig 3.1 
g-l) where fluorescence is more clearly localised to the parasite surface/PVM. 
However, with McAb 7.7 in the late-schizont stage parasite a pattern similar to 
that observed for the exp-3 sera is seen (Fig.6.6 lb and 2b). 
There is a possible explanation as to why the IFA pattern of the murine 
antisera raised to the 60kDa antigen and the rabbit antisera raised to common 
regions of both proteins differ. The mouse antisera may only recognise one form 
of exp-3 since the 60kDa antigen does contain a sequence unique to exp-3a. This 
protein as discussed previously (section 4.6) may localise to the PVM or parasite 
membrane. The rabbit antisera, raised to polypeptides common to exp-3a and 
exp-3b, recognises both forms of exp-3 which may not co-localise in the cell. 
Therefore the staining pattern observed with the sera raised against parts of the 
common region could represent a combined exp-3a and exp-3b pattern i.e. they 
recognise exp-3a localised to the PVM/parasite membrane and exp-3b which is 
maybe more diffusely distributed. 
This explanation is supported by the data obtained from the rabbit antisera 
pGEX76, raised against a unique region of exp-3a, and pGEX21 raised against a 
unique region of exp-3b (Fig.6.7). The pGEX76 anti-serum (Fig.6.7 lb-4b) gives 
an IFA pattern similar to that of the mouse antibodies raised against the exp-3a 
60kDa antigen (Fig.4.9). Fluorescence appears to be localised to a membrane 
surrounding the parasite which could be either the PVM or parasite membrane. 
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The pGEX21 antisera (Fig.6.7. 5b and 6b) when initially tested gave a pattern 
which was very similar to that previously observed with the pGEX8SH, 
pGEX4HH and pGEX4HS antisera (Fig.6.6 3b-8b), that is a diffuse pattern with 
some indication of staining of either the PVM or parasite membrane i.e a 
combined pattern of exp-3a and exp-3b. This was thought due to the fact that 
pGEX21 serum recognises both exp-3a and exp-3b which was indicated by the 
initial characterization of the sera (Fig.6.5e) or that exp-3b was not only found 
diffusely distributed within the intracellular parasite but also localised to either the 
PVM or parasite membrane. In order to examine this the pGEX21 serum was 
absorbed with beads bearing the pGEX76 fusion and IFA performed again. In 
addition, a double staining IFA method was used in order to also assess whether 
exp-2 and the antigen exp-3b, as recognised by the pGEX21 rabbit antisera, are 
co-localized to any extent in the parasitised cell. The pattern of staining observed 
with McAb 7.7 is clearly localised to the PVM (Fig.6.7 7b-10b) whereas the 
fluorescence observed with the pGEX76 sera is very diffuse as previously 
described and there is no indication of staining of the either the PVM or parasite 
surface (Fig.6.7 7c-10c). 
All the antisera were also tested by IFA on 3D7 slides which contain both 
asexual and sexual stage parasites (Fig.6.8). Unlike McAb 7.7 (panel 5a) the 
rabbit antisera pGEX8SH (panel 1), pGEX4HH (panel 2), pGEX76 (panel 3) 
and pGEX21 (panels 4 and 5b) all recognise gametocytes. The four rabbit 
antisera give a very similar fluorescence pattern with staining appearing to be 
associated with either the PVM or parasite surface. 
In conclusion the two forms of exp-3 appear not to be co-localised in RBCs 
infected with asexual stage parasites. Exp-3a as recognised by the mouse anti-
60kDa antigen and the rabbit pGEX76 antisera appears to be localised to the 
PVM or parasite surface while exp-3b as recognised by the rabbit pGEX21 
antisera appears to be diffusely distributed within the intracellular parasite in a 
weak reaction. Both proteins, unlike exp-2, are also present in 3D7 gametocyte 
stage parasites. In order to confirm these results, which are prone to over 
interpretation, immuno-gold localisation needs to be performed. 
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6.7 Discussion 
All the five antisera raised to exp-3 recognise a series of bands greater than 
200kDa as did the sera raised against the 60kDa SL13 antigen. It seems unlikely 
that these bands represent antigens with cross-reacting epitopes since the same 
pattern of bands is observed with antisera raised to different regions of exp-3. 
Another explanation which may account for this is that these bands represent 
processed forms of the exp-3 proteins which result from either specific proteolytic 
cleavage or proteolytic activity which occurs in vitro during detergent extraction. 
Alternatively exp-3 may be post-translational modified e.g. glycosylation or 
acylation. Several malarial antigens have been described which are specifically 
processed for example RAP-i (Ridley et at, 1990, Harnyuttanakorn a at, 1992), 
SERP (Debrabant et at, 1992, Knapp et at, 1989) while others are specifically 
processed and modified for example the glycoprotein MSP-1 (Holder and 
Freeman, 1982). 
The IFA performed indicated that both forms of exp-3 are expressed in 
asexual and gametocyte stage parasites. Furthermore it indicated that in asexual 
stage parasites exp-3a is localised to the PVM or parasite membrane and exp-3b 
is diffusely distributed in the parasitised cell. Northern blotting analysis is 
required to confirm that both forms of the protein are expressed in both stages 
while immuno-gold studies would further indicate the localisation of the antigens 




In recent years there has been a dramatic increase in the number of cases 
of malaria due in part to the spread of drug-resistant parasites. There is a now 
an urgent need to identify novei drug and vaccine targets. This strategy requires 
a better understanding of the molecular biology of the intracellular parasite. One 
aspect of this is the mechanism of import and export of molecules into and from 
the erythrocytic stages of the parasite. In addition the study of such trafficking 
pathways may indicate potential drug targets or possible routes by which cytotoxic 
drugs could be delivered to the intracellular parasite. In this study, malarial 
antigens which are exported by the parasite to the PVM and other locations in the 
parasitised cell have been characterized. It is hoped that the study of such 
proteins may elucidate the transport pathways established in the infected 
erythrocyte. 
7.1 Characterization of exp-1 and exp-2 
As Plasmodium falczamm develops from the ring stage to the trophozoite 
stage it extensively modifies the host cell plasma membrane. During this stage of 
development vesicles/clefts appear in the cytoplasm of the RBC which are 
believed to originate from the PVM. These vesicles are thought to be involved 
in the transport of material from the parasite to other locations in the host cell. 
Several proteins have been localized to these vesicles including the protein exp-1 
which is localized to Maurer's cleft vesicles (Simmons et at, 1987, Stenzel and 
Kara 1989). This protein contains a functional N-terminal signal sequence and a 
hydrophobic transmembrane domain (Simmons et at, 1987, GUnther et al., 1991). 
Chapter 3 describes the characterization of another antigen, termed exp-2, which 
was found to co-localise with exp-1 at the PVM and in vesicles in the RBC 
cytoplasm. Like exp-1, exp-2 is an integral membrane protein. 
What are the signals required to determine the location of exp-1 and exp-2 
to Maurer's clefts? From the location of these and other antigens coupled with 
examination of their sequences one can speculate on the signals required. For 
instance proteins that are transported outside the parasite contain hydrophobic 
regions considered to be part of a signal sequence e.g. exp-1 (Simmons et at, 
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1987), Pf-41.2 (Knapp et aL, 1989b) and HRP-2 (Wellems et aL, 1986). In 
addition antigens localised to Maurer's clefts contain transmembrane regions e.g. 
exp-1 (Simmons et aL, 1987), Pf-41.2 (Knapp et aL, 1989b) and presumably exp-2 
since it has been demonstrated that it is an integral membrane protein. In order 
to test these theories concerning the signals required to target proteins to specific 
locations in the parasitized cell other exported proteins must be characterized. 
7.2 Identification and characterization of the exp-3 gene family 
In the course of screening Agtll expression libraries for the gene encoding 
exp-2, DNA encoding a piece of another antigen was isolated (chapter 4). From 
immunolocalization studies this antigen, like exp-2, appeared to be localised to the 
PVM and therefore was termed exp-3. 
From further characterization of the exp-3 clone it became apparent that 
it encoded a fragment of one member of a two gene family, (chapter 5). The 
sequence of both genes, exp-3a and exp-3b, was determined using synthetic 
oligonucleotides to prime reactions on isolated overlapping clones. The following 
points summarize the major observations made about the two DNA sequences: 
The 3' ends of both genes were identified but the initiating 
methionines have not yet been identified. 
The two sequences diverge within a highly charged repeat region. 
This region was found to have homology to transglutaminase post-translational 
modification sites suggesting that this region is a potential cross linking site. 
Near the end of both genes there is a potential transmembrane 
region. This is consistent with the proteins being localised to the PVM since the 
PVM protein exp-1 contains a membrane spanning domain. 
Northern blotting analysis with a piece of DNA common to both genes 
indicated that at least one of the genes is expressed in asexual stage parasites. In 
order to further assess the expression of both genes antibodies were raised to 
common and unique regions of each (Chapter 6). The antisera were characterised 
by western blotting analysis and IFA. The western blotting analysis indicated that 
both exp-3a and exp-3b are expressed in erythrocytic stage parasites and are 
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greater than 200kDa in size. IFA studies indicated that exp-3a and exp-3b are 
both present in sexual and asexual erythrocytic stage parasites and suggested that 
they could both be localized to the PVM. 
7.3 Conclusions and further work 
This study has described the isolation and characterization of a two gene 
family which are expressed in erythrocytic stage malaria parasites. Several other 
gene families in malaria have been identified. It would be interesting to 
determine if, like the Pf-actin genes (Wesseling et aL, 1989) or the a-tubulins 
(Holloway et aL, 1990), the exp-3 genes are differentially expressed in blood stage 
parasites. This could be determined by performing northern blotting analysis of 
mRNA isolated from different stages of the erythrocytic parasite. 
The IFA studies presented in chapters 4 and 6 suggest that both exp-3a 
and exp-3b are localized to the PVM however, this conclusion is very tentative 
and requires confirmation by immunogold localization. If indeed the proteins are 
exported to the PVM one would expect, in addition to a transmembrane domain, 
the gene sequences to contain an N-terminal signal sequence to direct the export 
of the proteins from the parasite. As yet the N-terminal sequence of each gene 
has not yet been determined but this will be a priority in further studies of these 
genes. 
Another area of further research could be to affinity purify the exp-3 from 
in vitro cultures of malaria. This would give a source of the protein which then 
could be further analyzed. For example one could investigate whether the protein 
is modified or can act as a transglutaminase substrate in vitro (Buxman et al., 
1980) or if the purified protein extract already contains e-(y-glutamyl) isopeptide 
bonds (Mehta et aL, 1992). The results of such investigations may indicate 
possible functions of the exp-3 proteins. 
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Southern blot analysis of DNA prepared from cloned parasite lines HB3 and 307 
The Southern blot shown in Fig. 5.1a, of EcoRT digested total Ki genomic 
DNA, shows that the 1.8kb probe hybridises to two EcoRI fragments of 6.1kb and 
4.3kb. This indicates that there are two sequences in the P.falcparuin Ki genome 
related to the 1.8kb probe. Since the source of DNA is an uncloned isolate, the 
possibility exists that the DNA was prepared from a mixed population of parasites. 
If this is the case the two fragments observed could represent two allelic forms of 
a single exp-3 gene. Alternatively the two fragments may represent two members 
of a gene family. In order to investigate this further DNA prepared from two 
cloned parasite lines HB3 and 3137 was probed with DNA fragments specific for 
the 6.1kb and 4.3kb EcoRI fragments. If both fragments were present in the 
cloned lines, it would indicate that they represented two members of a gene 
family. 
l-1B3 and 3D7 parasite pellets were kindly provided by D.Walliker. DNA 
was prepared, by M. Goman, following the protocol of S. Chan (1991). Essentially 
the parasites (from lOOpl parasitized RBC), were lysed by the addition of 10% 
SDS (5il)  and incubated overnight at 370C with Proteinase K (5Opg). Parasite 
DNA was obtained after phenol extraction and ethanol precipitation (method 
2.4.1). P.falctpamm isolate Ki DNA was prepared as previously described in 
section 2.4.2.1. 
DNA prepared from P.falciparum isolate Ki, clones HB3 and 3D7 was 
digested with either EcoRI or HindIII, separated by gel electrophoresis and 
transferred onto Hybond-N (method 2.4.7). Blots were probed at 65 0C with 
either the exp-3a specific probe or the exp-3b specific probe, which have been 
previously described in section 5.5. The filters were then washed stringently (0.lx 
SSC, 0.1% SDS at 65 0C (4 x 15 minutes)) and autoradiographed. These 
experiments were kindly performed by J. White. The result is shown in Figure I. 
As previously observed (Fig. 5.3b) the ekp-3a probe hybridises to a 6.1kb. 
OZ, 16 
Figure I 
Genomic Southern blots of Ki, 3D7 and HB3 DNA probed with fragments of exp-
3a and exp-3b. 
Total genomic DNA prepared from P.falciparum isolate Ki, clone 3137 and clone 
HB3 was digested with either EcoRI (RI) or HindilI (1-13). Aliquots (approx. 
3pg) of each digest were separated by gel electrophoresis and transferred onto 
Hybond-N. Blots were probed with either a 350bp unique exp-3a probe (panel a) 
or a 800bp unique exp-3b probe (panel b) at 65 0C, washed stringently and 
autoradiographed. Molecular weight markers (M) are in kb. 
Ki 	3D7 	HB3 
M RI H3 RI H3 RI H3 
12 
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EcoRI Ki fragment and an 8kb HindIlI KI fragment. It also hybridises to 
fragments of apparently these sizes in the EcoRI and HindIII digests of 3D7 and 
HB3 DNA. Also, as previously observed (Fig. 5.3c), the exp-3b probe hybridises 
to a 4.3kb Ki fragment and a 4.6kb HindIII Ki fragment. It also hydridises to 
fragments of apparently these sizes in the EcoRI and HindIlI digests of 3137. 
Interestingly the probe hybridises to fragments of a slightly smaller size in the 
HB3 digests. It is unclear if this an artefact due to the running of the gel or 
whether it is a restriction fragment length polymorphism. This requires further 
analysis. 
Since both fragments are present in both cloned lines, this clearly shows 
that exp-3a and exp-3b are two members of a gene family. 
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